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Minimal change nephrotic syndrome (MCNS) is the most common childhood 
glomerulonephritis in Singapore and worldwide. We have previously described an 
upregulation of interleukin 13 (IL-13) in CD4+ and CD8+ T-cells of MCNS 
patients in relapse, associated with increased CD3+ intracytoplasmic IL-13 
production. Additionally, we showed that IL-13 overexpression in the rat resulted 
in podocyte foot process effacement, the hallmark of nephrotic syndrome, with 
upregulation of glomerular B7-1, inducing a minimal change-like nephropathy. 
As IL-13 is an important modulator of monocyte/macrophage function, polarizing 
these cells to an anti-inflammatory phenotype, we hypothesized that IL-13 and/or 
other immune mediators could either i) polarize monocyte/macrophage to 
modulate podocyte gene expression or ii) act through IL-13-induced B7-1 danger 
signaling in podocytes, thus causing podocyte effacement and proteinuria. 
 The aims of the study were to investigate the immunological basis of 
MCNS via characterization of the i) cytokine profile and ii) functional phenotype 
and specific ‘gene signature’ of monocytes isolated from MCNS patients, in both 
remission and relapse compared to controls. The findings were validated in-vivo 
utilizing our IL-13 overexpression rat model of MCNS. 
 In our study, it was demonstrated that MCNS patients in relapse had a 
significantly higher plasma level of IL-13 compared to controls (p<0.001) and 
paired MCNS patients in remission (p=0.028) and this was seemingly unique to 
MCNS as it was not evident in other form of nephrotic syndrome, namely, focal 
segmental glomerulosclerosis (FSGS). Characterization of monocytes showed that 
the proportion of ‘resident’ monocytes (CD14+CD16+) in paired MCNS patients 
in relapse was significantly higher as compared to when they are in remission 
(p=0.041), in keeping with the phenotype expected with IL-13-induced monocyte 
polarization. Microarray analysis of unstimulated monocytes in MCNS patients in 
relapse demonstrated an upregulation of IFN-inducible genes in the TIR-domain-
containing adapter-inducing interferon (IFN)-β (TRIF) pathway. This is a myeloid 
differentiation primary-response protein 88 (MyD88)-independent signaling 
pathway associated with toll-like receptor 3 (TLR3) which binds viral antigens 
ix 
 
and leads to a cascade of reactions leading ultimately to activation of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. This is 
consistent with the observation that relapses in MCNS patients are frequently 
triggered by viral infections. Following lipopolysaccharide (LPS) stimulation of 
monocytes in MCNS patients in relapse, genes usually responsive to LPS (CD86, 
IL-6, TNF-α) were downregulated instead of being upregulated. In addition, 
microarray analysis of unstimulated monocytes isolated from MCNS patients in 
relapse revealed IL-27, a known inducer of c-maf, which is a crucial factor in Th2 
polarization, to be 2.7 times upregulated. This was further verified by increased 
plasma IL-27 levels in MCNS patients in relapse compared to remission.  
 Our study results also demonstrated a similar picture in the IL-13 
overexpressed rat model which showed a minimal-change like nephropathy 
picture. These rats showed a predominance of ‘resident’ macrophages as well as 
an attenuated inflammatory response post-LPS stimulation as evidenced by the 
presence of general down-regulation of pro-inflammatory surface markers and 
pro-inflammatory cytokines, similar to the human study results. 
 Monocytes may, hence, be a crucial link in the pathogenesis of MCNS and 
its associated complication of predisposition towards bacterial infections.   
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1.1 Nephrotic Syndrome 
1.1.1 Definition of nephrotic syndrome 
Nephrotic syndrome is a clinical condition characterized by the presence of 
massive proteinuria (greater than 40 mg/m2/hr), hypoalbuminemia, edema and 
hyperlipidemia. The decrease in serum albumin levels occurs predominantly 
as a consequence to the massive proteinuria. The underlying cause of 
nephrotic syndrome is a permeability defect in the glomerular filtration barrier 
culminating in proteinuria.  
 
1.1.2 Classification of nephrotic syndrome 
Nephrotic syndrome maybe clinically classified into primary or secondary 
nephrotic syndromes. Secondary nephrotic syndrome is nephrotic syndrome 
that is associated with systemic diseases like Henoch-Schonlein purpura, 
systemic lupus erythematosus and diabetes mellitus. In contrast, primary or 
idiopathic nephrotic syndrome (INS) is the most common form of childhood 
nephrotic syndrome whereby the exact etiology is unknown. 
 
1.1.3 Epidemiology of idiopathic nephrotic syndrome 
With the decline in post-infectious glomerulonephritides (Rodriguez-Iturbe et 
al., 2008, Yap et al., 1990, Zhang et al., 1994, Coppo et al., 1998), INS is now 
the most common cause of significant morbidity amongst the childhood 
glomerular diseases both in Singapore (Yap et al., 1990) and worldwide (Eddy 
& Symons, 2003), with an estimated incidence of 2-7 cases per 100 000 
children and a prevalence of approximately 16 cases per 100 000 (Eddy & 
Symons, 2003). Amongst the various histological subtypes of INS, MCNS is 
the most common cause of childhood INS (ISKDC, 1978, Yap et al., 1990). 
 In a multi-center study of the underlying pathologies of INS conducted 
by the International Study of Kidney Diseases in Children (ISKDC), MCNS 




Table 1: Distribution of patients by histopathology in children with primary nephrotic 
syndrome (ISKDC, 1978) 
 
Categories No. of Patients % 
Minimal change nephrotic syndrome 398 76.4 
Membranoproliferative glomerulonephritis 39 7.5 
Focal & segmental glomerulonephritis 36 6.9 
Proliferative glomerulonephritis 12 2.3 
Pure diffuse mesangial proliferation 12 2.3 
Focal & global glomerulosclerosis 9 1.7 
Membranous glomerulopathy 8 1.5 
Chronic glomerulonephritis 3 0.6 
Unclassified 4 0.8 
Total 521 100 
  
In another separate study on the pattern of glomerulonephritis in 
Singapore children, it was also noted that MCNS accounted for the majority of 
children with INS (Table 2) (Yap et al., 1990).  
 
Table 2: Histopathological patterns of primary glomerulonephritis in Singapore children 
(Yap et al., 1990) 
 
Histopathology Frequency (%) 
Minor abnormalities 22 
Focal global sclerosis 20 
Focal segmental glomerulosclerosis 17 
Diffuse mesangial proliferative glomerulonephritis 11 
Focal mesangial proliferative glomerulonephritis 9 
Membranous glomerulonephritis 7 
Diffuse endocapillary glomerulonephritis 4 
Diffuse sclerosing glomerulonephritis 4 
Diffuse mesangial sclerosis 4 




1.2 Podocyte and nephrotic syndrome 
1.2.1 Structure of podocytes 
Podocytes are highly differentiated polarized epithelial cells consisting of the 
following: i) a cell body which extends into the urinary space, ii) major 
processes and iii) foot processes (FPs) which interdigitate with FPs of 
neighboring podocytes forming filtration slits that are abridged by an 
extracellular structure known as the slit diaphragm (SD) and also extend 
towards the capillaries for which they are embedded into the glomerular 
basement membrane (GBM) (Pavenstädt et al., 2003).  
 The cell body contains a prominent nucleus, a well-developed Golgi 
system, abundant smooth and rough endoplasmic reticulum, and many 
mitochondria which is in contrast to the cell processes which contain only a 
few organelles. The high density of organelles is required for provision of 
sufficient energy for maintenance of the structural integrity of these highly 
differentiated cells and for synthesis of most of the components of the GBM. 
 Both cell body and FPs comprise a well-developed cytoskeleton which 
accounts for the unique shape of the cells and the maintenance of the 
processes. In the cell body and the primary processes, microtubules and 
intermediate filaments such as desmin and vementin, predominate, whereas 
microfilaments, in addition to a thin cortex of actin filaments beneath the cell 
membrane are densely accumulated in the FPs (Drenckhahn & Franke, 1988).  
 The structural integrity of the FP is critical for establishing stability 
between the cell-cell and the cell-matrix contact of podocytes. The actin 
cytoskeleton of the FPs is formed by the polymerization of actin, called 
filamentous actin (F-actin), which is a highly dynamic structure with a polar 
orientation. F-actin binds with myosin, forming microfilament bundles which 
are interconnected by α-actinin-4 (ACTN4), a form of actinin-4 specifically 
expressed by podocytes. These loop-shaped microfilament bundles run along 
the longitudinal axis of the FPs connecting the sole of the FPs and the major 
processes (Drenckhahn & Franke, 1988; Mundel & Kriz, 1995). The 
intracellular actin bundles are linked to the extracellular SD by the adaptor 
protein complex consisting of zonula occludens (ZO)-1, β-catenin, CD2-
associated protein (CD2AP), podocin and non-catalytic region of tyrosine 
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kinase (NCK) and p130Cas, located at the intracellular SD insertion area near 
lipid rafts (Mundel & Shankland, 2002, Asanuma et al., 2003, Reiser et al., 
2000, Patrakka & Tryggvason, 2010, Pavenstädt et al., 2003, Faul et al., 2007, 
Welsh & Saleem, 2011).  
The SD membrane which connects adjacent podocyte FPs resting on 
the GBM, is a modified adherens junction with a filtration slit that is 25-60 nm 
wide and contains nephrin, proto-cadherin (P-cadherin), nephrin homolog 1 
(NEPH1) and  FAT (Mundel & Shankland, 2002, Asanuma et al., 2003, 
Reiser et al., 2000). Apart from maintaining the structural integrity of the SD, 
the adaptor protein molecules also serve as a signaling platform for regulation 
of podocyte function (Huber & Benzing, 2005).  
In addition, FPs contain longitudinal and arciform actin microfilaments 
and a thin cortex of actin filaments that run cortically and contiguously to link 
neighboring processes. Adjacent FPs are connected by a contractile apparatus 
consisting of F-actin, myosin II, β-actinin-4 and synaptopodin (Faul et al., 
2007, Welsh & Saleem, 2011). The FPs are also anchored to the GBM via by 
integrins and dystroglycans at the basal aspect of the tertiary FPs. The integrin 
complex consists of the cytoplasmic adaptor proteins, vinculin, paxillin and 
talin, and of the transmembrane α3/β1 integrin dimers, which bind to the α3, 
α4 and α5 chains of collagen IV as well as to laminin 11, a heterotrimer 
composed of α5/β2/γ1 laminin chains (Kreidberg & Symons, 2000). The 
dystroglycan complex is made up of the cytoplasmic adaptor protein utrophin, 
of the transmembranous β-dystroglycan subunit, and of the extracellular α-
dystroglycan subunit which bind to agrin and laminin α5 chains in the GBM 
matrix (Durbeej et al., 1998). Dystroglycans and integrins are believed to co-
ordinate the formation of a polygonal network of laminin in basement 
membranes (Schwarzbauer, 1999). Podocyte FPs represent a critical 
component of podocyte function and these protein molecules highlighted are 
important in maintaining the cell shape, the 3-dimensional architecture of the 
podocyte FPs and their attachment onto the GBM (Kerjaschki et al., 2001, Oh 
et al., 2004). Hence, a better understanding of the molecular aspect of the 
podocyte FPs may be helpful in understanding the disease processes in the 




Figure 1: Molecular anatomy of the podocyte foot process (FP) actin cytoskeleton.  
This schematic shows two adjacent podocyte FP with the interposed slit diaphragm (SD) 
complex. α-act4 = α-actinin-4; α3β1 = α3β1 integrin; α-DG = α-dystroglycan; β-DG = β-
dystroglycan; Na(+)/H(+)ERF2 =  Na(+)/H(+) exchanger regulatory factor 2; P =  paxillin; P-
cad = P-cadherin; Synpo = synaptopodin; T = talin; V = vinculin (Adapted from Mundel & 
Shankland, 2002) 
 
1.2.2 Podocyte and the glomerular filtration barrier 
The glomerulus is the chief filter of the nephron and is located within the 
Bowman's capsule in the renal cortex. The glomerulus consists of a mass of 
capillaries which received its blood supply via the afferent arteriole and leaves 
it via the efferent arteriole. Four resident cell types are found in the 
glomerulus, namely the endothelial cells, mesangial cells, parietal epithelial 
cells and visceral epithelial cells (podocytes). The endothelial cells form a 
porous layer known as the fenestrated endothelium, lining the luminal side of 
the GBM. The mesangial cells and the extracellular substances they secrete 
form into a matrix called the mesangium which gives support to the capillary 
mass. The podocytes are with their extensive cytoplasmic processes cover the 
outer aspect of the GBM. The parietal epithelial cells form the epithelium of 
the Bowman’s capsule facing the urinary space. The fenestrated endothelium, 
the GBM and the podocytes together form the filtration barrier in the 
glomerulus that regulates the outflow of solutes from the blood capillaries to 
the urinary space. The cytoplasmic extension of podocytes forms into 
secondary FPs and further extends into individual tertiary FPs. These 




forming in between (Figure 2). Adjacent tertiary FPs are linked together by the 
SD which can only be seen by transmission electron microscopy (Figure 3). 
 
Figure 2: Schematic drawing of the glomerular filtration barrier.  
The glomerular filtration barrier is composed of 3 layers: the inner endothelium, the GBM and 
the outer podocyte and its foot processes. Negative charge is associated with each of the three 
layers and is thought to retard filtration of anionic molecules (red) such as albumin, facilitate 
filtration of cationic molecules (green), and have little impact on neutral molecules (yellow). 







Figure 3: High power view of the podocyte tertiary foot processes.  
Individual podocyte tertiary FPs are resting on the GBM with slit pores in between and linked 
together by the electron dense SD. The GBM appears as homogeneous matrix material. The 
endothelial cells line the inner layer of the barrier with pores in between. (Rat glomerulus, 
TEM Magnification = x15500) (Courtesy of Dr Lai WK) 
 
 
1.2.3 Charge and size selectivity of the glomerular filtration barrier 
The glomerular filtration barrier is freely permeable by water and small 
solutes and is believed to have distinct charge and size selectivity to protein 
molecules. The charge barrier is mainly contributed by the negative residues 
on the GBM and the podocytes and size selectivity is mainly contributed by 
the SD of the podocytes.  
The GBM is a thin (250–400 nm) meshwork of extracellular matrix 
proteins which forms an integral part of the glomerular filtration barrier 
(Groffen et al., 1999, Suh et al., 2013). Most of the GBM is situated between 
two cellular layers, namely, the glomerular endothelial cells (GECs) and the 
podocytes. A small proportion of GBM lie between podocytes and mesangial 
cells at the bases of the capillary loops (Miner, 2011). The GBM provides both 
structural support for the glomerular capillaries and contains ligands for 




podocytes (Yurchenco & Patton, 2009, Miner, 2005). More importantly, the 
GBM contributes to glomerular permselectivity, restricting the passage of 
plasma proteins across the glomerular filtration barrier. The criticality of GBM 
in permselectivity is as evident by the findings that mutations in genes 
encoding the proteins found in the GBM give rise to renal diseases involving 
proteinuria (Alport syndrome, Pierson syndrome) (Kruegel et al., 2013, 
Matejas et al., 2010). The permselectivity is predominantly attributable to the 
protein components of the GBM. 
The GBM is made up chiefly of laminin‑521 (α5β2γ1), type IV 
collagen α3α4α5, nidogen, and the heparan sulphate proteoglycan such as 
perlecan and agrin which contain negatively charged heparan sulfate 
polysaccharide side chains (Miner, 2012, Groffen et al, 1999). These 
components are synthesized by the endothelial cells and podocytes (St John & 
Abrahamson, 2001). In addition to these polyanionic proteins, the podocyte is 
covered by a highly glycosylated layer of sialoprotein known as podocalyxin 
which contains negatively charged sialic acid residues (Kerjaschki et al., 
1984) and in tandem, these polyanionic sites oppose the movement of the 
negatively charged albumin molecules out from the blood capillaries.  
The SD forms part of the filtration barrier, between podocytes, and is 
responsible for about half of the total hydraulic resistance. It appears to be the 
key barrier for molecules larger than albumin, hence representing the main 
determinant of size selectivity (Drumond & Deen, 1994).  
 
1.2.4 Podocyte slit diaphragm (SD) 
The SD is a modified adherens junction (Reiser et al., 2000) that connects FPs 
of adjacent podocytes in the glomeruli. It assists in the maintenance of the 
structure of the interdigitating FPs overlying the GBM and the formation of 
the slit pore which is 25-60 nm wide. It contains nephrin, NEPH1, podocin, 
FAT1, ACTN4, vascular endothelial (VE)-cadherin and P-cadherin (Reiser et 
al., 2000, Tryggvason et al., 2006, Cohen et al., 2006). The SD serves as a 
size-selective barrier and is linked to the actin-based cytoskeleton by adaptor 
proteins, including CD2AP, zonula occludens 1 (ZO-1), β-catenin, and NCK 
(Mundel & Shankland, 2002, Asanuma et al., 2003, Reiser et al., 2000, 
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Patrakka & Tryggvason, 2010, Pavenstädt et al., 2003, Jones et al., 2006, 
Verma et al., 2006, Reiser et al., 2004, Winn et al., 2005).  
The SD initially arises from a tight junction during glomerular 
development, and the tight junction zonula adherens-associated ZO-1 is 
concentrated along the cytoplasmic surface of the SD (Schnabel et al., 1990). 
These tight junctions then start to move in a basolateral direction and loosen, 
while continuously changing their protein composition (Grahammer et al., 
2013). Although the expression of tight-junction proteins is maintained, 
despite the broadening of the cell–cell contact point, adherens junction 
proteins also appear such as nephrin and NEPH1 (Ruotsalainen et al., 2000). 
A schematic drawing of the SD is as illustrated in Figure 1. 
 
1.3 Mechanisms of proteinuria 
Proteinuria refers to urinary protein excretion of greater than 0.3 g/1.73m2/day 
of which microalbuminuria, defined as urine albumin:urine creatinine ratio 
greater than 30µg/mg,  is a more sensitive indicator of underlying renal 
disease (Hutchison et al., 1988, Mattix et al., 2002). The understanding of the 
underlying pathophysiology and mechanisms of proteinuria is of paramount 
importance as proteinuria is an independent predictor of progression of renal 
disease (Hemmelgarn et al., 2010). 
  The mechanisms of albumin leakage in the glomeruli primarily relate 
to disruptions in various components of the glomerular filtration barrier, 
namely, GECs, GBM and podocytes. 
 A chief characteristic of the GECs is the presence of numerous 
fenestrations. As these openings are substantially larger relatively to the 
albumin molecule, the GECs were deemed initially to be an ‘insignificant’ 
component of the glomerular filtration barrier. Subsequent studies, however, 
demonstrated otherwise. The GECs have a cell-surface layer, the glycocalyx – 
principally composed proteoglycans and sialoproteins (Pries et al., 2000), 
which under physiological conditions prevents the leakage of albumin and 
other proteins. Biophysical models indicate that fenestral glycocalyx 
contributes to 50% of the overall hydraulic resistance of the glomerular 
filtration barrier (Drumond et al., 1994). Hence, changes in the components of 
the glycocalyx may give rise to proteinuria. In agreement, defects in the 
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endothelial cell glycocalyx were demonstrated to be associated with 
proteinuria, highlighting the importance of this structure (Jeansson & 
Haraldsson, 2006, Jeansson et al., 2009).  
 Vascular endothelial growth factor (VEGF), a key protein involved in 
the crosstalk between components of the glomerular filtration barrier (Eremina 
et al., 2007), is needed for normal physiological functions of the GECs 
(Eremina et al., 2008, Satchell & Braet, 2009).  The expression of VEGF 
differs in various causes of proteinuria. In rat models of adriamycin-induced 
nephropathy and puromycin aminoglycoside-induced nephrosis, the 
expression of VEGF was noted to be decreased (Fan et al., 2002, Fan et al., 
2009). In contrast, patients with MCNS as well as patients with membranous 
glomerulonephritis, membranoproliferative glomerulonephritis, crescentic 
nephritis and diabetic nephropathy, VEGF was noted to be increased and the 
levels correlated with the severity of proteinuria even in certain causes of 
proteinuria (Horita et al., 1998, Bailey et al., 1999, Matsumoto & Kanmatsuse, 
2001, Hohenstein et al., 2010). 
 The other key component for glomerular filtration is the GBM. Type 
IV collagen is one of the chief constituents of the GBM which is secreted by 
the glomerular endothelial cell during early development and subsequently 
replaced by a more robust collagen network secreted by podocyte 
(Abrahamson et al., 2009). The other constituents of the GBM also include 
laminin, nidogen, and sulfated proteoglycan, which are produced by podocytes 
mainly and in less proportion by GECs (Miner, 2011). Modifications in some 
of the constituents give rise to proteinuria. Mutations in genes that encode 
GBM type IV collagens lead to Alport syndrome where hematuria in 
conjunction with moderate proteinuria is present (Hudson et al., 2003). 
Autosomal recessive mutations in laminin gene result in the Pierson 
syndrome, which is characterized as a congenital nephrotic syndrome 
accompanied by ocular and neurological defects. Most of the patients with 
Pierson syndrome with nephrotic-range proteinuria rapidly progress to end 
stage renal disease and die in the perinatal period (Zenker et al., 2005). 
 Podocytes, including SD, play a key role in the pathogenesis of 
proteinuria and the eventual progression to nephrotic syndrome (Tryggvason 
et al., 2006). Podocyte FP effacement is a common phenomenon of proteinuric 
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diseases (Oh et al., 2004). The exact mechanism of which, however, remains 
to be elucidated.  
Podocytes are anchored to the underlying GBM via transmembrane 
cell receptors such as dystroglycan and integrins. In podocytes, α3β1 integrin 
is the most abundant isoform present in podocytes and is localized exclusively 
to the basal membrane. The α3 chain is necessary for the development of the 
glomerular capillary tuft. Mice in which the integrin gene is inactivated during 
podocyte development demonstrate defects in glomerular capillary branching 
and failure in formation of proper FPs (Kreidberg et al., 1996). In addition, 
integrin is a major receptor for laminin and disruption of the integrin-laminin 
complex could potentially result in the weakening of the podocyte-GBM 
interaction leading to progressive detachment of podocytes, which is 
associated with proteinuria (Toblli et al., 2012).  
Dystroglycan is a laminin-binding component of the dystrophin-
glycoprotein complex which provides a linkage between the subsarcolemmal 
cytoskeleton and the extracellular matrix (Ibraghimov-Beskrovnaya et al., 
1992). In humans, they are translated from a single mRNA, a 5.5 kb transcript 
derived from the DAG1 gene located at chromosome 3 (Skynner et al., 1995). 
Dystroglycan is an important member of the dystrophin-glycoprotein complex. 
The dystrophin-glycoprotein complex, comprising of α- and β-dystroglycan, 
sarcoglycans, and utrophin/dystrophin, links the cytoskeleton to agrin and 
laminin in the basal lamina in muscle and epithelial cells. Dystroglycan is also 
expressed in cultured podocytes and mesangial cells. Immunofluorescence 
studies using antibodies against α- and β-dystroglycan revealed a granular 
podocyte-like staining pattern along the glomerular capillary wall (Raats et al., 
2000). Agrin was also identified to be a major heparan sulfate proteoglycan in 
the GBM and was found to be a high-affinity binding partner of dystroglycan 
(Gesemann et al., 1998). These results suggest that dystroglycan is involved in 
linking the podocyte cytoskeleton to the GBM. The role of dystroglycan in the 
pathogenesis of FP effacement leading to nephrotic syndrome as seen in 
MCNS is further reaffirmed via the observation of decreased glomerular 




Podocyte integrin-linked kinase (ILK), an intracellular serine/threonine 
protein kinase that interacts with the cytoplasmic domains of β integrins and 
mediates the integrin signalling (Wu, 2001, Hannigan et al., 2005), plays an 
essential role in the glomerular filtration barrier (Dai et al., 2006, El-Aouni et 
al., 2006). Dysregulation of ILK expression has been observed in a wide 
variety of chronic kidney diseases, including nephrotic syndrome, diabetic 
nephropathy and obstructive nephropathy (Kretzler et al., 2001, Guo et al., 
2001, Li et al., 2003, Liu et al., 2004). Ectopic expression of ILK in podocytes 
decreased levels of nephrin and ZO-1, induced desmin, fibronectin, matrix 
metalloproteinase-9, and alpha-smooth muscle actin, promoted cell migration, 
and increased the paracellular albumin flux across podocyte monolayers (Dai 
et al., 2006, El-Aouni et al., 2006, Kang et al., 2010).  
Tetraspanins, which are transmembrane proteins present in virtually all 
cell types, oligomerize into tetraspanin-enriched microdomains, in which they 
associate with integrins. This interaction is crucial for adhesion of the 
podocytes onto GBM as CD151-knockout mice develop proteinuria within a 
few weeks after birth and electron microscopic examination reveals the 
presence of lamination and spikes in the GBM as well as focal FP effacement, 
albeit with less severity than that seen in integrin knockout mice (Sachs et al., 
2006), suggesting CD151 has a role in strengthening α3β1-mediated GBM 
adhesion in podocytes.  
Podocytes are also covered by glycocalyx, principally podocalyxin, a 
type I transmembrane sialomucin which regulates both adhesion and cell 
morphology (Takeda et al., 2000). In the developing kidney, podocalyxin 
plays an essential role in the formation and maintenance of podocyte FPs, and 
its absence leads to lethality (Nielsen & McNagny 2009). In puromycin 
aminonucleoside nephrosis rats and protamine sulfate perfusion studies, 
whereby the podocalyxin's negative charge is neutralized, FP architecture is 
disrupted, and SDs are displaced or completely replaced by leaky, 
discontinuous junctions (Kurihara et al., 1992).  
As described earlier, the SD, which connects the FPs of adjacent 
podocytes, plays a central role in the control of proteinuria. The filtration 
barrier contains nephrin, podocin, NEPH1, FAT1, ACTN4, VE-cadherin and 
P-cadherin (Reiser et al., 2000, Tryggvason et al., 2006, Cohen et al., 2006). 
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and the SD is linked to the actin-based cytoskeleton by adaptor proteins, 
including CD2AP, ZO-1, β-catenin, and NCK (Mundel & Shankland, 2002, 
Asanuma et al., 2003, Reiser et al., 2000, Patrakka & Tryggvason, 2010, 
Pavenstädt et al., 2003, Jones et al., 2006, Verma et al., 2006, Reiser et al., 
2004, Winn et al., 2005).  
Nephrin is the chief component protein of the SD (Wartiovaara et al., 
2004). This is best illustrated in patients with congenital nephrotic syndrome 
of the Finnish type whereby mutations of the nephrin gene NPHS1 results in 
absence of SD between adjacent podocyte FPs (Kestila et al., 1998). Nephrin 
is encoded by the NPHS1 gene located on chromosome 19q13.1 and spans 
26kb and contains 29 exons (Kestila et al., 1998). The predicted protein has 
1,241 amino acid residues and is a putative member of the immunoglobulin 
family of cell adhesion molecules. It contains a transmembrane domain, 8 Ig-
like modules, and 1 fibronectin III-like module (Kestila et al., 1998).  In-vitro 
study on podocyte cell lines showed that nephrin colocalized with F-actin at 
cell-cell contacts as demonstrated by immunofluorescence (Schiwek et al., 
2004) and promotes cell-cell adhesion through homophilic interaction 
(Khoshnoodi et al., 2003). Using electron tomography, it was further 
demonstrated that nephrin exists as globular cross strands about 35 nm in 
length emanating from both sides of the slit, and interact with each other by 
their free distal end. These globular cross strands form a network of winding 
molecular strands with pores the same size as or smaller than albumin 
molecules (Wartiovaara et al., 2004).   Mutation of the NPHS1 gene causes a 
rare and severe form of glomerular disease known as congenital nephrotic 
syndrome of the Finnish type (CNF). CNF is an autosomal recessive inherited 
disorder which was originally described in Finland and predominantly in the 
pediatric population with an estimated incidence of 1.2 per 10 000 live births 
(Huttunen, 1976).  The condition is characterized by the presence of massive 
proteinuria in utero and nephrosis at birth secondary to the absence of nephrin 
and podocyte SDs (Kestila et al., 1998). The importance of nephrin in SD 
function was further illustrated in certain animal models of nephropathy. Mice 
homozygous for inactivated NPHS1 developed massive proteinuria and 
oedema immediately after birth and died within 24 hours. The kidneys of these 
mice showed enlarged Bowman’s spaces, dilated tubules, effacement of 
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podocyte FPs and absence of the SD, features of which are similar to those 
found in patients with CNF (Putaala et al., 2001). The nephritogenic mAB 5-
1-6, which identifies an antigen on rat podocyte slit-diaphragms and induces 
severe proteinuria when injected into rats, was shown to recognize the 
extracellular domain of nephrin (Topham et al., 1999). This was further 
supported by the presence of identical glomerular localization patterns of 
nephrin and mAB 5-1-6 antigen as identified by immunofluorescence in rat 
kidney (Topham et al., 1999). In the puromycin aminonucleoside-induced 
nephrosis rat model, the expression of nephrin-specific RNA was also shown 
to be downregulated and its expression was also inversely proportional to the 
severity of proteinuria (Kawachi et al., 2000; Luimula et al., 2000). 
Additionally, nephrin has been shown to redistribute from the filtration slits to 
the podocyte membrane in puromycin-induced nephropathic rats (Luimula et 
al., 2000) as well as in patients with primary acquired nephrotic syndrome 
(Doublier et al., 2001). Nephrin, hence, is crucial in the development and 
function of the glomerular filtration barrier, and appears to be an important 
molecule in the pathogenesis of proteinuria. 
Podocin was first identified as a product of the gene mutated in 
patients with autosomal recessive steroid-resistant nephrotic syndrome, 
characterized by early childhood onset of proteinuria, rapid progression to 
end-stage renal disease and focal segmental glomerulosclerosis (FSGS) (Boute 
et al., 2000). Podocin is encoded by the gene, NPHS2, which was identified by 
positional cloning and mapped to 1q25-31 in humans (Boute et al., 2000). It is 
a membrane-integrated protein that belongs to the stomatin protein family. It 
consists of a single hairpin-like integral membrane protein with intracellular 
NH2- and COOH- termini (Schwarz et al., 2001, Roselli et al., 2002).  
Podocin is exclusively expressed in the podocytes and localizes at the 
insertion site of the SD (Schwarz et al., 2001). Podocin accumulates in an 
oligomeric form in lipid rafts of the SD. It associates via its COOH-terminal 
domain with CD2AP, a cytoplasmic binding partner of nephrin, and with 
nephrin itself (Schwarz et al., 2001), ensuring a stable and proper functioning 
filtration barrier. Podocin dysfunction leads to alterations of the SD assembly 
and to proteinuria in experimental models.  In NPHS2-/- knockout mice, they 
developed proteinuria during the antenatal period and died a few days after 
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birth from renal failure caused by massive mesangial sclerosis alongside with 
enlarged and focally vacuolized podocytes (Roselli et al., 2004). Electron 
microscopy demonstrated extensive effacement of podocyte FPs and the lack 
of a SD in the remaining FP junctions (Roselli et al., 2004). 
NEPH1, a molecule with five extracellular immunoglobulin-like 
domains, is structurally related to nephrin (Donoviel et al., 2001). NEPH1(-/-) 
mice demonstrated high perinatal lethality rate and developed proteinuria 
ranging from 300 to 2,000 mg/dL together with effacement of podocyte FPs 
(Donoviel et al., 2001). NEPH1 is localized exclusively to lateral margins of 
podocyte FPs at the insertion of the SD and together with nephrin, participate 
in a direct cis-interaction involving their cytoplasmic domains (Barletta et al., 
2003). In addition, NEPH1 forms homodimers with each other and interact 
with nephrin through their extracellular domains to form heterodimers 
(Barletta et al., 2003, Liu et al., 2003, Gerke et al., 2003). NEPH1 has also 
been found to interact with the C-terminal domain of podocin (Sellin et al., 
2003). These findings illustrate the importance of NEPH1 in maintaining the 
integrity of the SD and the interactions between NEPH1 with nephrin and 
podocin may play a functional role in modulating glomerular permeability.  
FAT cadherins form a distinct subfamily of the cadherin gene 
superfamily which plays an important role in cell-cell adhesion and 
maintenance of cell architecture. The FAT cadherins contain an 
extraordinarily large extracellular region comprising of 34 repeated domains, 
making them the largest cadherin molecules (Mahoney et al., 1991). One of 
the mammalian homologs, FAT1 is found to be a component of the glomerular 
SD and is highly expressed in podocytes. Immunofluorescence staining of 
FAT1 showed a distribution along the glomerular capillary wall. Double 
immunostaining technique and double immunogold electron microscopy 
demonstrated that FAT1 colocalizes with ZO-1 and the 5-1-6 antigen which 
are closely associated with the SD (Inoue et al., 2001). In addition, FAT1 was 
found to be an important regulator of actin dynamics and cell-cell interactions 
through its binding with Ena/vasodilator-stimulated phosphoproteins 
(Ena/VASP) proteins (Tanoue & Takeichi, 2005). 
ACTN4 is the product of the ACTN4 gene and is highly expressed in 
healthy podocytes. It is a member of the spectrin superfamily, exists as a head-
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to-tail homodimer and is thought to crosslink and bundle actin filaments via its 
N-terminal actin binding domain. The central spectrin repeats are involved in 
dimer formation and serve as a docking platform for numerous molecular 
partners (Otey & Carpen, 2004). The actin binding domain of ACTN4 requires 
two calponin homology (CH1 and CH2) domains which contain three actin 
binding sites (ABS1-3). CH2, in addition to its actin binding activity, may 
play a modulatory role as a phosphoinositide-binding site has been mapped to 
the CH2 domain of ACTN4 (Honda et al., 1998). Binding of 
phosphoinositides to α-actinin-1 prevent bundling by blocking the binding of 
α-actinin to F-actin, thereby affecting cytoskeletal remodelling (Fraley et al., 
2003, Fraley et al., 2005). Mutations in the ACTN4 gene are responsible for 
an autosomal dominant form of FSGS (Kaplan et al., 2000). Transgenic mice 
which contain a mutation in ACTN4 expressed in a podocyte specific manner 
also developed significant albuminuria, associated with a downregulation of 
nephrin gene and protein in the kidney (Michaud et al., 2003). Mice deficient 
in ACTN4 showed progressive proteinuria, podocyte FP effacement and died 
within a few months (Kos et al., 2003).  
In addition to SD filtration barrier proteins, SD adaptor proteins or 
linker proteins, including CD2AP, ZO-1, β-catenin, NCK and TRPC6, also 
play a role in regulation of proteinuria.  
CD2AP, an 80 kDa adaptor protein containing multiple Src homology 
3 (SH3) domains, facilitates receptor patterning in the contact area between T 
cells and antigen-presenting cells (APCs) by linking specific adhesion 
receptors to the cytoskeleton (Dustin et al., 1998). It was first associated with 
nephrotic syndrome when CD2AP (-/-) mice was noted to die from kidney 
failure at the age of 6-7 weeks. Examination of the glomeruli revealed 
podocyte FPs effacement, mesangial cell hyperplasia and extracellular matrix 
deposition (Shih et al., 1999). In the kidney, CD2AP is localized to the SD and 
the C-terminus of CD2AP interacts with the C-terminal cytoplasmic domain of 
nephrin (Shih et al., 2001). CD2AP directly interacts with actin (F-actin) and 
synaptopodin, an actin-bundling protein. CD2AP was found to co-localize 
with F-actin in the podocyte FPs and seems to partake in the regulation of the 
highly dynamic F-actin structures in podocyte FPs. (Welsch et al., 2001). It 
also interacts with the actin cytoskeleton through its carboxyl terminus 
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(Lehtonen et al., 2002) and is involved in endosomal sorting and/or trafficking 
through its regulatory action on dynamic actin on podocyte vesicles (Welsch 
et al., 2005). In a recent study, CD2AP has been shown to regulate the 
transforming growth factor (TGF)-β1–dependent translocation of dendrin from 
the SD to the nucleus. Nuclear dendrin acted as a transcription factor 
promoting expression of cytosolic cathepsin L (CatL). CatL proteolyzes the 
regulatory GTPase dynamin and synaptopodin, an actin-associated adaptor 
protein, leading to a reorganization of the podocyte microfilament system with 
consequent proteinuria. CD2AP was also proteolyzed by CatL during 
podocyte injury, increasing the apoptotic susceptibility of podocytes to TGF-
β1 (Yaddanapudi et al., 2011). The above findings suggest CD2AP as a SD 
associated molecule that is crucial in the maintenance of the integrity of the 
glomerular filtration barrier. 
NCK belongs to the family of adaptor proteins and are almost 
exclusively comprising of one SH2 and three SH3 domains (Buday et al., 
2002, Lettau et al., 2009). The NCK family has two known members in 
human cells, namely NCK-1 and NCK-2. NCK serves as a critical connection 
between nephrin and actin in podocytes (Jones et al., 2006, Verma et al., 
2006). Phosphorylation of tyrosine residues on nephrin leads to interaction 
with the SH2 domain on NCK protein with subsequent recruitment of other 
proteins involved in the regulation of the actin assembly through the SH3 
domains (Jones et al., 2006, Verma et al., 2006). Mice whose podocytes 
lacked NCK developed massive proteinuria (Jones et al., 2006) and this is 
associated with podocyte FP effacement (Verma et al., 2006). The above 
findings suggest the importance of NCK proteins in normal glomerular 
development. 
 The transient receptor potential cation (TRPC) is a group of calcium-
permeable cation channels that are involved in the regulation of Ca2+ influx. 
These ion channels can be activated subsequently to either depletion of Ca2+ 
from internal stores or through receptor-mediated processes (Riccio et al., 
2002). One of the members TRPC6 is localized to the podocyte cell body, 
primary processes and in close vicinity to the slit membrane where it interacts 
with nephrin and podocin (Reiser et al., 2005). The integral role for TRPC6 in 
kidney podocytes is underscored by the observation that mutations of TRPC6 
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are associated with FSGS (Reiser et al., 2005, Winn et al., 2005). TRPC6 has 
been found to be mutated in families with an autosomal dominant form of 
FSGS (Winn et al., 2005). These mutations may result in a gain of function, 
leading to enhanced Ca2+ influx, especially after the activation of the G-
protein-coupled receptor AT1 by angiotensin II (Ang II), resulting in an 
altered channel regulation or an altered interaction with other SD proteins 
leading to proteinuria. Elevated levels of wild-type TRPC6 protein have also 
been found in some acquired glomerular diseases, like membranous 
nephropathy and puromycin aminonucleoside-induced albuminuria, and this 
may lead to podocyte dysfunction (Moller et al., 2007). Recently it has been 
demonstrated that Ang II contributes to podocyte injury by increasing TRPC6 
expression via an nuclear factor of activated T cells (NFAT)-mediated positive 
feedback signaling pathway. This finding highlights the crucial role of TRPC6 
in the pathogenesis of podocyte injury and proteinuria (Nijenhuis et al., 2011). 
ZO-1, a protein found on the cytoplasmic face of tight junctions, is expressed 
on the cytoplasmic surface of podocyte FPs at the point of insertion of the SD 
(Schnabel et al., 1990). Several studies have demonstrated that the change of 
ZO-1 distribution and/or its expression in podocytes is associated with 
proteinuria (Kawachi et al., 1997, Macconi et al., 2000, Kurihara et al., 1992). 
The monoclonal antibody 5-1-6 has been shown to alter the expression of both 
nephrin and ZO-1 proteins in rat podocytes (Kawachi et al., 1997). In the 
puromycin mucleoside-treated rat model, it was noted that ZO-1 protein was 
significantly increased compared to the control group, leading to proteinuria 
(Kim et al., 2005).  
In addition to the above-mentioned podocyte proteins, other proteins 
expressed in glomerular podocytes, such as glomerular epithelial protein 1 
(GLEPP-1) and podoplanin, have also been proposed to be involved in a 
number of glomerular diseases. Reduction in GLEPP-1 has been found 
associated to podocytopathies not only in biopsies of patients with IgA 
nephropathy and FSGS (Hill et al., 2011) but also in women with 
preeclampsia (Zhao et al., 2009). In addition, GLEPP-1 is considered a 
contributor to podocyte’s FP structure regulation. GLEPP-1 is a 132 kDa 
membrane protein tyrosine phosphatase with a large extracellular domain 
containing eight fibronectin-type-III-like repeats, a hydrophobic 
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transmembrane segment, and a single protein-tyrosin phosphatase domain. 
Podoplanin, a 43 kDa integral membrane glycoprotein localized on the surface 
of rat podocytes, is downregulated in puromycin nephrosis (Breiteneder-
Geleff et al., 1997). Additionally, in the spontaneously proteinuric Dahl SS 
rat, segmental loss of podoplanin expression accompanied proteinuria and 
preceded widespread podocyte alterations for several weeks (Koop et al., 
2008).   
In summary, changes in the expression of protein molecules associated 
with the SD or the actin cytoskeleton may alter glomerular permeability in 
several ways:  
1) Direct damage to the SD 
The critical role of the SD in regulating glomerular permeability suggests that 
any changes in its structural component may alter the normal function of the 
filtration barrier. Hence, changes in the expression of its component proteins, 
such as nephrin, may directly lead to structural changes in the SD, altering its 
size-selectivity with consequent a loss of function as a physical barrier to 
protein molecules; 
2) Structural changes of the filtration barrier 
Since the SD helps to maintain the in-vivo 3-dimensional architecture of the 
podocytes, changes in the expression of protein molecules associated with the 
SD may result in changes of the podocyte cell shape or even loss of the slit 
pore. This will affect the spatial distribution and structural integrity of the 
filtration barrier and subsequently loss of function. For example, nephrin has 
been shown to redistribute both in puromycin nephropathy (Luimula et al., 
2000) and in patients with primary acquired nephrotic syndrome (Doublier et 
al., 2001). Downregulation in the expression of ZO-1, a structural component 
of the SD complex, was found to be associated with increased glomerular 
permeability (Kawachi et al., 1997). 
3) Rearrangement of the actin cytoskeleton.  
Modulation of the actin cytoskeleton has been associated with the onset of 
proteinuria. For example, ACTN4 mutations were associated with an 
autosomal dominant form of familial FSGS (Kaplan et al., 2000). This implies 
that mutation of proteins that are closely associated with actin may impair the 
proper organization of the actin cytoskeleton, initiating changes in the shape 
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and form of the podocyte FPs. The actin cytoskeleton is also linked to the SD 
by adaptor proteins such as CD2AP and FAT cadherins (Lehtonen et al., 2002; 
Tanoue & Takeichi, 2005) and therefore, mutations in proteins associated with 
the SD may also potentially interfere with the organization of the actin 
cytoskeleton. Rearrangement of the actin skeleton leads to changes in 
podocyte cell shape, which may affect the structural integrity of the filtration 
barrier and alter glomerular permeability; 
4) Dissociation of the podocyte FP from the GBM 
The podocyte FPs are linked to the GBM via α3β1 integrin and dystroglycans 
(Adler, 1992). Detachment of podocytes from the GBM has been associated 
with massive proteinuria (Whiteside et al., 1989). Therefore, cell matrix 
contacts of the podocyte FPs may be crucial in the maintenance of the 
glomerular capillary wall substructure and hence of barrier function. 
Alteration in the expression of integrins or dystroglycans or their linking 
molecules will inevitably affect the binding of podocyte FPs to the GBM and 
glomerular permeability.  
 
1.4 Minimal change nephrotic syndrome (MCNS) 
MCNS is a histological variant of primary INS. It is the most common cause 
of nephrotic syndrome in children, accounting for up to 90% of nephrotic 
syndrome cases in children younger than 10 years of age and an estimated 
50% of cases in children older than 10 years of age (Nachman et al., 2008, 
Fogo, 2001). Most of the children with MCNS achieve remission [defined as 
reduction of proteinuria to less than 4 mg/m2/h or an urinary albumin dipstick 
of 0 or trace for 3 consecutive days (ISKDC, 1981)] after an 8-week course of 
on prednisolone (60mg/m2/day for 4 weeks, followed by 40mg/m2 on alternate 
days for weeks), with approximately 75% of them achieving remission within 
2 weeks of commencement (ISKDC, 1981). Consequently, young children 
with nephrotic syndrome are a priori treated empirically with corticosteroids, 
in the absence of atypical features of MCNS. Renal biopsies are advocated for 
patients who are steroid-dependent or steroid-resistant, patients who exhibit 
features atypical for MCNS and prior to the initiation of nephrotoxic 
immunosuppressants like calcineurin inhibitors (cyclosporine, tacrolimus). 
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 Despite the effectiveness of steroid therapy in MCNS patients, up to 
70% of children with MCNS will have multiple relapses, of which at least half 
will require long-term steroid therapy or courses of cytotoxic drugs, with their 
attendant adverse effects on growth and puberty, cataract formation (Mendoza 
et al., 1990, Tune et al., 1995), and risk of malignancy.  
 In addition to the risk of complications from therapy, MCNS patients 
in relapse are also at increased risk of morbidity and mortality pertaining to 
the underlying disease, including progression to end-stage renal disease, 
especially in patients with steroid-resistant nephrotic syndrome and 
predisposition to life-threatening infections. Patients with NS are at increased 
risk for infections. Sepsis remains one of the main causes of morbidity and 
mortality in children with nephrotic syndrome (Gorensek et al., 1988). The 
risk of clinical infection is even greater in those treated with cytotoxic drugs 
compared to prednisolone only (Latta et al., 2001). These children are at 
increased risk of infection by organisms such as Streptococcus pneumoniae 
and other β-hemolytic streptococci, Haemophilus spp. and gram-negative 
bacteria (Tain et al., 1999). Several immunological factors including low 
serum immunoglobulin G concentrations (Kemper et al., 2002), factor B and 
factor I in the alternative complement pathway (Patiroglu et al., 1998), 
transferrin (Vaziri, 2001), and depressed T-cell function (Sasdelli et al., 1981, 
Matsumoto et al., 1984)  may play a major role in the susceptibility of 
nephrotic patients to infection.  
 In an attempt to devise better therapeutic strategies for the treatment of 
this dreadful disease and its complications, a greater in-depth understanding of 
the etiology of the disease is hence required. 
 
1.4.1 Role of podocyte in the pathogenesis of MCNS 
The constellation of features characterizing nephrotic syndrome develops from 
primary alterations of the permselectivity barrier of the glomerular capillary 
walls, resulting in inability to resist the loss of protein to less than 100 mg/m2 
body surface per day (Eddy & Symons, 2003).  The glomerular capillary wall 
consists of three structural components that form the permselectivity barrier, 
namely endothelial cells separated by fenestrae, the GBM which is made up of 
matrix proteins, and terminally differentiated specialized epithelial cells 
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(podocytes) from inner to outer layer.  The filtration barrier is freely 
permeable by water and small solutes, but not by proteins the size of albumin 
(69 kD) and larger.  
Current knowledge on the pathogenesis of INS suggests that this is 
primarily a podocyte disease, as podocyte FP effacement is the hallmark of 
nephrotic syndrome (Figure 4).  Podocytes form a tight network of 
interdigitating cellular extensions, called FPs, which are bridged by SDs 
(Pavenstadt et al., 2003). The SD complex is important for the following two 
functions: firstly, it establishes and maintains the specific extracellular 
filtration route of the filtration slits between FPs; and secondly, it counteracts 
the elastic distension of the GBM resulting from comparatively high 
transmural hydrostatic pressure gradients in the range of 30-40 mm Hg by 
means of the contractile apparatus in FPs (Kriz et al., 1995, Kriz et al., 1996).  
The SD is composed of a number of proteins, including nephrin, P-cadherin, 
CD2AP, ZO-1, FAT, and podocin (Mundel & Shankland, 2002). 
In MCNS, the major morphologic lesion is FP effacement, and the 
degree of FP effacement has been shown to roughly correlate with the amount 
of proteinuria (Powell, 1976, Seefeldt et al., 1981).  This was not due to fusion 
of neighboring processes, but to retraction, widening, and shortening of the 
processes of each cell (Inokuchi et al., 1993). Current research is centred on 
the molecular mechanism underlying FP effacement.  FP effacement has been 
shown to be associated with conspicuous changes in the cytoskeleton.  An 
increase in microfilaments together with elaboration as a broad belt attaching 
the basal membrane has been noted (Inokuchi et al., 1993).  Recent studies 
showed significant alterations in the expression of cytoskeleton and adhesion 
molecules such as alpha-actinin, heat-shock protein (Inokuchi et al., 1993), 
and integrins (Smoyer & Mundel, 1998).  There are also many molecules in 
FPs and/or SDs, such as CD2AP, podocin, which are associated with the actin 
cytoskeleton (Kaplan et al., 2000, Shih et al., 1999). Unfortunately, little is 








Figure 4: Effacement of podocyte tertiary FPs.  
Electron micrograph demonstrating diffuse podocyte FP effacement (arrows). (Minimal 
change disease in human, TEM Magnification = x7800) (Courtesy of Dr Lai WK) 
 
 
1.4.2 Immunological basis for MCNS 
The fundamental cause and pathogenesis of MCNS is still largely unknown. 
The onset of INS has been associated with prior respiratory tract infections or 
other immunogenic stimuli such as insect stings (Tareyeva et al., 1982, 
Cuoghi et al., 1988), vaccinations (Kuzemko, 1972, Macario et al., 1995) or 
allergic reactions to inhaled allergens (Williamson, 1970, Wittig & Goldman, 
1970, Reeves et al., 1975, Florido et al., 1992). Clinical observations such as 
remission induced by measles, the occurrence of nephrotic syndrome in 
Hodgkin’s disease, both of which modify cell-mediated immunity, and the 
therapeutic benefits of steroids and cyclophosphamide, which suppresses cell-
mediated responses, all support Shalhoub’s hypothesis (1974) (Shalhoub, 
1974) that MCNS might be related to T-cell dysfunction, resulting in the 
production of a lymphocyte-derived permeability factor that induces 
proteinuria. In addition, the lack of morphological changes in the kidney 
suggested that MCNS represented a generalized disorder of the immune 
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system resulting in renal manifestations, rather than a specific disease of the 
kidney.  
Since then, a number of studies have shown immunologic 
abnormalities in this disease, including an increase in the CD4+CD45RO+ and 
CD8+CD45RO+ memory subsets in patients with active relapse (Yan et al., 
1998) as well as abnormalities in serum immunoglobulins during nephrotic 
relapses characterized by depressed IgG, and elevated IgM and 
immunoglobulins (Yokohama et al., 1987, Cheung et al., 2004). Although it is 
still unclear how an altered immune system may cause proteinuria in INS, 
there is strong evidence suggesting that the proteinuria in INS could be 
mediated by a circulating factor(s) such as cytokines (Mathieson, 2003, Eddy 
& Symons, 2003). Persistent massive proteinuria, in turn, contributes to the 
phenomenon of glomerular hyperfiltration and ultimately progressive 
glomerulosclerosis, through the mediation of other cytokines like TGF-β, 
produced by the resident glomerular cells such as the mesangial cells 
(Schnaper et al., 2003). 
 
1.4.3 Cytokine profiling in MCNS patients 
In an attempt to further elucidate the underlying immunological pathogenesis 
of MCNS, numerous studies have been performed, including the examination 
of various immunological subsets and cytokines in MCNS patients in relapse, 
compared to remission and controls, in the hope of elucidating the putative 
permeability factor(s) which leads to MCNS. 
 Various studies demonstrating changes in cytokine production during 
MCNS have been published, which, unfortunately, not all are in agreement 
with each other. This may be consequent to the different immunogenetic 
backgrounds of the patients, the different co-morbidities of the patients, the 
different environments in which the cells are cultured and the different modes 
of cytokine assay. 
 
Interleukin-1 and MCNS 
IL-1, a pro-inflammatory cytokine, was noted to be decreased in MCNS 
patients in relapse compared to normal controls (Matsumoto, 1989). The 
results was in contrast to a subsequent study by Saxena and co-workers who 
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demonstrated an increase in the supernatants of phytohemagglutinin-activated 
lymphocyte cultures from MCNS patients compared with controls, suggesting 
a possible role of IL-1 in the pathogenesis of MCNS (Saxena et al., 1993). The 
above findings, however, were refuted by subsequent studies which reported 
no significant changes in IL-1 in MCNS patients in relapse (Suranyi et al., 
1993, Bustos et al., 1994, Daniel et al., 1997). 
 
IL-2 and MCNS 
IL-2, a Th-1 related cytokine, was noted to be increased in supernatants 
isolated from MCNS patients in relapse compared to normal controls (Saxena 
et al., 1993). This finding was further reiterated in subsequent studies 
(Neuhaus et al., 1995, Daniel et al., 1997, Lama et al., 2002, Zachwieja et al., 
2002, Shimoyama et al., 2004). The finding of increased IL-2 was not 
demonstrated, however, in two other separate studies, including one by our 
group (Suranyi et al., 1993, Yap et al., 1999). 
 
IL-4 and MCNS 
IL-4, a Th-2 related cytokine, was noted to be increased in peripheral blood 
mononuclear cells (PBMCs) from patients with MCNS, and this was 
associated with increased B-cell expression of the type II IgE receptor and 
high IgE production (Cho et al., 1999), further supporting the association of 
atopy with nephrotic syndrome. The finding was similar to a study by 
Neuhaus and co-workers (Neuhaus et al., 1995). This contrasted with the 
finding of decreased IL-4 in patients with MCNS in relapse compared to 
remission in two separate studies by Daniel and co-workers (Daniel et al., 
1997) and Zachwieja and co-workers (Zachwieja et al., 2002).  
Yap and co-workers, on the other hand, did not demonstrate an 
increase in IL-4 in MCNS patients in relapse compared to remission, similar to 
that found by Kimata and co-workers and Shimoyama and co-workers (Yap et 
al., 1999, Kimata et al., 1995, Shimoyama et al., 2004).  
 
IL-6 and MCNS 
IL-6, another Th-2 associated cytokine, was noted to be decreased in MCNS 
patients in relapse (Zachwieja et al., 2002). In a study by Bustos and co-
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workers, there was no noted difference in IL-6 mRNA expression between 
patients and controls (Bustos et al., 1994). 
 
IL-8 and MCNS 
In a study by Garin and co-workers, it was noted that MCNS patients in 
relapse showed IL-8 serum concentration above the level of detection. 
Supernatants of PBMC cultures from MCNS patients in relapse increased the 
35sulfate uptake by rat GBM. This effect was abolished by the addition of anti-
IL-8 neutralizing antibody to the culture media and reproduced by the addition 
to the media of IL-8 in concentrations found in the serum of MCNS patients in 
relapse, suggestive of the role of IL-8 in the pathogenesis of MCNS (Garin et 
al., 1994). In a separate study by Daniel and co-workers, it was, however, 
noted that IL-8 levels were decreased in nephrotic patients compared to 
controls (Daniel et al., 1997). 
 
IL-10 and MCNS 
IL-10, a regulatory cytokine secreted several cell types, including monocytes, 
was noted to be decreased in supernatants of cultured peripheral blood 
monocytes that were obtained from nephrotic patients compared to healthy 
controls (Matsumoto, 1995). IL-10 levels were, however, noted to be similar 
between nephrotic children in relapse compared to remission (Shimoyama et 
al., 2004).  
 
IL-12 and MCNS 
IL-12, a key cytokine involved in the differentiation of naïve T cells into Th1 
cells (Hsieh et al., 1993), was first suggested to be a key component in the 
pathogenesis of nephrotic syndrome by Matsumoto and co-workers 
(Matsumoto et al., 1998, Matsumoto & Kanmatsuse, 1999, Mastumoto & 
Kanmatsuse, 1999, Matsumoto & Kanmatsuse, 2000). This was further 
illustrated in another study by Lin and co-workers who demonstrated that sera 
IL-12 levels and LPS-stimulated IL-12 productions for PBMCs were 
significantly increased in MCNS patients in relapse as compared to normal 
controls and in remission stage. There was, in addition, a noted correlation 
between in vitro IL-12 release by PBMCs and in vivo sera IL-12 level from 
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MCNS patients as with disease activity (Lin et al., 2004). The finding was in 
contrast to that found by Sahali and co-workers who, using a CDNA library 
differential screening technique, found that c-maf was upregulated while IL-
12R-β-2 gene expression was downregulated during relapses of MCNS 
(Sahali et al., 2002).  No differences in IL-12 levels were, however, illustrated 
in separate studies by Stefanović and co-workers (Stefanovic et al., 1998) and 
Yildiz and co-workers (Yildiz et al., 2013).  
 
Tumor necrosis factor-alpha and MCNS 
In a study by Bustos and co-workers, it was demonstrated that MCNS patients 
in relapse had higher serum TNF-α levels and TNF-α production by 
monocytes than patients in remission and controls. TNF-α mRNA expression 
was also noted to be increased in MCNS patients in relapse compared to 
remission and controls (Bustos et al., 1994), suggestive of a possible role of 
TNF-α in the pathogenesis of MCNS. Elevated levels of TNF-α in MCNS 
patients in relapse compared to controls were also reported in two other 
studies (Suranyi et al., 1993, Lama et al., 2002). The finding of elevated TNF-
α levels in MCNS patients in relapse was, however, not found in studies 
performed by Daniel and co-workers (Daniel et al., 1997) and Shimoyama and 
co-workers (Shimoyama et al., 2004).  
 
Gamma-interferon and MCNS 
Gamma-interferon (γ-IFN), a Th1-related cytokine, was noted to be markedly 
decreased (P<0.001) in pokeweed mitogen-stimulated PBMC of relapsing 
nephrotic patients (Stefanovic et al., 1998). There were, however, no noted 
changes in γ-IFN levels by several other groups, comparing relapsing MCNS 
to remission and controls (Suranyi et al., 1993, Yap et al., 1999, Zachwieja et 
al., 2002, Shimoyama et al., 2004). 
 
1.4.4 IL-13 and MCNS 
IL-13 is an important immunoregulatory protein that is produced by different 
T-cell subsets and dendritic cells (de Vries, 1998).  It consists of 132 amino 
acids and has a molecular mass of 12 kD.  The human IL-13 gene is located on 
28 
 
chromosome 5q31, in the same cluster of genes encoding IL-3, IL-4, IL-5, IL-
9 and granulocyte-monocyte colony stimulating factor (GM-CSF).  IL-13 acts 
through its receptors on the cell surface, activating predominately the 
JAK/STAT pathway (Hershey, 2003). The IL-13 receptor complex consists of 
3 subunits, including interleukin-4 receptor alpha (IL-4Rα), interleukin-13 
receptor alpha 1 (IL-13Rα1) and interleukin-13 receptor alpha 2 (IL-13Rα2).  
IL-13 shares many biologic activities with IL-4, due to the fact that they share 
the common IL-4Rα subunit in the multimeric IL-4 and IL-13 receptor 
complexes (Heinzmann et al., 2000, Shirakawa et al., 2000). However, unlike 
IL-4, it fails to activate T cells since IL-13 receptors are virtually absent on T 
lymphocytes (Zurawski & de Vries, 1994, de Waal Malefyt et al., 1995). 
Our previous study examined the Th1 and Th2 cytokine profiles in 
children with steroid-sensitive nephrotic syndrome (SSNS) (Yap et al., 1999). 
Both cross-sectional and paired data demonstrated increased CD4+ and CD8+ 
IL-13 mRNA expression in patients with nephrotic relapse as compared to 
remission, normal and patient controls (p<0.008). This was also associated 
with increased cytoplasmic IL-13 expression in puromycin/ionomycin-
activated CD3+ cells (6.66±3.39%) from patients with nephrotic relapse 
compared to remission (2.59±1.35%) (p<0.001). Additionally, we were able to 
demonstrate that genetic polymorphisms in the 3’ untranslated region (3’UTR) 
of the IL-13 gene correlated with long-term outcome of MCNS, rather than 
disease susceptibility, in Singapore Chinese children (Wei et al., 2005). 
Moreover, PBMC IL-13 mRNA expression in patients with haplotype AAT 
(relapsing nephrotic syndrome) was significantly higher than those with 
haplotype GCC (long-term remission). 
Involvement of IL-13 in nephrotic syndrome is further supported by its 
association with atopy and Hodgkin’s disease (Kapp et al., 1999).  
The close relationship between atopy and INS, as demonstrated by our 
group and other workers, suggests a common immune pathway (Yap et al., 
1983; Lin et al., 1990). Stimuli, such as allergens, may activate common 
immune mechanisms, which subsequently result in proteinuria in children with 
MCNS. We have previously demonstrated that the total serum IgE level was 
found to be significantly higher in children with SSNS in relapse (550±391 
U/ml), compared to remission (226±156 U/ml) or normal controls (185±139 
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U/ml) (p<0.001). Moreover, the elevated serum total IgE levels found in 
patients in nephrotic relapse correlated significantly with the increase in CD3+ 
IL-13 producing cells (r=0.782, p<0.001) (Cheung et al., 2004). Our finding of 
an increased IL-13 gene expression from both CD4+ and CD8+ cells in 
nephrotic children in relapse, was consistent with Kimata’s study where IL-13 
was shown to be important for the spontaneous production of IgE and IgG4 by 
PBMC in nephrotic syndrome. Importantly, this activity was specifically 
blocked by anti-IL-13 antibody (Kimata, Fujimoto & Furusho, 1995).  
The association between Hodgkin’s disease and MCNS has been 
described. IL-13 expression has been shown to be upregulated in Reed-
Sternberg (RS) cells found in Hodgkin’s lymphoma. IL-13 is secreted by RS 
cells and stimulates the growth of the tumor by an autocrine mechanism (Kapp 
et al., 1999). Symptoms of nephrotic syndrome disappear after successful 
treatment of the tumor. This further supports our findings that increased IL-13 
gene expression may be important in the pathogenesis of MCNS. 
In IL-13 overexpressed rat model, we have demonstrated that 
overexpression of IL-13 gene resulted in podocyte injury with downregulation 
of nephrin, podocin and dystroglycan and concurrent upregulation of B7-1 in 
the glomeruli (Lai et al., 2007). This corresponded with an increased 
glomerular IL-4Rα and IL-13Rα2 gene expression, as well as increased 
fluorescent signal for IL-4Rα in the glomeruli of nephrotic rats, suggesting 
that IL-13 may act directly on podocytes in the glomeruli. There was also a 
significant correlation between serum IL-13 levels and B7-1 expression in the 
glomeruli of the IL-13 overexpressed rats with nephrotic syndrome. The 
concomitant upregulation of B7-1 expression in the glomeruli following IL-13 
overexpression suggests a possible pathogenic relation between IL-13 and 
podocyte dysfunction. 
 
1.4.5 B7-1 (CD80) and MCNS 
Recent studies have suggested the costimulatory molecule B7-1 (CD80) as an 
inducible modifier of glomerular permselectivity and proteinuria (Reiser et al., 
2004, Reiser & Mundel, 2004).  
B7-1 (CD80) is a transmembrane protein normally expressed on the 
surface of B cells and other APCs (Abbas & Sharpe, 1999, Henry et al., 1999, 
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Chambers & Allison, 1999). On APCs, B7-1 acts as a costimulatory molecule 
via binding to its cognate receptors CD28 and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) on T cells (Abbas & Sharpe, 1999, Henry et 
al., 1999, Chambers & Allison, 1999).  
Podocyte-specific expression of B7-1 has been implicated as the final 
common pathway in the genesis of proteinuria in various models of 
glomerulopathies including genetic, drug-induced, autoimmune, and bacterial 
toxin-induced experimental kidney diseases with nephrotic syndrome, 
whereby B7-1 expression in podocytes was upregulated. This was increased 
with concurrent actin cytoskeleton reorganization. B7-1 knockout mice were 
protected from LPS-induced proteinuria, suggesting a functional relation 
between podocyte B7-1 expression and proteinuria. Though LPS does cause 
proteinuria in rodents, it does not cause full-blown nephrotic syndrome in 
humans. 
Specific urinary CD80 excretion was reported in MCNS patients in 
relapse which was not observed in other forms of glomerular diseases (Garin 
et al., 2009). In addition, renal biopsy results showed high expression of CD80 
in glomeruli of MCNS patients in relapse but not FSGS patients. CD80 
expression was shown to be co-localized with podocin expression in the 
glomeruli from an MCNS patient in relapse (Garin et al., 2010). 
 The plausible role of B7-1 in the pathogenesis of MCNS is further 
reiterated in our IL-13 overexpressed rat model whereby serum IL-13 
correlated with the B7-1 expression in the rat glomeruli, suggestive of a 
pathogenic link between B7-1 and MCNS (Lai et al., 2007). 
 In view of the above findings, the downregulation of the gene 
expression of nephrin, podocin and dystroglycan in the glomeruli of IL-13 
transfected rats could, hence, either be due to a direct or indirect consequence 
of IL-13-induced B7-1 danger signaling function in podocytes.   
 
1.4.6 Role of monocyte/macrophage in the pathogenesis of MCNS 
Monocyes may play a key role in the pathogenesis of MCNS as illustrated by 
the following: 
1. Monocytes from SSNS patients with proteinuria displayed enhanced 
phagocytosis of opsonized particles and hexose-monophosphate pathway 
31 
 
and suppressed chemotaxis. It was suggested that the dissociation between 
phagocytosis and chemotaxis might be due to the alteration of the surface 
receptors and lymphokines (Nagata et al., 1981); 
2. Depressed function of Fc-receptors of monocytes and macrophages were 
observed in children with MCNS (Davin et al., 1983). This may be related 
to the dysfunction of T cells present in MCNS since previous studies had 
shown that the interactions between macrophage and T lymphocytes were 
determined by Fc receptors, lymphokines and macrophage mediators 
(Nathan et al., 1980, Rosenthal, 1980); 
3. Hydrogen peroxide release, hallmark of macrophage/monocyte activation, 
was shown to be released in significant amounts from puromycin-triggered 
monocytes of SSNS patients with proteinuria, as compared with patients in 
remission and normal controls (Tanaka et al., 1996). Hence monocyte 
activation resulting in hydrogen peroxide release may have a role in the 
development of proteinuria in SSNS; 
4. Evidence of a supernatant factor that caused a significant increase in 
35sulphate uptake in rat GBM when glomeruli were co-cultured with 
PBMC from MCNS patients, showing that both monocytes and 
lymphocytes were needed for the production of a supernatant factor 
responsible for the increased GBM sulphate uptake. It was postulated that 
monocytes could trigger or amplify the production of the supernatant 
factor by lymphocytes (Garin & Boggs, 1987); 
5. Stimulation of MCNS patients' peripheral blood monocytes with bacterial 
LPS had been shown to produce less IL-1 compared to normal controls 
and patients presenting with other forms of renal disease without nephrotic 
syndrome. The suppression of IL-1, a monokine required for the activation 
of T-lymphocytes suggested a possible monocyte cell defect that might be 
partly responsible for the impaired cell-mediated immunity in MCNS 
(Nassar et al., 1997); 
6. IL-13 decreased FLAP protein (5-LO activating protein) expression and 
induced 15-LO expression and activity (Nassar et al., 1997). In monocytes, 
5-LO pathway is a major route of arachidonic acid metabolism, leading to 
the formation of leukotrienes (Samuelsson et al., 1987, Goldyne, 1984). 
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The decreased 5-LO activity may account for the decreased inflammatory 
response in MCNS patients. 
Whether monocyte deficiency or activation found in MCNS is primary or 
secondary to the postulated T-cell defect in this disease remains to be 
elucidated. In view of our initial findings that IL-13 was upregulated in CD4+ 
and CD8+ T-cell in MCNS relapse patients and the important role it plays in 
the modulation of monocyte function, we postulate that IL-13 may act on 
monocytes to release other mediators that are important in the pathogenesis of 
proteinuria. 
 
1.5 Alternative activation of monocytes/macrophages  
The markers used to differentiate various humans monocyte subsets are CD14 
(co-receptor with TLR-4 and MD-2 for recognition of LPS) and CD16 
(FcγRIII). These markers define three chief monocyte subsets: classical or 
‘inflammatory’ monocytes that express high levels of CD14 and no CD16 
(CD14++CD16−, also termed CD14+CD16−), intermediate or ‘resident’ 
monocytes that express intermediate levels of CD14 and CD16 
(CD14++CD16+ or CD14+CD16+), and nonclassical monocytes that express 
very low levels of CD14 and high levels of CD16 (CD14dimCD16+ or 
CD14−CD16+) (van de Veerdonk & Netea, 2010, Ziegler-Heitbrock et al., 
2010). The CD14+CD16+ cells express high levels of CX3CR1 and low levels 
of CC-chemokine receptor 2 (CCR2), as opposed to the low CX3CR1 and high 
CCR2 expression levels of the CD14hiCD16– subset. The function of these 
monocyte subsets as cells secreting either pro- or anti-inflammatory cytokines 
remains controversial. For example, individual monocytes subsets that were 
stimulated ex-vivo with LPS demonstrated increased IL-10 secretion from 
CD14+CD16+ cells, whereas LPS-stimulated CD14dimCD16+ cells showed 
increased secretion of TNF-α (Skrzeczyńska-Moncznik et al., 2008). Hence, 
the monocytic subsets cannot be simply defined as pro- or anti-inflammatory, 
and their functions depend on the nature of the stimulus. 
Another characteristic hallmark of cells of the mononuclear phagocyte 
system is the exhibition of marked phenotypic heterogeneity and plasticity by 
these cells (Mantovani et al., 2002, Taylor & Gordon, 2003, Mantovani et al., 
2004). Upon stimulation with cytokines and microbial products, mononuclear 
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phagocytes express specialized and polarized functional properties (Mantovani 
et al., 2005), in which the polarized macrophages have been broadly 
categorized into polarized as M1 and M2 macrophages. Classically activated 
M1 macrophages are induced by IFN-γ alone or in concert with microbial 
stimuli (e.g., LPS) or cytokines (e.g., TNF-α and GM-CSF), participating as 
potent effector cells in polarized Th1 responses with production of toxic 
intermediates (reactive oxygen species and nitric oxide) and proinflammatory 
cytokines (IL-1β, TNF-α, IL-6). This is in stark contrast to ‘alternative 
activation’ of macrophages whereby macrophages are polarized into the M2 
phenotype (‘resident’ monocytes) after being exposed to IL-4 or IL-13, 
immune complexes, IL-10, glucocorticoid, or secosteroid (vitamin D3) 
hormones. M2 macrophages promote Th2 responses and perform a diversity 
of roles which include promoting killing and encapsulation of parasites (M2a) 
(Noel et al., 2004); immunoregulatory functions (M2b) (Mantovani et al., 
2004); promoting progression, tissue repair, and remodeling (M2c) (Wynn, 
2004).     
The differential expression of chemokines in the various polarized 
macrophages integrates these cells into polarized circuits of resistance to, or 
promotion of, susceptibility to microbial pathogens, tumours, and 
immunoregulation, tissue repair and remodeling. Transcriptional profiling and 
proteomic analysis may lead to the identification of new fingerprints useful to 
relate in vitro defined states to the complexity of pathology of diseases. 
 
1.6 IL-13 and monocytes 
Besides exerting its effect on the activation, proliferation and differentiation of 
human B cells, IL-13 is known to be an important modulator of monocyte 
function. It has been shown to induce significant changes in the phenotype and 
morphology of monocytes. It enhances the expression of CD11b, CD11c, 
CD18, Class II major histocompatibility complex (MHC), CD13 and CD23, 
whereas it down-regulates the expression of CD64, CD16, CD32 and CD14 in 
a dose-dependent manner (de Waal Malefyt et al., 1993, Cosentino et al., 
1995). IL-13 has also been shown to exert its anti-inflammatory activities by 
inhibiting the production of pro-inflammatory cytokines, like IL-8, IL-6, TNF-
α, IL-1α and IL-1β, by LPS-activated monocytes (de Waal Malefyt et al., 
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1993, Defrance et al., 1994). In fact, IL-13 has been recently defined as an 
important modulator of monocyte/macrophage function which polarize these 
cells to an anti-inflammatory, M2 (M2a) phenotype that supports a type-2 
immune response (Mantovani et al., 2004, Scotton et al., 2005). In particular, 
ex-vivo treatment of human monocytes with IL-13 has also been shown to 
inhibit LPS-induced activation of human monocytes by selectively blocking 
the production of proinflammatory cytokines like IL-1β and upregulation of 
anti-inflammatory molecules like interleukin-1 receptor antagonist (IL-1RA) 
(Matsumoto, 1989). This may account for the increased susceptibility to 
bacterial sepsis seen in nephrotic children in active relapse.  
 
1.7 Research hypothesis and scope of thesis 
Despite recent advances in our understanding of podocyte biology, the exact 
mechanism in the pathogenesis of MCNS remains an enigma. Studies 
attempting to elucidate the etiology of MCNS have suggested an underlying 
immunological basis, with a Th2 cytokine bias. We have previously 
demonstrated an increase in IL-13 expression in CD4+ and CD8+ T-cells of 
MCNS patients in relapse, associated with increased CD3+ intracytoplasmic 
IL-13 production. Our laboratory have also demonstrated that IL-13 
downregulated proinflammatory cytokines, IL-8 and TNF-α in LPS-stimulated 
monocytes from patients with MCNS during nephrotic relapses compared to 
remission and normal controls as well as downregulation of monocyte 
proinflammatory cytokine IL-8 and IL-12 gene expression (Chen et al., 2003). 
Additionally, we showed that IL-13 overexpression in the rat resulted in 
podocyte FP effacement, the hallmark of nephrotic syndrome, with 
upregulation of glomerular B7-1, inducing a minimal change-like 
nephropathy. As IL-13 is an important modulator of monocyte/macrophage 
function, polarizing these cells to an anti-inflammatory phenotype, we 
hypothesized that IL-13 may either i) act directly through IL-13-induced B7-1 
danger signalling in podocytes or ii) indirectly via other immune cells like 
monocytes/macrophages to modulate podocyte gene expression, leading to 








Figure 5: Schematic drawing of proposed hypothesis.  
IL-13 may either i) act directly through IL-13-induced B7-1 danger signalling in podocytes or 
ii) indirectly via other immune cells like monocytes/macrophages to modulate podocyte gene 
expression, leading to podocyte effacement and proteinuria. 
 
 
The aim of the thesis is thus to investigate role of monocytes in the 
pathogenesis of MCNS and its associated complications, namely 
predisposition towards bacterial infections, via characterization of the 
functional phenotype and specific ‘gene signature’ of monocytes isolated from 
MCNS patients, in both remission and relapse compared to controls. This was 
accomplished by: 
1. Determining the surface phenotype of monocytes from MCNS patients 
using markers such as CD14, CD16, CCR2, CX3CR1;  
2. Quantification of intracellular production of pro-inflammatory cytokines, 
such as TNF-α, IL-6, IL-12, and anti-inflammatory cytokines such as IL-
10 in lipopolysaccharide-stimulated monocytes;  
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3. Identifying the differentially expressed genes from monocytes of children 
with relapse nephrotic syndrome by global screening methods using 
microarray technology.  
 
The secondary aim of this project was to validate the findings from the human 
MCNS patient monocyte studies using our previously described IL-13 
overexpression rat model of MCNS by: 
1. Analysis of gene expression profile by real-time PCR to define the 
polarization state of the macrophages in the IL-13 overexpression rat 
model.  Quantitative Real-time PCR is carried out for the following 
genes, IL-1β, IL-12β, TNF-α, IL-10, Arginase, CD62L, CD80, CCL3, 
CCR2, IL-10, CD43, and CX3CR1 using SYBR Green I;  
2. Phenotyping/cytokine profiling of macrophages isolated from the spleen of 
the IL-13 overexpression rat model using flow cytometry. The following 
monocyte defining markers will be examined: CD43, CD80, IL-10, and 
TNF-α. 
Studying the molecular basis of IL-13-induced dysfunction of monocytes 
will contribute significantly to defining the “immune signature” related to 




MATERIALS AND METHODS 
 
2.1 Human subject recruitment for monocyte studies 
Our study population consisted of pediatric patients with idiopathic steroid-
sensitive nephrotic syndrome (SSNS) followed up at the Pediatric Nephrology 
Clinic, Khoo Teck Puat – National University Children’s Medical Institute, 
National University Hospital (NUH).  A presumptive diagnosis of MCNS was 
made in SSNS patients which is accurate in more than 90%, based on the large 
population study conducted by the International Study of Kidney Disease in 
Children (ISKDC, 1978).   
Pediatric patients with SSNS were included in a paired longitudinal 
study where samples were obtained from nephrotic children in relapse and 
remission.  Blood sampling was performed either while the patient was not on 
any steroids, or when they were on prednisolone both during relapse and 
remission in the steroid-dependent group. None of them were on angiotensin-
converting enzyme inhibitors, non-steroidal anti-inflammatory drugs, 
cyclosporine or cyclophosphamide, which might affect interpretation of the 
differential gene expression.  
Nephrotic relapse was defined as having increased urinary protein 
excretion (Albustix ≥2+ for at least 3 consecutive days or > 40 mg/m2/hour) 
and serum albumin ≤25 g/L.  Remission was defined as serum albumin ≥35 
g/L and normal urinary protein excretion (Albustix trace or negative for at 
least 3 consecutive days or <5 mg/m2/hour).  Pediatric patients with two or 
more relapses within a 6-month period were defined as frequent relapsers and 
those with lesser than 2 relapses within a 6-month period were defined as 
infrequent relapsers. Steroid-dependence was defined inability to be tapered 
off prednisolone therapy or relapsing within 14 days of its discontinuation.  
In addition, normal healthy controls as well as patients with non-
MCNS renal disease (FSGS) were included for comparison. Ethics approval 
was obtained from the Institutional Review Board and informed consent 




2.2 Blood sampling 
Sample collection was performed with 15ml blood taken from respective 
groups of study subjects as depicted above. All samples were processed within 
four hours to prevent influence of ex-vivo handling on expression profiles. 
 
2.3 Phenotyping of monocytes by FACS analysis 
The percentage of CD14+CD16- (inflammatory) and CD14+CD16+ (resident) 
monocyte as well as surface expression of CCR2 and CX3CR1 on monocyte 
was determined using flow cytometer. Blood samples were collected in EDTA 
tube. Briefly, for every 50µl of blood, 10µl of fluorochrome-conjugated 
monoclonal antibody (MoAb) of various markers (Becton Dickinson, NJ, 
USA) was added, and incubated for 30 minutes at room temperature in the 
dark. Fluorochrome-conjugated non-specific mouse IgG1 were used as 
negative controls. Red blood cells were then lysed with 1ml of FACS Lysing 
Solution (Becton Dickinson, NJ, USA), and washed two times with PBS and 
fixed in 0.5% paraformaldehyde.  Cells were analysed on a FACSCantoTM II 
flow cytometer using CellQuest softwareTM (Becton Dickinson, NJ, USA). 
  
2.4 Cytoplasmic cytokine assay by flow cytometry  
Blood samples were collected in sodium heparin tube. One ml of blood was 
incubated with 1µg/ml of LPS (InvivoGen, San Diego, CA, USA) in the 
presence of 1 µl GolgiPlugTM (Becton Dickinson, NJ, USA) to inhibit 
intracellular protein transport. The mixture was then maintained at 37oC and 
5% CO2. After 6 hours of incubation, blood was stained with MoAb specific 
for monocytes surface marker CD14 as well as intracellular cytokine TNF-α, 
IL-6, IL-10, and IL-12 to detect monocytes production of these cytokines after 
LPS stimulation.   
Briefly, for every 50 µl of activated blood, red blood cells were lysed 
with 1 ml of FACS Lysing Solution (Becton Dickinson, NJ, USA) and 
permeabilized with 500 µl of FACS Permeabilizing Solution (Becton 
Dickinson, NJ, USA). Cells were then washed and 10 µl of Fluorescein 
isothiocyanate (FITC)-conjugated MoAb against CD14 and 20 µl of 
intracellular cytokine-specific Phycoerythrin (PE)-conjugated MoAbs against 
each of the specific cytokines were added and incubated for 25 minutes at 
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room temperature. Cells were then washed and resuspended in 1% 
paraformaldehyde. Cells were subsequently acquired on the FACSCantoTM II 
flow cytometer and analysed using CellQuest softwareTM (Becton Dickinson, 
NJ, USA). 
 
2.5 Plasma cytokine/chemokine profile by multiplex suspension bead 
array system 
Blood samples were collected in EDTA tube and centrifuged at 3,000 rpm for 
10 minutes to obtain plasma. Aliquots of plasma were stored at -80°C until 
assay.  Plasma levels of various cytokines were analysed using multiplex 
suspension bead array system (Bio-Plex® Precision Pro™ assays, Bio-Rad, 
CA, USA) according to the manufacturer’s protocol (Appendix 1). Both neat 
and 4x diluted plasma were assayed in duplicates and analyzed with Luminex 
200 Labmap system. Data was processed using Bio-Plex® Manager Software. 
 
2.6 PBMC isolation 
Blood samples were collected in sodium heparin tube and PBMCs were 
isolated by density gradient centrifugation with Lymphoprep™ (STEMCELL 
Technologies, Vancouver, BC, Canada). (Appendix 2) 
  
2.7 Monocytes isolation 
Monocytes were isolated from the PBMCs by negative selection using MACS-
Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Non-monocytes, i.e. T cells, NK cells, B cells, dendritic cells and basophils, 
are indirectly magnetically labeled using a cocktail of biotin-conjugated 
antibodies against CD3, CD7, CD16, CD19, CD56, CD123 and Glycophorin 
A, and Anti-Biotin MicroBeads. The magnetically labelled cells were depleted 
by retaining them on a MACS column in the magnetic field of the 
MidiMACS.  
Briefly, PBMCs were resuspended in MACS buffer in a total volume 
of 30 µl per 107 total cells. Ten µl of FcR blocking reagent and 10 µl of 
Biotin-Antibody Cocktail were added per 107 total cells, mixed well and 
incubated at 4–8oC. After 10 minutes incubation, 30 µl of MACS buffer and 
20 µl of Anti-Biotin MicroBeads were added per 107 total cells and incubated 
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at 4–8oC for 20 minutes. Cells were then washed with 1ml of MACS buffer, 
centrifuged and supernatant was removed completely. Cell pellet was 
resuspended with 1ml of MACS buffer and applied to preprimed LS column in 
the magnetic field of MidiMACS separator. Unlabelled cells were allowed to 
pass through and the column rinsed with 3 x 3 ml of MACS buffer. Effluent 
was collected as the negative fraction containing the enriched monocytes 
fraction. Purity of monocytes fraction was assessed using flow cytometry.  
The monocytes population thus obtained was divided into 2 portions: 
one was stimulated with 1µg/ml of LPS for 4hrs; and the other unstimulated. 
The cells were then harvested and stored at -80°C for subsequent RNA 
extraction. Culture supernatants were stored for subsequent cytokines analysis. 
  
2.8 RNA extraction 
Total RNA was extracted by TRIzol® reagent (Invitrogen Life Technologies, 
CA, USA) and further cleaned up using RNeasy minElute Cleanup kit 
(QIAGEN GmbH, Hilden, Germany). Briefly, cells were lysed in 1ml of 
TRIzol® reagent and incubated for 5 minutes at room temperature. Two 
hundred µl of chloroform (Fisher Scientific, MA, USA) was added for each ml 
of TRIzol® reagent and the mixture was shaken vigorously for 15 seconds and 
subsequently incubated at room temperature for 3 minutes. The samples were 
thereafter centrifuged at 12000g for 15 minutes at 4oC. Following 
centrifugation, the mixture separated into a lower red, phenol-chloroform 
phase, an interphase, and a colourless upper aqueous phase. RNA was isolated 
from the aqueous phase. The aqueous phase was transferred to a clean tube 
and 500µl of isopropanol (Fisher Scientific, MA, USA) was added per 1ml of 
initial TRIzol® reagent to precipitate the RNA. Samples were then incubated at 
room temperature for 10 minutes and centrifuged at 12000g for 10 minutes at 
4oC. The RNA pellet was thereafter washed with 1 ml of 75% ethanol (Merck, 
NJ, USA) for each ml of TRIzol® reagent initially added. The RNA pellet was 
then air-dried and subsequently dissolved in RNase-free water. RNA 
concentration was measured using the NanoDrop 1000 Spectrophotometer 




2.9 RNA cleanup using RNeasy minElute Cleanup kit 
Monocyte RNA was further purified using RNeasy minElute Cleanup kit 
(QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
instructions (Appendix 3). 
  
2.10 Quantification and quality analysis of RNA using Bioanalyzer 
6000 Nano kit (for microarray) 
Monocyte RNA integrity was processed using Bioanalyzer 6000 Nano Kit 
(Agilent Technologies Inc, Waldbronn, Germany) and analyzed using the 
Bioanalyzer 2100 (Agilent Technologies Inc, Waldbronn, Germany). Only 
high quality RNAs, with RNA Integrity Number (RIN) greater than 7, were 
considered for microarray analysis.  
Briefly, RNA samples with concentrations ranging from 25 to 500 
ng/µl were used. For gel preparation, 550 µl of RNA 6000 Nano gel matrix 
was added into a spin filter and centrifuged at 1500g for 10 minutes at room 
temperature. Sixty-five µl of filtered gel was subsequently aliquoted to an 
RNase-free microcentrifuge tube. For gel-dye mix preparation, 1µl of the 
RNA 6000 Nano dye concentrate was added to the 65 µl aliquot of filtered gel, 
mixed by vortexing and centrifuging at 13000g for 10 minutes at room 
temperature. Loading of the gel-dye mixture was done on the chip priming 
station by adding 9 µl of gel-dye mix in the well marked , plunging the 
syringe in 1 ml volume, waiting for 30s prior to releasing the clip and pulling 
back the plunger to the 1 ml position. This was followed by adding 9 µl of gel-
dye mix in the well marked . Five µl of RNA 6000 Nano marker was then 
added to all the sample wells as well as the ladder well marked . The 
reaction mix was completed by adding 1 µl of prepared ladder in the well 
marked  and 1 µl of sample in the sample wells. The mixture was vortexed 
by placing the chip on the IKA vortexer for 1 minute at 2400 rpm and the chip 




2.11 Synthesis of cDNA via One-Cycle Target Labelling Assay by 
Epicentre TargetAmp Nano-g Biotin-aRNA Labelling kit for Illumina® 
system (for microarray) 
Biotinylated cRNA was prepared from 50 ng of total RNA according to the 
protocol by Epicentre TargetAmp Nano-g Biotin-aRNA Labelling kit for 
Illumina® system. Very strict quality control measures were applied during the 
target preparation procedures.  cRNA was analysed by Bioanalyzer 2100 
(Agilent Technologies Inc, Waldbronn, Germany).  Typical cRNA products 
examined on an Agilent 2100 Bioanalyzer have a size range from 200 nt to 
4000 nt with a peak around 1000 nt.  The expected amount of cRNA obtained 
should be above 100 times more than the amount of starting total RNA 
material. 
 
2.12 Array hybridization and Illumina® quality controls 
Labelled cRNAs were hybridized to Illumina® Human Ref 8 chips for 16 
hours at 58°C; the arrays were then washed and stained base on Illumina Wash 
Protocol and scanned using BeadArray Scanner 500GX at BSF Microarray 
Facility (Appendix 4). The images were analyzed using GenomeStudio Gene 
Expression v 1.7.0 and comparison analyses were carried out according to the 
instructions provided by Illumina® Standard array quality controls. 
  
2.13 Microarray analysis 
The raw intensity values of the array were extracted with background 
subtraction via BeadStudio (Illumina®, San Diego, CA, USA) for analysis. 
The raw data was preprocessed to correct unreliable intensities for each array. 
The intensities with detection p-values greater than 0.05 were considered as 
unreliable and replaced by the intensity with detection p-value equal to 0.05. 
The preprocessed data was normalized by the Cross-Correlation method (Chua 
et al., 2006). Differentially expressed genes (DEGs) were selected based on 
the criteria of equal or greater than 2-fold change. Gene ontology (GO) 
analysis was done using DAVID (Huang da W et al., 2009) and pathway 
analysis was carried out using Ingenuity Pathway Analysis (Ingenuity, CA, 




2.14 Validation of microarray gene expression by quantitative real-time 
PCR 
Selected genes from our microarray experiments were validated by real-time 
PCR. Single-stranded cDNA was synthesized from 150 ng of total RNA using 
the Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, CA, USA), according to the manufacturer’s instructions 
(Appendix 5).  Quantitative real-time PCR was performed using the 
LightCycler® 480 SYBR Green I Master (Roche, Germany).  Briefly, real-
time PCR was performed in a final volume of 10 µl reaction mixture 
containing 1 µM each of the primers, 5 µl of master mix, 1 µl of PCR grade 
water and 2 µl of cDNA.  The thermal cycling conditions consisted of one 
cycle of 10 minutes at 95°C, 45 cycles of 5 seconds at 95°C, 10 seconds at 
58°C, and 20 seconds at 72°C, followed by melting curve analysis and cooling 
to 40°C.  All samples were run in duplicates and GAPDH was used as the 
housekeeping gene. For microarray validation, mean fold change was 
calculated using the formula 2∆∆Ct (where Ct was the threshold cycle, and 
∆∆Ct was converted to an absolute value). 
 
2.15 Development of an IL-13 overexpression rat model of MCNS 
All animal studies were approved by the Institutional Animal Care and Use 
Committee of the National University of Singapore prior to commencement. 
In order to study the effect of IL-13 on podocytes in-vivo, an IL-13 
overexpression rat model of MCNS was set up using a gene delivery method 
as previously described (Lai et al., 2007).  
Rat IL-13 mRNA was amplified via RT-PCR and cloned using the 
TOPO® TA cloning kit (Invitrogen Life Technologies, CA, USA). It was then 
ligated into a mammalian expression vector pCI (Promega, WI, USA) and 
following selection of the positive clones, the plasmid DNA was extracted 
using QIAGEN HiSpeedTM Plasmid Midi Kit (QIAGEN GmbH, Hilden, 
Germany). Female Wistar rats, weighing 150-200 g, maintained at the Animal 
Holding Unit of National University of Singapore, were used in the study. 
Rats were placed into metabolic cages prior to electroporation for collection of 
24hr urine sample for protein quantification prior to electroporation. Blood 
was also collected from the ventral artery of the rat tail using a 23G needle 
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prior to electroporation. Rats were electroporated every 10 days over a period 
of 72 days with endotoxin-free, purified plasmid DNA injected into the 
quadriceps of rats. An electric current consisting 6 pulses of 20 milliseconds 
each at 160V was generated using the “Electro Square Porator ECM830” 
(BTX Technologies Inc, NY, USA) and delivered through the 10mm 2-Needle 
Array™ tip (BTX Technologies Inc, NY, USA) connected to a 2-Needle 
Array™ electrode (BTX Technologies Inc, NY, USA) (Nickoloff et al., 1995). 
Control rats received 200 µg of the pCI (Promega, WI, USA) mammalian 
expression vector and test rats received 200 µg of the pCI mammalian 
expression vector cloned with rat IL-13 gene.  
Body weight, urine volume, serum albumin and creatinine, urine 
albumin, as well as IL-13 plasma levels were monitored weekly. Once 
proteinuria develops, the rats were euthanised by overdose of anaesthetic 
(ketamine 75mg/kg and xylazine 10mg/kg) via intra-peritoneal injection. 
Heparinized blood was collected via cardiac puncture and spleen was removed 
for subsequent isolation of monocytes/macrophages as detailed below. Both 
blood and urine were centrifuged at 3,000rpm for 10 minutes to obtain plasma 
and remove sediment respectively. Plasma levels of albumin, cholesterol, 
creatinine and IL-13, and urine albumin concentration were measured serially 
to ensure successful induction of frank nephrosis in rats.  
 
2.16 Plasma IL-13 ELISA 
Plasma level of IL-13 was measured using commercially available Enzyme 
Linked Immuno Sorbent Assay (ELISA) kit (Invitrogen, CA, USA) according 
to the manufacturer’s instructions. Briefly, 50µl of samples, IL-13 standards 
and positive controls were added to the wells, followed by 150µl of a 
biotinylated secondary monoclonal antibody. Plasma from the IL-13 
overexpression rats was diluted five times, while the control plasma was used 
undiluted. After two hours incubation, the wells were washed with wash 
buffer provided to remove excess biotinylated antibody. Following 30 minutes 
incubation with 100µl of streptavidin-peroxidase, the wells were washed to 
remove unbound enzyme and 100µl of stabilized chromogen (substrate) was 
added to produce colour signal in proportion to the amount of IL-13 bound. 
The colour development was stopped by adding 100µl of stop solution and the 
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intensity of the colour was measured using a microplate reader (Bio-Rad 
Laboratories, Inc, CA, USA) with wavelength set at 450 nm. The 
concentrations of IL-13 in the samples were determined from the standard 
curve, factoring in the dilution. 
 
2.17 Plasma albumin quantification 
Plasma albumin level was determined by bromocresol green (BCG) method 
using a commercial reagent kit (Randox Laboratories, Antrim, UK). Briefly, 
5µl of samples and standard were added to 1.5ml of BCG reagent and 
incubated for 5 minutes at room temperature. Two hundred µl of the reaction 
mixture was transferred to the microtiter plate in duplicate and the absorbance 
of the reaction mixtures was read at 600nm using a microplate reader (Bio-
Rad Laboratories, Inc, CA, USA) against the reagent blank consisting of 0.9% 
w/v NaCl in distilled water. Concentration of albumin in the sample was 
calculated by multiplying the absorbance ratio of the sample (Asample) and the 
standard (Astandard) with the concentration of the standard provided by the 
manufacturer ( Asample
Astandard
×	concentration of standard). 
 
2.18 Plasma cholesterol quantification 
Plasma cholesterol level was determined by an enzymatic endpoint method 
using a commercial reagent kit (Randox Laboratories, Antrim, UK). Briefly, 
10µl of the samples and standard were added to 1ml of the reagent provided 
and incubated for 10 minutes at room temperature. Two hundred µl of the 
reaction mixture was transferred to the microtiter plate in duplicate and the 
absorbance of the reaction mixtures was read at 500nm using a microplate 
reader (Bio-Rad Laboratories, Inc, CA, USA) against the reagent blank 
consisting of 0.9% w/v NaCl in distilled water. Concentration of cholesterol in 
the sample was calculated by multiplying the absorbance ratio of the sample 
(Asample) and the standard (Astandard) with the concentration of the standard 
provided by the manufacturer ( Asample
Astandard




2.19 Plasma creatinine quantification 
Plasma creatinine was determined by the alkaline picrate method. Briefly, 
100µl of samples and standards were added to a mixture containing 100µl of 
ddH2O, 100µl of 5% w/v sodium tungstate in distilled water and 100µl of 
2/3N sulphuric acid and incubated for 10 minutes at room temperature. The 
mixture was then centrifuged at 6,000rpm for 2 minutes. One hundred µl of 
the supernatant was transferred to the microtiter plate in duplicate. Following 
20 minutes incubation with 20µl of saturated aqueous picric acid and 30µl of 
1N NaOH for colour development, the absorbance of the reaction mixtures 
was read at 490nm using a microplate reader (Bio-Rad Laboratories, Inc, CA, 
USA). The concentrations of creatinine in the samples were determined from 
the standard curve. 
 
2.20 Urine albumin ELISA 
A direct sandwich ELISA was developed to detect the concentration of rat 
albumin in 24-hour urine samples. One hundred µl of rabbit antiserum to rat 
albumin antibody (MP Biomedicals, CA, USA) diluted 1/2000 was used as the 
coating antibody and 50µl of horseradish peroxidase (HRP)-conjugated sheep 
polyclonal antibody to rat albumin secondary antibody (MP Biomedicals, CA, 
USA) diluted 1/20000 was used as the detecting antibody. o-
Diphenylenediamine (OPD) (MP Biomedicals, CA, USA), in citrate buffer pH 
5.0, was used as the substrate for colour development. Rat albumin standards 
(MP Biomedicals, CA, USA) of known concentrations were included in each 
assay. Endpoint absorbance was read at 490nm by a microplate reader (Bio-
Rad Laboratories, Inc, CA, USA). The total amount of albumin excreted in 24-
hour urine was calculated by multiplying the concentration of albumin 
(mg/ml) with the total volume (ml) of 24-hour urine sample (Appendix 6). 
 
2.21 Isolation of macrophages from IL-13 overexpressed rat model of 
MCNS 
Rats were euthanized as described above. Single cell suspension was obtained 
from the spleen and seeded on cell culture flask, and incubated for 2 hours, at 
37oC and 5% CO2, to allow the macrophages to adhere. Subsequently, non-
adherent cells were removed by washing with 1X PBS. The adhering cells 
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were dislodged using 1x PBS with 2mM EDTA. These cells were washed and 
resuspended with MACS buffer before further purification by depleting T- and 
B-cells using MACS microbeads (Miltenyi Biotec, Germany) (Appendix 7). 
Purity of the monocytes/macrophages was assessed by staining for CD11b 
antigen and assessed using flow cytometry. 
Purified macrophages were resuspended in Complete Media consisting 
of RPMI 1640 with L-glutamine (Gibco®, Invitrogen Life Technologies, CA, 
USA), 10% heat-inactivated Fetal Bovine Serum (Gibco®, Invitrogen Life 
Technologies, CA, USA), 100units/ml Penicillin/Streptomycin solution 
(Gibco®, Invitrogen Life Technologies, CA, USA) and stimulated with 1ug/ml 
LPS (Sigma, St Louis, MO, USA). After overnight incubation, at 37oC and 5% 
CO2, the cells were harvest for RNA extraction using TRIzol® reagent.  
 
2.22 Cytoplasmic cytokine assay by flow cytometry of rat macrophages 
Cells were stimulated with 1ug/ml LPS (Sigma, St Louis, MO, USA) and 
0.1% GolgiPlug (Becton Dickinson, NJ, USA) in complete medium for 6 
hours at 37oC and 5% CO2. Unstimulated control cells were incubated with 
0.1% GolgiPlug (Becton Dickinson, NJ, USA) only. After 6 hours stimulation, 
cells were centrifuged and resuspended in Staining Buffer (RPMI-1640 with 
2.5% Fetal Bovine Serum and 0.02% sodium azide). For each staining 
reaction, 1x106 cells were incubated with 1X FACS Perm Solution (Becton 
Dickinson, NJ, USA) for 10 minutes, at room temperature. Subsequently, cells 
were stained with fluorochrome-conjugated MoAb against CD11b, TNFα and 
IL-10 for 20 minutes in the dark, at room temperature. Cells were then 
washed, fixed with 0.5% paraformaldehyde and analysed using flow 
cytometry. 
 
2.23 Rat macrophage gene expression by real-time PCR 
Single-stranded cDNA was synthesized from 25ng of total RNA using the 
Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, CA, USA), according to the manufacturer’s instructions 
(Appendix 8). Quantitative real-time PCR was performed using the 
LightCycler® 480 SYBR Green I Master (Roche, Germany). Briefly, the real-
time PCR was performed in a final volume of 10µl reaction mixture 
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containing 1µM each of the primers, 5µl of master mix, 1µl of PCR grade 
water and 2µl of cDNA. The thermal cycling conditions consisted of one cycle 
of 10 minutes at 95ºC, 45 cycles of 5 seconds at 95ºC, 10 seconds at 60ºC, and 
20 seconds at 72ºC, followed by melting curve analysis and cooling to 40ºC. 
Standard curves were created for each PCR run using serial dilutions of 
plasmid standards that were cloned with the PCR products generated by their 
respective primers (Appendix 9). All samples were run in duplicates and copy 
number for each sample was determined from the respective standard curve. 
Results were expressed as an index of the housekeeping gene GAPDH. 
 
2.24 Statistical analysis 
Statistical analysis was performed using Statistical Package for the Social 
Sciences for Windows version 17. The results were expressed as mean values 
± standard error of mean (SEM). The differences between groups were 
determined using the Mann-Whitney U test. Paired data for nephrotic patients 
in relapse and remission were compared using the Wilcoxon signed-rank test. 









MCNS is the most common cause of significant morbidity amongst the 
childhood glomerulonephritis in Singapore and worldwide.  The pathogenesis 
of this disease remains unclear and is probably the consequence of a primary 
immune disturbance with a Th2 cytokine bias (Mathieson, 2003, Cunard & 
Kelly, 2002). Following immunological triggers such as viral infections or 
allergy, changes occur in the permselectivity barrier of the glomerular 
capillary wall, resulting in proteinuria and the nephrotic syndrome. Recent 
studies indicate that podocyte FP effacement is the hallmark of nephrotic 
syndrome (Eddy & Symons, 2003).  Little is known, however, about the exact 
etiology of podocyte injury in MCNS resulting in leakage of protein.   
Numerous studies performed have suggested the possible involvement 
of various cytokines and no definitive consensus has been reached regarding 
the identity of the cytokine(s) which may play a role in the pathogenesis of 
MCNS. The disparity in conclusions could be consequent to differences in the 
patient population, the types of cells studied, and methodology used in 
measurement of cytokines. There may be an interplay of cytokines, with 
unique cytokine profile, potentially resulting in the pathogenesis of the 
disease, in patients with MCNS in relapse as compared to remission and 
healthy controls. A significant number of studies have suggested a Th2 
cytokine bias in MCNS. 
Our laboratory was the first to describe upregulation of IL-13 in CD4+ 
and CD8+ T cells in relapse of MCNS (Yap et al., 1999). This was associated 
with increased intracytoplasmic IL-13 production by CD3+ cells, as well as 
downregulation of gene expression of the monocyte proinflammatory 
cytokines IL-8 and IL-12 (Chen et al., 2003). Our finding of IL-13 
upregulation in the active phase of MCNS in children was further validated in 
our recently described model of IL-13 overexpression in the rat which resulted 
in podocyte injury with downregulation of nephrin, podocin and dystroglycan, 
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inducing a minimal change-like nephropathy.  This was associated with 
upregulation of glomerular B7-1. 
As IL-13 has been defined as an important modulator of 
monocyte/macrophage function, polarizing these cells to an anti-inflammatory 
M2 (M2a) phenotype further supporting a type-2 immune response, we 
hypothesized that IL-13 may either i) act directly through IL-13-induced B7-1 
danger signalling in podocytes or ii) indirectly via other immune cells like 
monocytes/macrophages to modulate podocyte gene expression, leading to 
podocyte effacement and proteinuria. 
 
3.2 Aim of chapter  
In this chapter, we aimed to i) further delineate the involvement of cytokines 
in the pathogenesis of MCNS via a high throughput strategy using multiplexed 
Luminex® assay to determine the cytokine profile of MCNS patients and ii) 
define the monocyte signature in patients with MCNS in relapse compared to 
remission, healthy controls and control patients.  
 
i) The cytokine profiling in MCNS patients was accomplished by:  
Utilizing multiplexed Luminex® Cytokine Human 27-Plex assay (inclusive of 
IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), 
IL-13, IL-15, IL-17, eotaxin, basic-FGF, G-CSF, GM-CSF, IFN-γ, IP-10, 
MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF) to determine 
comprehensively, the cytokine profile of patients with MCNS in relapse as 
compared to remission, healthy and patient controls. 
 
ii) The definition of monocyte profile in MCNS patients was 
accomplished by: 
a. Determining the surface phenotype of monocytes from MCNS patients 
using markers such as CD14, CD16, CCR2, CX3CR1;  
b. Quantification of intracellular production of pro-inflammatory 
cytokines, such as TNF-α, IL-6, IL-12, and anti-inflammatory 





3.3.1 Patient Recruitment 
The study subjects consisted of 40 MCNS patients of whom 12 had paired 
samples in relapse and remission. The median age of these patients was 12.5 
years old (range 3-25 years old).  Paired blood samples were obtained from 
these patients, in relapse and remission either when they were i) not on any 
treatment during the time of blood sampling, or ii) on prednisolone only 
during relapse and remission for steroid-dependent patients. None of them 
were on angiotensin-converting enzyme inhibitors, non-steroidal anti-
inflammatory drugs, cyclosporine or cyclophosphamide, at time of blood 
sampling. A total of 40 aged-matched controls, median age 12 years (range 4-
21 years), were also recruited for the study. Age-matched controls were 
recruited to enable a meaningful comparison of the immunological profiles of 
MCNS patients compared to controls. In addition, 7 pediatric FSGS patients in 
relapse (median age 13 years old; age range 4-22 years) were included as 
patient controls.  
              The breakdown of the study recruitment numbers is as depicted in  
Table 3. The patient details are as described in Appendix 10.   
 
Table 3: Study Recruitment Numbers 





1 – 3 0 4 0  
4 - 7 11 8 1  
8 - 13 15 12 3  
14 - 19 9 12 2  
20 - 40 5 4 1 
Total 40 40 7 
 
3.3.2 Plasma cytokine profiling 
Plasma cytokine levels were measured using Luminex® multiplex suspension 
bead array system. Unpaired analysis using Mann-Whitney U test was 
performed in pediatric nephrotic patients in relapse compared to patients in 
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remission. Forty age-matched healthy controls and 6 FSGS patients in relapse 
were also included for comparison. Table 4 summarized the results obtained. 
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IP-10  1277±214 
MCP-1  10.8±1.00  
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MIP-1β  20.2±3.70 
RANTES  468±59.4 
§Denotes significantly different (p<0.05) plasma cytokine level between MCNS patients in 
relapse and controls 
*Denotes significantly different (p<0.05) plasma cytokine level between unpaired MCNS 
patients in relapse and MCNS patients in remission 
¥Denotes significantly different (p<0.05) plasma cytokine level between FSGS patients in 
relapse and controls 
 
Of the 27 cytokines analyzed, there was no significant difference in each of 
the measured plasma cytokine level between age-matched controls and MCNS 
patients in remission.  
Comparing the individual plasma cytokine levels between age-matched 
controls and MCNS patients in relapse, there were significantly higher plasma 
levels of IL-1β, IL-1RA, TNF-α, IL-6, IL-2, IL-5, IL-9, IL-13, IL-10, PDGF-
BB, IL-8 in MCNS and a significantly lower plasma level of RANTES in 
MCNS patients in relapse compared to age-matched controls (p<0.05). MCNS 
patients in relapse were also noted to have significantly higher levels of IL-4, 
IL-6 and IL-10 than those in remission (p<0.05). 
In order to ascertain if the cytokine profile of MCNS patients in relapse 
was unique or present in other forms of nephrotic syndrome, the cytokine 
profiles of FSGS patients in relapse were also determined. It was demonstrated 
that only plasma levels of IL-1RA, IL-10 and PDGF-BB were significantly 
higher in FSGS patients in relapse compared to age-matched controls 
(p<0.05), which is a different cytokine profile compared to that demonstrated 
by MCNS patients in relapse. There was, however, no significant difference in 
any of the plasma cytokine levels between MCNS patients in relapse and 
FSGS patients in relapse and this may be attributable to the small number of 
FSGS patients used for comparison. 
 The above illustrates the uniqueness of the immune profile in MCNS 
patients, which is not present in other forms of nephrotic syndrome like FSGS. 
 Paired analysis of the cytokine profiles between MCNS in relapse 







Table 5: Summary of plasma cytokines/chemokines level in paired MCNS patients in 








IL-1β 2.81±0.36 2.06±0.27 .050 
IL-1RA 274.0±68.8 204.6±67.9 .050 
TNFα 34.6±5.14 27.1±5.20 .117 
IL-6 10.9±1.47 8.22±1.17 .034 
IL-2 6.36±1.59 4.79±1.83 .272 
IL-15 5.05±1.51 3.38±1.05 .041 
Th1-related 
IL-12 10.3±1.57 7.69±1.27 .062 
IFN-γ 192.5±29.0 150.3±16.5 .060 
Th2-related 
IL-4 2.83±0.39 2.24±0.43 .019 
IL-5 6.08±0.75 4.79±0.79 .041 
IL-9 23.6±4.16 79.9±62.4 .308 
IL-13 6.88±0.71 5.27±0.53 .028 
Eotaxin 40.1±7.19 32.8±4.53 .239 
Th17-related 
IL-17 23.3±7.01 13.7±3.11 .023 
Treg cell-related 
IL-10 4.33±0.63 2.43±0.49 .004 
Bone marrow-derived 
IL-7 8.41±1.19 6.61±0.70 .071 
GM-CSF 29.9±5.16 20.8±3.11 .114 
G-CSF 18.4±4.27 14.9±3.66 .084 
Stromal cells and angiogenic factors 
bFGF 24.0±4.71 18.2±2.48 .209 
PDGF-BB 3278±500 2245±506 .071 
VEGF 16.9±4.58 10.6±2.11 .015 
Chemokines 
IL-8 8.54±0.96 6.81±1.16 .050 
IP-10 1883±470 1469±394 .638 
MCP-1 12.0±1.66 11.4±1.03 .433 
MIP-1α 3.83±0.76 3.47±0.73 .374 
MIP-1β 20.6±2.32 20.8±2.23 .158 




Using paired analysis, it was demonstrated that MCNS patients in relapse have 
a significantly higher plasma level of IL-6, IL-15, IL-4, IL-5, IL-13, IL-17, IL-
10, and VEGF compared to remission (p<0.05). 
 Further analysis of plasma cytokine profile results from both unpaired 
and paired analysis demonstrated the common cytokines that were consistently 
significantly different between MCNS patients in relapse and 
remission/controls were IL-5, IL-6, IL-10, and IL-13, majority of which are 
Th2-related cytokines. 
  
3.3.3 Monocyte phenotype  
Cross-sectional unpaired analysis comparing proportion of ‘resident’ 
(CD14+CD16+), ‘inflammatory’ (CD14+CD16-) and CD14-CD16+ 
monocytes were performed in controls, MCNS patients in relapse, MCNS 
patients in remission and FSGS patients in relapse. The results are as 
summarized in Table 6.  
 
Table 6: Summary of proportion of various monocyte subsets in controls, FSGS patients 



























*Denotes significantly different (p=0.016) proportion of CD14-CD16+ monocytes between 
MCNS patients in relapse and controls. 
 
The comparison of proportion of ‘resident’ (CD14+CD16+) and 
‘inflammatory’ (CD14+CD16-)  monocytes amongst the various groups as 
depicted above did not demonstrate any significant difference between i) 
MCNS patients in relapse and age-matched controls, ii) MCNS patients in 
remission and age-matched controls, iii) unpaired MCNS patients in relapse 
compared to MCNS patients in remission, iv) FSGS patients in relapse 
compared to MCNS patients in relapse and v) FSGS patients in relapse 
compared to age-matched controls (p>0.05). Analysis of the proportion of 
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CD14-CD16+ monocytes in the various groups demonstrated a significantly 
lower proportion of CD14-CD16+ monocytes in MCNS patients in relapse 
compared to controls (p=0.016) (Figure 6). There was no demonstrable 
significant difference in the proportion of CD14-CD16+ monocytes between i) 
FSGS patients in relapse and controls and ii) MCNS patients in remission and 
controls (p>0.05). The proportion of CD14-CD16+ monocytes was also not 
significantly different between i) unpaired MCNS patients in relapse 
compared to remission and ii) MCNS patients in relapse compared to FSGS 
patients in relapse. 
Figure 6: Significantly lower proportion of CD14-CD16+ monocytes in MCNS in relapse 
compared to controls.  
Graph showing percentage of CD14-CD16+ monocytes in controls, MCNS patients in relapse, 
MCNS patients in remission and FSGS patients in relapse. Bars represent the mean and SEM. 
 
 
Paired analysis of pediatric MCNS patients showed a significantly higher 
proportion of ‘resident’ (CD14+CD16+) monocytes in relapse compared to 
remission (8.12±2.95% vs 4.38±2.39%, p=0.026, respectively) (Figure 7 and 
Figure 8). The proportion of CD14-CD16+ monocytes was also noted to be 
significantly lower in MCNS patients in relapse compared to remission 
(1.00±0.29% vs 2.05±0.50%, p=0.041, respectively). There was also lower 
proportion of ‘inflammatory’ (CD14+CD16-) monocytes in MCNS patients in 
relapse compared to remission, though it did not reach statistical significance 
(86.7±2.46% vs 89.1±1.08%, p>0.05, respectively). There was also a 
decreased monocyte expression of CCR2 which is a pro-inflammatory 
chemokine receptor in MCNS patients in relapse compared to remission 
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(80.1±3.35% vs 85.1±2.25%, p=0.033, respectively) (Figure 9). Surface 
expression of CX3CR1 on monocytes, which is an anti-inflammatory 
chemokine receptor, was not significantly different between MCNS patients in 






Figure 7: Increased population of CD14+CD16+ monocytes in pediatric MCNS patients 
in relapse.  
Representative scatter plot showing the percentage of CD14+CD16+ (inflammatory) and 




Figure 8: Paired analysis of the monocyte population revealed higher proportion of 
‘resident’ (CD14+CD16+) monocytes in patients with relapse as compared to remission.  
Graph showing percentage of CD14+CD16+ in controls, MCNS patients in remission and 







Figure 9: Decreased monocyte expression of CCR2 in patients with relapse as compared 
to remission.  
Graph showing percentage of CCR2+ monocytes in controls, MCNS patients in remission and 
relapse (paired). Bars represent the mean and SEM.  
 
 
In order to ascertain if presence of increased ‘resident’ monocyte is a 
phenomenon observed in only MCNS patients in relapse or other forms of 
nephrotic relapse, the percentage of ‘resident’ monocytes were quantitated in 
FSGS patients in relapse compared to MCNS relapse and controls.  FSGS 
patients in relapse had a significantly lower percentage of ‘resident’ 
monocytes compared to MCNS patients in relapse and controls (2.99±0.59% 
vs 8.12±2.29% vs 5.09±0.57%, respectively, p<0.05) (Figure 10), thus 
suggesting that the phenomenon of increased ‘resident’ monocytes may be 





Figure 10: Decreased percentage of 'resident' (CD14+CD16+) monocytes in FSGS 
patients in relapse compared to MCNS patients in relapse and controls.  
Graph showing percentage of CD14+CD16+ in controls, MCNS patients in relapse and FSGS 
patients in relapse. Bars represent the mean and SEM. 
 
3.3.4 Monocyte intracellular cytokine level production  
Monocyte intracellular cytokine level production post-LPS stimulation was 
quantitated in monocytes isolated from MCNS patients in relapse and 
remission. Using paired sample analysis, monocyte production of IL-6 and 
TNF-α were noted to be significantly decreased in MCNS patients in relapse 
compared to remission (50.6±9.53% vs 76.9±4.20%, p=0.005 and 45.1±10.1% 
vs 79.4±3.95%, p=0.013, respectively) (Figure 11). Monocyte IL-10 
production was noted to be significantly elevated in MCNS patients in relapse 
compared to remission (72.3±19.2 pg/ml vs 44.7±21.0% pg/ml, p=0.041, 
respectively) (Figure 12). There was no significant difference in monocyte IL-
12 production in pediatric MCNS patients in relapse compared to remission 




Figure 11: Decreased monocyte production of IL-6 and TNF-α in MCNS patients in 
relapse compared to remission.  
Graph showing percentage of intracellular monocyte production of IL-6 and TNF-α in 
controls, MCNS patients in remission and relapse (paired). Bars represent the mean and SEM. 
 
 
Figure 12: Increased monocyte production of IL-10 in MCNS patients in relapse 
compared to remission.  
Graph showing percentage of intracellular monocyte production of IL-10 in controls, MCNS 






3.4 Discussion  
Studies attempting to elucidate the underlying pathogenesis of MCNS have 
suggested a Th2-cytokine bias.  
 Our group has previously demonstrated an upregulation of IL-13 in 
CD4+ and CD8+ T- cells in relapse of MCNS (Yap et al., 1999).  This was 
associated with increased intracytoplasmic IL-13 production by CD3+ cells, as 
well as downregulation of gene expression of the monocyte proinflammatory 
cytokines IL-8 and IL-12 (Lama et al., 2002).  These findings were further 
validated in our recently described model of IL-13 overexpression in the rat 
which resulted in podocyte injury with downregulation of nephrin, podocin 
and dystroglycan, inducing a minimal change-like nephropathy (Lai et al., 
2007).   
 In order to comprehensively understand the immunological basis of 
MCNS, multiplexed Luminex® Cytokine Human 27-Plex assay was performed 
to determine comprehensively, the cytokine profile of patients with MCNS in 
relapse compared to remission, and healthy. Cytokine profiles of pediatric 
patients with other forms of nephrotic syndrome (namely FSGS) was also 
performed in order to determine if the cytokine profile seen in MCNS is 
specific to the disease itself or is present in other forms of nephrotic syndrome. 
 In the unpaired analysis, it was demonstrated that MCNS patients in 
relapse have a significantly higher plasma level of IL-1β, IL-1RA, TNF-α, IL-
6, IL-2, IL-5, IL-9, IL-13, IL-10, PDGF-BB, IL-8 and a significantly lower 
plasma level of RANTES compared to age-matched controls (p<0.05). 
 IL-1β is part of a group of 11 cytokines belonging to the IL-1 family. 
The presence of elevated levels of IL-1 and IL-2 in MCNS patients in relapse 
compared to controls was previously reported by Saxena and co-workers 
(Saxena et al., 1993). These findings, however, were not replicated in studies 
by other groups (Suranyi et al., 1993, Bustos et al., 1994, Daniel et al., 1997, 
Yap et al., 1999). The trigger for MCNS commonly involves viral infections 
(MacDonald et al., 1986) and viral infections may give rise to elevated IL-1 
(Pirhonen et al., 1999) and IL-2 (Kristensen et al., 2002) plasma levels in a bid 
to combat the viral infection, hence possibly accounting for the elevated levels 
of these cytokines in MCNS patients in relapse compared to controls. 
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 Plasma TNF-α was also noted to be elevated in MCNS patients in 
relapse compared to controls. The finding was similar to that found by several 
other groups (Bustos et al., 1994, Suranyi et al., 1993, Lama et al., 2002). In a 
study by Ikezumi and co-workers, it was demonstrated that the addition of 
recombinant TNF-α to podocytes caused a decrease in podocin and nephrin 
expression via a TNF-α-JNK/p38-dependent mechanism (Ikezumi et al., 
2008).  
 Plasma IL-5 level was noted to be significantly higher in MCNS 
patients in relapse than controls, which is similar to the finding by Youn and 
co-workers (Youn et al., 2012). In addition, IL-5 is found in a gene cluster 
(Kelly & Locksley, 2000) regulated by GATA-3 (Takemoto et al., 2000). This 
is consistent with the finding of increased GATA-3 expression in MCNS 
patients in relapse compared to remission and healthy controls (Komatsuda et 
al., 2009). 
 IL-6 was previously reported to be elevated in nephrotic patients in 
relapse compared to remission and age-matched controls (Rizk et al., 2005), 
similar to what we found in this study. In another study by Jafar and co-
workers, it was noted that a polymorphism in IL-6 [IL-6-G174C (G vs. C)] 
was associated with nephrotic syndrome compared to controls (Jafar et al., 
2011), further suggesting a plausible role of IL-6 in the pathogenesis of 
MCNS. 
 Plasma IL-8 level was noted to be increased in MCNS patients in 
relapse compared to controls, similar to findings by Garin and co-workers 
(Garin et al., 1994). The mechanism of IL-8 in the pathogenesis of proteinuria 
has been postulated to be mediated via a decrease in sulfation of the 
glomerular basement membrane (Garin et al., 1994). 
 IL-9, a Th2-associated cytokine (Goswami & Kaplan, 2009), is noted 
to be increased in MCNS patients compared to controls in our study. The 
finding is novel with no precedent studies. 
 Plasma IL-10 level was noted to be significantly higher in MCNS 
patients in relapse compared to controls. This is a novel finding and is in 
contrast to previous finding of decreased IL-10 in supernatants of cultured 
peripheral blood monocytes that were obtained from nephrotic patients 
compared to healthy controls (Matsumoto, 1995) and finding of similar IL-10 
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levels between nephrotic children in relapse compared to remission 
(Shimoyama et al., 2004). IL-10 is predominantly produced by monocytes and 
it is also well-characterized that IL-13 polarizes monocytes into M2a 
phenotype which leads to IL-10 production.  
 Plasma IL-13 level was also noted to be elevated in MCNS patients in 
relapse compared to remission and this was further reiterated in the paired 
analysis. The finding is in accordance with what our group has previously 
published demonstrating an upregulation of IL-13 in CD4+ and CD8+ T- cells 
in relapse of MCNS (Yap et al., 1999) and further illustrated the pathogenic 
role of IL-13 in our IL-13 overexpressed rat model (Lai et al., 2007).  
 The findings of increased IL-5 and IL-13 production during relapses in 
children with MCNS further support Th2 polarization in this disease. IL-13 is 
found in a gene cluster, regulated co-ordinately by GATA-3.  
Plasma IL-17 level was noted to be elevated in MCNS patients in 
relapse compared to remission during paired analysis. The finding was similar 
to that found by Liu and co-workers, who demonstrated IL-17 protein 
expression in the renal biopsy tissue of MCNS patients (Liu et al., 2011). In 
another study by Wang and co-workers, the expression of IL-17 was noted to 
be significantly higher in MCNS patients than in controls (Wang et al., 2013). 
Recombinant murine IL-17 was also shown to cause a decrease in the 
expression of podocalyxin as well as promoted apoptosis in podocytes in a 
dose- and time-dependent fashion (Wang et al., 2013). 
 As IL-13 has been defined as an important modulator of monocyte, we 
went on to characterize the monocytes in MCNS patients compared to controls 
and other forms of nephrotic syndrome, namely FSGS. 
 Surface phenotyping of monocytes demonstrated that MCNS patients 
have a higher percentage of ‘resident’ monocytes (CD14+CD16+) monocytes 
in keeping with the phenotype expected with IL-13-induced monocyte 
polarization (Scotton et al., 2005).  
Characterization of monocyte intracellular cytokine production also 
revealed an endotoxin anergy state i.e. monocyte intracellular production of 
IL-6 and TNF-α were noted to be significantly decreased in MCNS patients in 
relapse compared to remission post-LPS stimulation. This may account for the 
predisposition of MCNS patients in relapse towards bacterial infection, in 
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addition to other mechanisms such as defects in humoral immunity and a 
decrease in complement pathway proteins during relapse (Krensky et al., 
1982, Matsell & Wyatt, 1993, Patiroglu et al., 1998). This finding does not 
contrast with the earlier results of increased plasma TNF-α level in MCNS 
patients in relapse which is performed in a non-septic state.  
Monocyte IL-10 production was also noted to be significantly elevated 
in MCNS patients in relapse compared to remission and this correlates with 
the finding of increased ‘resident’ monocytes in MCNS patients in relapse as 
‘resident’ monocytes are known to be key producers of IL-10.  
Thus, in order to comprehensively understand the role of monocytes in 
MCNS, a high throughput strategy of using microarray analysis was utilized to 





DELINEATING THE MOLECULAR MECHANISMS OF 




In the previous chapter, we have demonstrated that patients with MCNS 
exhibited an unique cytokine profile, distinct from other forms of nephrotic 
syndrome, namely focal segmental glomerulosclerosis.  
Amongst the 27 cytokines studied, MCNS patients in relapse were 
noted to have significantly higher plasma levels of IL-1β, IL-1RA, TNF-α, IL-
6, IL-2, IL-5, IL-9, IL-13, IL-10, PDGF-BB, IL-8 in MCNS and a 
significantly lower plasma level of RANTES in MCNS patients in relapse 
compared to age-matched controls (p<0.05).  In paired MCNS patients, it was 
noted that these patients in relapse had significantly higher plasma levels of 
IL-6, IL-15, IL-4, IL-5, IL-13, IL-17, IL-10, and VEGF compared to paired 
patients in remission (p<0.05).  Cytokines noted to be commonly higher in 
MCNS patients in relapse compared to remission/controls were Th2-related 
cytokines (i.e. IL-5, IL-6, IL-10, and IL-13) and in particular IL-13 which we 
have shown to be upregulated in MCNS patients in relapse and overexpression 
of which resulted in a minimal change-like nephropathy in our IL-13 
overexpressed rat model. 
Although IL-13 shares many of its biologic activities with the Th2 
cytokine IL-4, including induction of B-cell class switch to IgE (Punnonen et 
al., 1993), it is also an important modulator of monocyte function (McKenzie 
et al., 1993, Zurawski & de Vries, 1994).  The anti-inflammatory effect of IL-
13 is indicated by its ability to suppress the production of pro-inflammatory 
cytokines TNF-α (Cosentino et al., 1995) and IL-8 in LPS-activated 
monocytes (Minty et al., 1997).  
In our previous chapter, we have also demonstrated a unique monocyte 
phenotype and monokine production profile in MCNS patients in relapse.  As 
monocytes and macrophages are an integral component of the innate immune 
system, providing important defence against bacterial infections, it may be 
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worthwhile to examine the role of monocytes in the increased susceptibility of 
MCNS patients to bacterial infections. 
 Hence, we proceeded further to characterize the gene signature of 
monocytes in MCNS patients to delineate its roles in MCNS pathogenesis and 
increased predisposition of MCNS patients to bacterial infections. 
 
4.2 Aim of chapter 
In this chapter, we employed global screening methods using microarray 
technology to characterize the differentially expressed genes in relapse, 
remission and healthy controls, so as to: 
1. Identify and characterize the molecular mechanisms of unstimulated 
monocytes in the pathogenesis of MCNS; and  
2. Identify and characterize the molecular mechanisms of LPS-stimulated 
monocytes in the pathogenesis of MCNS-related complication of 





4.3.1 Microarray data of differentially expressed genes of unstimulated 
monocytes from MCNS patients in relapse compared to remission and 
healthy controls 
In order to further elucidate the underlying molecular mechanisms of 
monocytes which may play a role in the pathogenesis of MCNS and its 
associated complications, microarray was performed on monocytes isolated 
from MCNS patients in relapse and compared to remission and healthy 
controls. Of the 24526 genes analyzed, the transcription profile of 
unstimulated monocytes from MCNS patients in relapse demonstrated a 
greater than 2-fold change in expression of 667 genes as compared to 
remission. These differentially expressed genes (DEGs) were hierarchically 
clustered into low (green) to high (red) expression level (Figure 13). Of the 
667 genes, 596 genes were up-regulated (maximum fold-change of 26.2) and 






Figure 13: Hierachical clustering of DEGs.  
Hierachical clustering of the genes that were differentially expressed in the unstimulated 
monocytes isolated from MCNS patients in relapse (RL) compared to remission (RM) and 
controls (C). Expression was indicated by a colour scale from low (green) to high (red).  
 
 
These differentially expressed genes (DEGs) were principally involved in a 
variety of responses including inflammatory response, immunological disease 




Figure 14: Biological function analysis of DEGs.  
These DEGs were principally involved in inflammatory and immune responses. 
 
 
MetacoreTM analysis performed revealed involvement of genes in IL-1 
signaling, regulation of actin cytoskeleton by RhoGTPases, Toll-interleukin 
receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF) and 
IFN-induction (IRF4, IRF7, IFI6, IFI27, IFI35, IFI44, SERPING1, OAS1, 
OAS2, OAS3, OASL, CXCL9, CXCL10, DDX58) (Figure 15) pathways, in 
MCNS patients in relapse compared to remission. Interestingly, IL1F9, a 
member of the IL-1 cytokine family and agonist of NF-κB was noted to be 
upregulated. IL-27, which is a known inducer of c-maf (Pot et al., 2009), was 
also noted to be 2.7 times upregulated. c-maf is a known crucial factor 





Figure 15: DEGs in unstimulated monocytes from patients with nephrotic syndrome.  
GO analysis showed upregulation of genes involved in TRIF pathway and IFN-induction. 
 
4.3.2 Validation of microarray data using quantitative real-time 
polymerase chain reaction on resting monocytes isolated from MCNS 
patients in relapse compared to remission.  
In order to validate the microarray results, five DEGs (involved in IL-1 
signaling and IFN-induction pathway) were selected from the list of DEGs and 
their expressions were analyzed using qRT-PCR in resting monocytes isolated 
from 7 patients with paired samples in relapse and remission. The DEGs, 
namely IL1R1, OAS2, CXCL9, CXCL10, IL1F9, were significantly 
upregulated during relapse compared to remission (p = 0.018, 0.018, 0.028, 
0.018 and 0.018, respectively) (Figure 16), in concordance with microarray 
results. 
Figure 16: Validation of microarray data of resting monocytes isolated from paired 
MCNS patients in relapse and remission using qRT-PCR.  
The DEGs, namely IL1R1, OAS2, CXCL9, CXCL10, IL1F9, were significantly upregulated 





4.3.3   Quantification of plasma IL-27 level  
As highlighted in the microarray results, gene expression of IL-27 was noted 
to be 2.7 times upregulated in MCNS patients in relapse compared to 
remission. As IL-27 is a known inducer of c-maf (Pot et al., 2009), which is a 
crucial factor in Th2 polarization (Valanciuté et al., 2004), plasma IL-27 
levels were measured in controls, paired MCNS patients in relapse and 
remission to validate the microarray results. It was noted that plasma IL-27 
levels were significantly higher in MCNS patients in relapse (1.54±0.16 
pg/ml) compared to remission (1.03±0.16) (p=0.008) and controls (0.85±0.12) 
(p=0.002) (Figure 17). 
 
Figure 17: Increased plasma level of IL-27 in patients with relapse as compared to 
remission and controls.  
Graph showing plasma concentration of IL-27 in MCNS patients with remission and relapse 
(paired). Bars represent the mean and SEM. 
 
 
4.3.3 Microarray data of differentially expressed genes of LPS-
stimulated monocytes from MCNS patients in relapse compared to 
remission and healthy controls 
In order to ascertain the role of monocytes in the predisposition towards 
bacterial infection in MCNS patients in relapse, microarray of LPS-stimulated 
monocytes isolated from MCNS patients in relapse was performed and 
compared to LPS-stimulated monocytes isolated from remission and healthy 
controls. It was demonstrated that genes normally up-regulated by LPS, were 
noted to be non-inducible or even down-regulated in monocytes isolated from 




Figure 18: Hierarchical clustering of LPS-inducible genes (CD & chemokines).  
Genes normally induced by LPS are non-inducible or even down-regulated in monocytes 






Figure 19: Hierarchical clustering of LPS-inducible genes (Interleukins).  
Genes normally induced by LPS are non-inducible or even down-regulated in monocytes 




Figure 20: Hierarchical clustering of LPS-inducible genes (TNF family).  
Genes normally induced by LPS are non-inducible or even down-regulated in monocytes 
isolated from MCNS patients in relapse. 
 
 
Genes usually responsive to LPS (CD86, IL-1, IL-6, TNF-α) were noted to be 





Figure 21: Refractory state of monocytes in MCNS patients.  
Following LPS stimulation, genes that are usually responsive to LPS (CD86, IL-1, IL-6, TNF-
α) were downregulated in patients with relapse as compared to remission, exhibiting a 
refractory state of monocytes. 
 
The above findings were similar to the earlier findings of decreased monocyte 




Despite extensive studies on the pathogenesis of MCNS, its exact 
pathogenesis remains an enigma.  
 Our group has previously demonstrated an upregulation of IL-13 in 
CD4+ and CD8+ T- cells in relapse of MCNS (Yap et al., 1999).  This was 
associated with increased intracytoplasmic IL-13 production by CD3+ cells 
(Yap et al., 1999). Our findings were further validated in our IL-13 
overexpressed rat model which demonstrated podocyte injury with 
downregulation of nephrin, podocin and dystroglycan, inducing a minimal 
change-like nephropathy (Lai et al., 2007).  As IL-13 has been defined as an 
important modulator of monocyte/macrophage function and several earlier 
studies have demonstrated a plausible role of monocytes in MCNS, we went 
on to elucidate the role of monocytes in the pathogenesis of MCNS and its 
associated complications via the high throughput method of microarray 
analysis in order to comprehensively identify the molecular mechanisms 
involved.  
 Microarray performed on unstimulated monocytes isolated from 
MCNS patients in relapse demonstrated an increase in activity of the IL-1 
signaling pathway. The finding was similar to that of up-regulation of IL-1 
system in IL-13-stimulated monocytes as shown by Scotton and co-workers 
(Scotton et al., 2005). Our finding thus is consistent with the presence of an 
IL-13 induced monocyte polarization state in monocytes isolated from MCNS 
patients in relapse. The plausible role of IL-13 in the pathogenesis of MCNS 
was further reinforced with the finding of increased plasma IL-13 level in 
MCNS patients in relapse compared to remission and controls.  
 Microarray analysis of unstimulated monocytes in MCNS patients in 
relapse also demonstrated an upregulation of IFN-inducible genes in the TRIF 
pathway, a MyD88-independent signaling pathway associated with toll-like 
receptor 3 (TLR3) which binds viral antigens and leads to a cascade of 
reactions leading ultimately to activation of the NF-κB pathway (Jiang et al., 
2004). The activation of the NF-κB pathway has been proposed as a possible 
mechanism in the pathogenesis of MCNS (Sahali et al., 2001, Grimbert et al., 
2003). Hence, that may account for the observation that relapses in MCNS 
patients are frequently triggered by viral infections. 
77 
 
 The upregulation of IL1F9 in unstimulated monocytes of MCNS 
patients in relapse compared to remission suggests a plausible role of IL1F9 in 
the pathogenesis of MCNS. The protein encoded by this gene is a member of 
the IL-1 cytokine family. The activity of this cytokine is mediated by IL-1 
receptor-like 2 (IL1RL2/IL1R-rp2). IL1F9 functions as an agonist of the NF-
κB system through the IL1RL2 (Tripodi et al., 2012). One of the proposed 
mechanisms of pathogenesis of MCNS is that of NF-κB activation (Grimbert 
et al., 2003). In a study by Das and co-workers, there were two NF-κB-
responsive elements on the IL-13 promoter, hence making this cytokine as a 
potential downstream target of NF-κB. NF-κB may also mediate IL-13 
production via GATA3, a transcription factor vital for Th2 differentiation (Das 
et al., 2001). These findings suggest a crucial role of IL-13 in the pathogenesis 
of MCNS.  
 Another interesting finding in our microarray data is the up-regulation 
of IL-27 in MCNS patients in relapse compared to remission. IL-27 is a known 
inducer of c-maf (Pot et al., 2009), which is a crucial factor in Th2 
polarization (Valanciuté et al., 2004). Additionally, c-maf has been shown to 
be highly induced in MCNS T-cells during relapse (Valanciuté et al., 2004). It 
is hence certainly plausible that IL-27 may be another crucial mediator in the 
pathogenesis of MCNS in humans. 
 Infection is one of the most common complications and remains a 
significant cause of morbidity and occasionally mortality in MCNS patients 
(Harris & Ismail, 1994). Some of the proposed mechanisms for susceptibility 
towards infection include defects in humoral immunity and a decrease in 
complement pathway proteins during relapse (Krensky et al., 1982, Matsell & 
Wyatt, 1993, Patiroglu et al., 1998). In order to elucidate the contributory role 
of monocytes in the predisposition towards bacterial infection, LPS-inducible 
genes in monocytes were examined following LPS stimulation. It was 
observed that genes usually responsive to LPS (CD86, IL-1, IL-6, TNF-α) 
were down-regulated instead of being upregulated in monocytes isolated from 
MCNS patients in relapse compared to remission. This was consistent with the 
earlier finding of decreased monocyte intracellular production of IL-6 and 
TNF-α. Our microarray data on LPS-stimulated monocytes in MCNS patients 
in relapse is consistent with the observation that the binding TLR4 with 
78 
 
endotoxin and activation of the TRIF pathway with consequent up-regulation 
of IFN-β played a role in endotoxin tolerance with decreased production of 
inflammatory cytokines like TNF-α (Biswas et al., 2007).  
As TNF-α and IL-6 also partake in the process of opsonisation, 
neutrophil mobilization and initiation of the adaptive immune response, a 
defective production of TNF-α and IL-6 may account for the increased 
susceptibility towards bacterial infection in these patients.   
 The above microarray findings suggest a crucial role of monocytes in 
the pathogenesis of MCNS and its associated complication of predisposition 





MONOCYTE AND CYTOKINE PROFILE IN IL-13 
OVEREXPRESSED RAT MODEL OF MCNS 
 
5.1  Introduction 
We have previously demonstrated that overexpression of IL-13 gene in the rat 
resulted in podocyte injury with downregulation of nephrin, podocin and 
dystroglycan and concurrent upregulation of B7-1 in the glomeruli, inducing a 
minimal change-like nephropathy (Lai et al., 2007).  As IL-13 is a known 
modulator of monocyte function, the effect of IL-13 on podocytes may be 
mediated via monocytes or directly upon podocytes. 
 Previous studies have demonstrated a plausible association between 
monocytes and MCNS (Nagata et al., 1981, Davin et al., 1983, Nathan et al., 
1980, Rosenthal, 1980, Tanaka et al., 1996, Garin & Boggs, 1987, Nassar et 
al., 1997, Samuelsson et al., 1987, Goldyne, 1984). Further in-depth study on 
the role of monocytes in the pathogenesis of MCNS and its associated 
complications hence may bring us a step closer to comprehensively understand 
the pathogenesis of this dreadful disease and enable the design of targeted 
therapy.  
 As highlighted previously, the heterogeneity of monocytes is defined 
by the surface expression of CD14 and CD16 as well as differential expression 
of chemokine receptors. In humans, there are three main monocyte subsets, 
namely, ‘inflammatory’ (CD14+CD16-), ‘resident’ (CD14+CD16+) and 
nonclassical (CD14-CD16+) monocytes. Similarly in rats, monocyte 
heterogeneity was determined by the differential expression of CD43: CD43hi 
or CD43+ and CD43low or CD43- monocytes. These 2 populations can be 
further characterized with the former expressing lower amounts of CCR2 and 
CD62L, and higher levels of CX3CR1 (Taylor & Gordon, 2003; Mantovani et 
al., 2004). Hence, with reference to the human subsets, the CD43+ monocytes 
are analogous to the CD14+CD16+ cells while the CD43- monocytes have a 
similar profile as the CD14+CD16– subset.  
 In order to further define the role of monocyte in MCNS and to 
ascertain if the action of IL-13 on podocytes is directly on podocytes or 
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indirectly mediated via monocytes/macrophages, the determination of the 
macrophage profile in our IL-13-overexpressed rat model was performed.  
 
5.2  Aim of chapter 
The aim of this chapter is to validate the findings from the human MCNS 
patient monocyte studies using our previously described IL-13 overexpression 
rat model of MCNS by: 
1. Analysis of gene expression profile by real-time PCR to define the 
polarization state of the macrophages in the IL-13 overexpression rat 
model.  Quantitative Real-time PCR is carried out for the following 
genes, IL-1β, IL-12 β, TNF-α, IL-10, Arginase, CD62L, CD80, CCL3, 
CCR3, IL-10, CD43, and CX3CR1 using SYBR Green I;  
2. Phenotyping/cytokine profiling of macrophages isolated from the spleen of 
the IL-13 overexpression rat model using flow cytometry. The following 









5.3.1 Biochemical profile of IL-13 overexpressed rats  
Serum IL-13 levels were significantly higher in IL-13 overexpressed rats 
(n=10) than control rats (n=5) (446±117 pg/ml vs. 20.4±3.91 pg/ml, p=0.002) 
(Figure 22). The IL-13-overexpressed rats also showed a minimal change-like 
nephropathy with features of nephrotic syndrome, namely increased 
proteinuria (2899±2020 µg/24hr vs. 223±39.5 µg/24hr, p=0.01), and 
hypercholesterolemia (2.92±0.43 mmol/L vs. 1.89±0.07mmol/L, p=0.027) 
(Figure 22). Serum albumin levels were slightly lower in IL-13 overexpressed 
rats (38.0±2.30 g/L vs 39.3±3.80 g/L) but that did not achieve statistical 
significance (Appendix 12). Serum albumin levels were not significantly low 
in IL-13 overexpressed rats as the rats were sacrificed early after the 
development of nephrotic-range proteinuria as older transfected rats developed 
infections (e.g. helminthic infections) which would affect the subsequent 
immunological/cytokine profile results. 
 
Figure 22: Biochemistry profile of rats.  
Overexpression of IL-13 in rats results in significant proteinuria and hypercholesterolemia. 
 
5.3.2 Quantitative analysis of macrophage gene expression level 
To determine the effects of IL-13 on macrophage gene transcriptional activity, 
total RNA was extracted from splenic macrophages and analysed using real-
time PCR. In this study, 5 control rats and 10 IL-13-overexpressed rats were 
included, and the splenic macrophages were cultured overnight with or 
without LPS stimulation. The macrophage gene expression levels were 
standardized against the housekeeping gene, GAPDH, and the results are as 




Table 7: Effects of IL-13 on macrophage gene expression.  
Gene expression levels were analyzed in splenic macrophages with and without LPS stimulation.  Results are normalised against GAPDH expression and presented as mean 
± SEM (Controls, n = 5; IL-13-overexpressed rats, n=10). 
Gene Without LPS stimulation With overnight LPS stimulation 
Control IL-13-Transfected P-value Control IL-13-Transfected P-value 
Pro-inflammatory cytokines                
IL-1β 99.6 ± 48.3 27.3 ± 6.90 0.270 175 ± 93.5 64.3 ± 14.0 0.713 
IL-12β 0.008 ± 0.004 0.004 ± 0.001 0.462 0.049 ± 0.025 0.016 ± 0.003 0.806 
TNFα 0.174 ± 0.056 0.075 ± 0.012 0.111 0.455 ± 0.225 0.090 ± 0.021 0.014 
Anti-inflammatory cytokines                
IL-10 0.090 ± 0.015 0.064 ± 0.014 0.270 0.516 ± 0.195 0.148 ± 0.024 0.066 
Arginase 0.027 ± 0.012 0.011 ± 0.003 0.142 0.081 ± 0.029 0.159 ± 0.049 0.327 
Pro-inflammatory surface markers               
CD62L 0.707 ± 0.190 0.386 ± 0.150 0.050 0.404 ± 0.160 0.115 ± 0.026 0.050 
CD80 0.132 ± 0.048 0.039 ± 0.008 0.007 0.201 ± 0.085 0.054 ± 0.008 0.037 
CCL3 2.157 ± 0.745 0.852 ± 0.248 0.111 5.84 ± 2.54 2.467 ± 0.793 0.111 
CCR2 0.060 ± 0.004 0.051 ± 0.005 0.142 0.029 ± 0.005 0.030 ± 0.015 0.142 
Anti-inflammatory surface markers               
CD163 0.015 ± 0.007 0.314 ± 0.238 0.903 0.007 ± 0.001 0.936 ± 0.624 0.066 
CX3CR1 1.478 ± 0.492 0.504 ± 0.127 0.050 0.134 ± 0.048 0.034 ± 0.006 0.005 
CD43 0.009 ± 0.002 0.027 ± 0.007 0.027 0.006 ± 0.001 0.004 ± 0.001 0.178 
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The surface markers were analyzed without LPS stimulation. All the pro-
inflammatory surface markers showed a general down-regulation trend in IL-13-
transfected rats as compared to the control, although significant decrease was only 
detected in CD80 (3.3-fold reduction (p=0.007) (Figure 23)). CD62L was also 
noted to be decreased in IL-13-transfected rats albeit it did not reach statistical 
significance (p=0.05) (Figure 23). All the anti-inflammatory surface markers, 
except CX3CR1, were up-regulated in IL-13-transfected rats as compared to 
control rats. CD43 was noted to be significantly increased in IL-13 transfected 
rats compared to control rats (Figure 23). Pro-inflammatory cytokines also 
showed a general down-regulation trend in IL-13-transfected rats though it did not 
reach statistical significance. Anti-inflammatory cytokines showed an up-
regulation trend in IL-13 transfected rats but it did not reach statistical 
significance. 
 
Figure 23: Gene expression of rat macrophage surface markers.  
Splenic macrophages were cultured without LPS, and comparison was done between controls and 
IL-13 treated rats. Gene expression levels are normalised against GAPDH expression. Results are 





Post-LPS stimulation, the inflammatory response in macrophages isolated from 
IL-13-transfected rats seemed to be attenuated as evidenced by decreased 
expression of pro-inflammatory cytokines (IL-1β, IL-12β, TNF-α), especially 
TNF-α, which is significantly decreased (p=0.014) as compared to control rats 
(Figure 24). 
 
Figure 24: Gene expression of rat macrophage TNF-α.  
Splenic macrophages were stimulated overnight with LPS, and comparison was done between 
controls and IL-13 transfected rats. Gene expression levels are normalised against GAPDH 





5.3.3 Flow cytometric analysis for definition of polarization state of splenic 
macrophages in IL-13 overexpressed rats 
Flow cytometric analysis of surface markers in splenic macrophages (‘pro-
inflammatory’ – CD43- or CD80+, ‘resident’- CD43+ or CD80-) was performed 
in order to define the polarization state of splenic macrophages in IL-13-
overexpressed rats. Cells were gated on CD11b+ population and mean 
fluorescence intensity of surface markers were determined in both surface and IL-
13  overexpressed rats. In the IL-13 overexpressed rat model, it was noted that the 
percentage of CD43+ splenic macrophages was higher as compared to control rats 
(56.7±3.08% vs 35.3±3.38%, respectively, p=0.003) (Figure 25). In the IL-13 
overexpressed rat model, the percentage of CD80+ splenic macrophages was 
lower as compared to control rats (25.5±4.52% vs 29.9±4.13%, respectively, 
p=0.220) (Figure 25). The above finding points towards a predominance of 
‘resident’ macrophages in IL-13 overexpressed rats, which is similar to findings in 
the human study (Figure 25).  
 










5.3.4. Splenic macrophage intracellular cytokine production following LPS 
stimulation 
Flow cytometry was used to assess the splenic macrophage intracellular cytokine 
production following LPS stimulation. Both TNF-α (pro-inflammatory) and IL-10 
(anti-inflammatory) were evaluated to determine response towards LPS 
stimulation. Flow cytometry performed demonstrated significantly decreased 
TNF-α in IL-13 overexpressed rats compared to control rats (24.8±3.74% vs 
77.2±4.35, respectively, p=0.020) (Figure 26). IL-10 was seemingly increased in 
IL-13 overexpressed rats compared to control rats, though it did not reach 
statistical significance. (13.6±3.53% vs 10.9±9.45, p=0.111) (Figure 26). 
 







Heterogeneity is one of the hallmarks of the monocyte/macrophage system. 
Differential expression of antigenic markers, production of different 
cytokines/chemokines and hence the differential physiological activities, allowed 
monocytes to be categorised into ‘inflammatory’, ‘resident’ or nonclassical 
monocytes (Mantovani et al., 2004, van de Veerdonk & Netea, 2010, Ziegler-
Heitbrock et al., 2010). In rats, inflammatory monocytes express lower levels of 
CD43 compared to resident monocytes. Upon stimulation with cytokines and 
microbial products, activated monocytes express specialized and polarized 
functional properties (Mosser, 2003). The polarized macrophages have been 
broadly categorized into M1 and M2 macrophages. The M1 phenotype has a well-
defined role in mediating pro-inflammatory responses upon activation. On the 
other hand, the M2 phenotype has been generalized to include anti-inflammatory 
and other responses which are not included in the M1 phenotype (Mantovani et 
al., 2004). The M2 phenotype is further subdivided into M2a, M2b and M2c 
according to the activation stimuli and responses (Mantovani et al., 2004). 
Differential gene expression analysis suggests that the subsets of 
monocytes in IL-13 over-expression rats had a bias towards the ‘resident’ 
phenotype with up-regulation of the anti-inflammatory surface markers (except 
for CX3CR1), especially CD43 which was statistically significantly up-regulated 
in IL-13 overexpressed rats compared to control rats. In addition, there was also 
down-regulation of pro-inflammatory surface markers, especially CD80 which 
was statistically significantly down-regulated in IL-13 overexpressed rats 
compared to control rats. CD62L was also 1.8-fold down-regulated in IL-13 
overexpressed rats compared to control rats though it was of borderline 
significance, likely related to the small numbers.   
CD80 is a co-stimulatory molecule which is recognized by the CD28 
receptor on T-cells during antigen presentation (Kuchroo et al., 1995). This 
interaction is required for the induction of a Th1-type response from activated T-
cells, and the absence of CD80 during antigen presentation results in T-cell 
apoptosis (Sabzevari et al., 2001). Hence, the down-regulation of CD80 at the 
transcription level implies that one of the anti-inflammatory functions of M2a 
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polarization is to inhibit activation of inflammatory T-cells. This is supported by 
the finding that in co-culture, alternatively-activated macrophages induced 
minimal T-cell activation (Edwards et al., 2006). However, the significant down-
regulation of CD80 gene expression in our model was not reflected at the protein 
level, and this might due to post-transcriptional modification, which requires 
further study. 
Similarly, CD62L, or L-selectin, is an adhesion molecule which is 
expressed broadly on the surface of leukocytes (Rosen, 2004). Its ability to form 
rolling interactions with the endothelium to promote extravasation highlights its 
primary involvement in inflammatory trafficking (Tedder et al., 1995). Hence, the 
down-regulation of the gene would decrease the infiltrative capacity which is 
typical of inflammatory monocytes. This was demonstrated by the decreased 
recruitment of macrophages following experimentally induced inflammation in L-
selectin deficient mice (Ricardo et al., 2008).  
Contrary to the resident monocyte subset expression profile demonstrated 
above, gene expression of the chemokine receptor CX3CR1, which has been 
associated with the non-inflammatory subset, was shown to be significantly 
down-regulated in the IL-13 overexpression rats compared to controls. 
Interestingly, inhibition of this receptor function has been reported to reduce 
macrophage accumulation and inflammatory lesion development (Furuichi et al., 
2006). This phenotype therefore is consistent with the anti-inflammatory 
histopathological picture in MCNS. Fractalkine, the ligand for CX3CR1, can exist 
in either soluble or membrane-bound forms. The former serves as a chemotactic 
agent, while the latter can form adhesions with leukocytes expressing the 
CX3CR1 chemokine receptor to facilitate extravasation (Truman et al., 2008). 
Hence, similar to CD62L, down regulation of CX3CR1 could result in less 
leukocyte infiltration and thus account for the absence of mononuclear infiltration 
in MCNS.  
Another interesting finding in the monocytes isolated from IL-13 
transfected rats is the attenuated inflammatory response post-LPS stimulation as 
evidenced by the presence of general down-regulation of pro-inflammatory 
surface markers and pro-inflammatory cytokines. This was further supported by 
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the finding of decreased intracellular TNF-α production post-LPS stimulation. 
This finding is similar to that found in monocytes isolated from patients with 
MCNS in relapse. 
TNF-α is one of the inflammatory cytokines that mediate many of the 
immunopathological features of LPS-induced shock (Dinarello, 1997). They are 
secreted within the first 30–90 minutes after exposure to LPS with subsequent 
activation of a second level of inflammatory cascades including cytokines, lipid 
mediators and reactive oxygen species, as well as upregulating cell adhesion 
molecules resulting in the initiation of inflammatory cell migration into tissues. 
This ‘endotoxin tolerance’ exhibited by the IL-13 overexpressed rats (and similar 
to the finding in MCNS patients in relapse) may lead to an increased 
susceptibility to bacterial sepsis, in addition to other factors including defects in 
humoral immunity and a decrease in complement pathway proteins during relapse 






CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1  Conclusion 
Cytokine profiling of MCNS patients in relapse compared to remission and 
controls demonstrated a Th2-cytokine bias (IL-5, IL-13). This was consistent with 
our previously published findings of increased IL-13 expression in CD4+ and 
CD8+ cells of MCNS patients in relapse, compared to remission and controls 
(Yap et al., 1999). The involvement of IL-13 as a key mediator in the 
pathogenesis was further reinforced in our IL-13 overexpressed rat model 
whereby we demonstrated down-regulation of nephrin, podocin and dystroglycan 
and concurrent upregulation of B7-1 in the glomeruli of these rats, resulting in a 
minimal change-like nephropathy (Lai et al., 2007). As IL-13 is a known 
modulator of monocyte polarization and function and the multiple associations of 
monocytes with MCNS (Nagata et al., 1981, Davin et al., 1983, Nathan et al., 
1980, Rosenthal, 1980, Tanaka et al., 1996, Garin & Boggs, 1987, Nassar et al., 
1997, Samuelsson et al., 1987, Goldyne, 1984), we went on to characterize the 
monocyte profile in MCNS patients. 
In this study, we have defined the monocyte phenotype in MCNS patients 
in relapse compared to remission and controls. MCNS patients in relapse 
seemingly have a higher proportion of ‘resident’ monocytes compared to 
remission and control, though it did not achieve statistical significance.  The 
difference in the proportion of ‘resident’ monocytes, however, was more evident 
and statistically significant during paired analysis of MCNS patients in relapse 
compared to remission. This was accompanied by a relative decrease in monocyte 
expression of the pro-inflammatory chemokine receptor, CCR2 in MCNS patients 
in relapse compared to remission. There was no corresponding statistical 
significance difference in the anti-inflammatory chemokine receptor, CX3CR1, 
which maybe secondary to its expression in both ‘resident’ and ‘non-resident’ 
(including ‘inflammatory’ monocytes). The phenotype is in keeping with an IL-
13-induced polarization state. The result is also in accordance with the 
demonstration of presence of increased plasma IL-13 levels in MCNS patients. 
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Monocyte intracellular cytokine production post-LPS stimulation also 
showed an interesting picture of ‘endotoxin tolerance’, with decreased production 
of pro-inflammatory cytokines, in contrast to what is anticipated post-LPS 
stimulation. 
Gene expression profiling via microarray of unstimulated monocytes 
isolated from MCNS patients in relapse demonstrated an increased expression of 
IL-1 signaling pathway which is accordance with a monocyte polarization state 
induced by IL-13 (Scotton et al., 2005). The up-regulation of the components in 
both the TRIF and IFN-induction pathway, both pathways of which are 
commonly up-regulated in viral infections (Jiang et al., 2004) is not unanticipated 
as viral infections are common triggers for relapse in these patients. Microarray 
analysis of the unstimulated monocytes also revealed an up-regulation of IL1F9 
and IL-27.  
IL1F9 is a known agonist of NF- κB activation through the orphan IL-1-
receptor-related protein 2. NF-κB plays a key role in the regulation of cytokine 
expression (Siebenlist et al., 1994). The human NF-κB/Rel family consists of five 
members, i.e., NF-κB1 (p50), NF-κB2 (p52), Re1A (p65), cRel, and RelB, which 
form various homo- and heterodimers. Their activity is regulated by IκB proteins 
(IκBα, IκBβ, and Bcl-3) (Siebenlist et al., 1994). IκBα and IκBβ interact with 
RelA (p65), whereas Bcl-3 binds p50 homodimers. NF-κB, which is primarily 
composed of p50 and p65, is inactivated through reversible association with IκB 
proteins (Siebenlist et al., 1994, Lain de Lera et al., 1999). After activation, the 
IκB kinase complex phosphorylates cytosolic IκBα (Siebenlist et al., 1994). Free 
NF-κB complexes subsequently translocates to the nucleus, where they regulate 
NF-κB-dependent gene expression (Siebenlist et al., 1994). NF-κB activity has 
been shown to be increased in MCNS patients in relapse (Sahali et al., 2001). The 
up-regulation of NF-κB activity maybe one of the mediating mechanisms via 
which monocytes contribute to the pathogenesis of MCNS.  
IL-27, a member of the IL-12/IL-23 heterodimeric family of cytokines 
produced by antigen-presenting cells, is composed of two chains, IL-27p28 and 
EBV-induced gene 3 (Stumhofer & Hunter, 2008). IL-27 is also a known inducer 
of the transcription factor, c-Maf (Pot et al., 2009) which in turn is a Th2-
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transcription activator (Ho et al., 1998). In our study, IL-27 was noted to be up-
regulated in unstimulated monocytes isolated from MCNS patients in relapse 
compared to remission and this was accompanied by corresponding higher plasma 
IL-27 levels in MCNS patients in relapse. As MCNS has been proposed to be a 
Th2 cytokine-mediated disease, the findings of increased IL-27 expression and 
plasma IL-27 levels may suggest IL-27 as another candidate mediator in the 
pathogenesis of MCNS. 
Microarray analysis of LPS-stimulated monocytes also demonstrated an 
endotoxin anergic picture with genes normally induced by LPS, noted to be non-
inducible or even down-regulated in monocytes isolated from MCNS patients in 
relapse. This finding was similar to the earlier finding of decreased monocyte 
intracellular pro-inflammatory cytokine production post-LPS stimulation.  
Our findings of a ‘resident’ monocyte phenotype and an endotoxin-
tolerant profile in MCNS patients in relapse, was further validated in our IL-13 
overexpressed rat model of MCNS, which showed also a ‘resident’ monocyte 
phenotype and an endotoxin-tolerant profile. The ‘resident’ monocyte phenotype 
in our rat model of minimal change-like nephropathy was characterized by 
significant downregulation in splenic macrophage gene expression of the pro-
inflammatory markers, CD80 and CD62L, as well as significant increase in gene 
and protein expression of the anti-inflammatory marker, CD43. Following LPS 
stimulation, gene and protein expression of TNF-α were also significantly 
reduced, which is consistent with the endotoxin-tolerant profile observed in our 
population of children with MCNS in relapse. 
In conclusion, our study demonstrated a ‘resident’ monocyte phenotype in 
MCNS patients in relapse, possibly induced by IL-13, and this was further 
validated in the IL-13 overexpressed rat model. The endotoxin tolerant profile 
exhibited by these monocytes may possibly account for the increased 
susceptibility towards bacterial infections in MCNS patients in relapse. The 
results of our study on monocytes also suggest monocytes as a possible 
contributor in the pathogenesis of MCNS via secretion of cytokines such as IL1F9 
and IL-27, but further mechanistic studies are needed to validate their roles in the 
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Figure 27: Schematic drawing of proposed role of monocytes in MCNS.  
Monocytes assume the ‘resident’ phenotype in MCNS patients in relapse and may be 
consequent to cytokines like IL-13. The ‘resident’ monocyte exhibits an ‘endotoxin 
tolerant’ state which predisposes MCNS patients in relapse towards bacterial infections. 
Monocyte may also contribute to the pathogenesis of MCNS via secretion of cytokines like 
IL1F9 and IL-27, which may act directly and independently, or synergistically with IL-13 









6.2  Future directions 
In this study, we have successfully characterized the monocyte profile, in terms of 
phenotype, intracellular cytokine production and genetic signature, in MCNS 
patients in relapse compared to remission. Our findings were further validated in 
the IL-13 overexpressed rat model. The next step to adopt will involve the 
performance of mechanistic studies on the role of monocytes in the pathogenesis 
of MCNS and its associated complications, including predisposition towards 
bacterial infections and also to investigate the role of some of the proposed 
cytokines (i.e. IL1F9 and IL-27) in the pathogenesis of MCNS via in-vitro 
podocyte culture systems. This will certainly enhance the understanding of the 
mechanistic role of monocytes in the pathogenesis of MCNS and bring us a step 
closer towards designing a targeted therapy for the treatment of MCNS, hence 
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Appendix 1: Protocol for plasma cytokine/chemokine profile by multiplex 
suspension bead array system (Bio-Plex® Precision Pro™ assays) 
 
Samples and standards preparation: 
Bring all buffers to room temperature. 
For samples stored at -80ºC, thaw the samples at room temperature. 
Dilute the plasma with sample diluent provided; dilute the culture supernatant 
samples with culture medium. 
To reconstitute standards, gently tap the glass vial containing the lyophilized 
cytokine standard on a solid surface to ensure the pellet is at the bottom. 
Reconstitute 1 vial of lyophilized standard with 500µl of the standard diluent 
(when running serum or plasma samples) or culture medium (when running 
culture supernatant samples). 
Gently vortex 1–3s and incubate on ice for 30 min. Be consistent with the 
incubation time for optimal assay performance. 
Label a set of 1.5mL microcentrifuge tubes as shown in the diagram. Pipet the 




After making each dilution, vortex gently and change the pipet tip after every 
transfer. Keep the standards on ice until ready for use. Standards should be used 
immediately and should not be frozen for future use. 
 
Assay: 
Assay Key – The following terms are repeated throughout the assay procedure. 
Refer to these detailed instructions when wash, incubate, and vacuum-filter are 
shown in bold. 
 
Equilibrate the diluted standards and samples at room temperature for 20 min 
prior to use. 
Prewet and block the desired number of wells in a 96-well filter plate with 100µl 
of assay buffer and vacuum-filter. 
Vortex the 1X coupled magnetic beads for 15–20s at medium speed. Add 50µl to 
each well and immediately vacuum-filter. 
Wash twice. 
Gently vortex the diluted standards and samples for 1–3s. Add 50µl of standard or 
sample to each well, changing the pipet tip after every volume transfer. Incubate 
at room temperature for 30 min. 
While the samples are incubating, prepare 1X detection antibody. 
After incubating the samples, slowly remove and discard the sealing tape, then 
vacuum-filter.  
Wash 3 times. 
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Vortex the 1X detection antibodies gently and add 25µl to each well. Incubate for 
30 min. 
While incubating, prepare 1X streptavidin-PE. 
After the detection antibody incubation, slowly remove and discard the sealing 
tape, then vacuum-filter. 
Wash 3 times. 
Vortex the 1X streptavidin-PE vigorously and add 50µl to each well. Incubate for 
10 min. 
After the streptavidin-PE incubation, slowly remove and discard the sealing tape, 
then vacuum-filter. 
Wash 3 times. 
Add 125µl of assay buffer to each well. Incubate for 30s to resuspend the beads.  
 
Data acquisition: 
Samples are acquired using xMAP system with Bio-Plex Manager™ version 4 or 
higher. Turn on the reader and microplate platform. Allow the system to warm up 
for 30 min. 
Calibrate using Bio-plex® calibration beads and low RP1 target value. 
Create protocol and plate format according to the run. 
Shake the assay plate at 1,100 rpm for 30s immediately before acquiring data. 
Change the data acquisition for 50 beads per region, confirm the bead map is set 




Data is analysed using Bio-Plex Manager™ version 4 or higher. Standard curves 
are generated using weighted 5 parameter logistic regression. Ensure the 
standards fall within 70-130% recovery range.  
 
Reagents 
Ready to use: 




1X coupled magnetic beads: 
Quick-spin the 10X coupled magnetic beads. Carefully open the cap and gently 
resuspend the coupled beads with a pipet before removing desired volume. 
Prepare a sufficient volume of 1X coupled beads in assay buffer. Each well 
requires 5µl of 10X coupled beads adjusted to a final volume of 50µl with assay 
buffer.  
 
1X detection antibodies: 
Vortex the 10X detection antibody for 15-20s at medium speed. Perform a 30s 
spin to collect the entire volume at the bottom of the vial. Prepare a sufficient 
volume of 1X detection antibodies using detection antibody diluent. Each well 
requires 2.5µl of 10X detection antibodies adjusted to a final volume of 25µl with 
detection antibody diluent. 
 
1X streptavidin-PE: 
Vortex the 100X streptavidin-PE for 15-20s at medium speed. Perform a 30s spin 
to collect the entire volume at the bottom of the vial. Prepare a sufficient volume 
of 1X streptavidin-PE using assay buffer. Each well requires 0.5µl of 100X 




Appendix 2: Protocol for PBMC isolation 
 
Distribute 3mL of Lymphoprep™ in a 15mL Leucosep™ tube (Greiner Bio-One, 
Monroe, NC, United States). 
Centrifuge at 800g for 1min at room temperature to transfer the solution below 
the filter. 
Add 3mL of blood followed by 3ml of RPMI. 
Mix gently by slowly inverting the tube once. 
Centrifuge the tube for 15min at 800g for 15min at room temperature with lowest 
deceleration. 
After centrifugation, the sequence of layers occurs as follow (top to bottom): 
plasma, enriched cell fraction/PBMCs, Lymphoprep™, filter membrane, 
Lymphoprep™, pellet (red blood cells and granulocytes). 
Gently remove the plasma above the ring of PBMCs (white ring). 
Harvest the PBMCs by pouring the supernatant above the filter membrane into 
another 15mL Falcon tube. 
Top up to 10mL with RPMI and centrifuge the tube at 1500rpm for 5min at room 
temperature. 
Repeat the washing step in 9. 




Appendix 3: RNA cleanup using RNeasy® minElute Cleanup kit (RNeasy® 
MinElute Cleanup Handbook 10/2010) 
 
Mix the following in a microcentrifuge tube: 
≤87.5 µl RNA solution 
10 µl Buffer RDD 
2.5 µl DNase I stock solution 
Make the volume up to 100 µl with RNase-free water.  
Incubate at room temperature for 10mins.  
Add 350µl Buffer RLT, and mix well. 
Add 250µl absolute ethanol to the mixture and mix well by pipetting.  
Transfer all the sample to an RNeasy MinElute spin column placed in a 2 ml 
collection tube supplied. Close the lid, and centrifuge for 15s at 13,000rpm. 
Discard the flow-through.  
Place the RNeasy MinElute spin column in a new 2 ml collection tube. Add 500 
µl Buffer RPE to the spin column. Close the lid gently, and centrifuge for 15s at 
13,000rpm to wash the spin column membrane. Discard the flow-through. 
Add 500µl of 80% ethanol to the RNeasy MinElute spin column. Close the lid, 
and centrifuge for 2mins at 13,000rpm. Discard the flow-through. 
Place the RNeasy MinElute spin column in a new 2ml collection tube. Open the 
lid of the spin column, and centrifuge at 13,000rpm for 5mins. Discard the flow-
through and collection tube. 
Place the RNeasy MinElute spin column in a new 1.5ml collection tube. Add 14µl 
of RNase-free water directly to the center of the spin column membrane. Close 




Add 10 µl β-ME per 1 ml Buffer RLT. 
 
DNase I stock solution: 
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Prepare DNase I stock solution before using the RNase-Free DNase Set for the 
first time. Dissolve the lyophilized DNase I (1500 Kunitz units) by injecting 
550µl of the RNase free water provided using RNase-free needle and syringe. Mix 
gently by inverting the vial. Do not vortex. Aliquot the stock solution into single-








Preheat the oven (with rocking platform) to 58°C. 
 
Mix with Hyb Reagents: 
Add up to 5µl of RNase free water to 750ng cRNA, and mix. 
Incubate at room temperature for 10 minutes to resuspend cRNA. 
Place the HYB and HCB bottles in the 58°C oven for 10 minutes to dissolve any 
salt precipitation. Cool to room temperature and mix thoroughly before use. 
Add 10µl of HYB to each cRNA sample. 
 
Set up Hybridization: 
Place Illumina Hyb Chamber Gaskets into BeadChip Hyb Chamber. 
Dispense 200µl of HCB into each of the two humidifying buffer reservoirs in 
each Hyb Chamber. Only add buffer to chambers that will be used. 
Seal Hyb Chamber with lid and keep on bench at room temperature until ready to 
load BeadChips into Hyb Chamber. 
Remove all BeadChips from their packages. (3 fingers at the notches to release) 
Holding BeadChip by coverseal tab with tweezers using powder-free gloved 
hands, slide BeadChip into Hyb Chamber Insert such that the barcode lines up 
with barcode symbol on the Insert. 
Preheat the assay sample at 65°C for 5 minutes. 
Briefly vortex, then briefly centrifuge to collect the liquid in the bottom of the 
tube. Allow sample to cool to room temperature before using. Pipet sample 
immediately after cooling to room temperature. 
Dispense 15µl of assay sample onto the large sample port of each array, ensuring 
pipet tip does not touch array. 
Load Hyb Chamber Inserts containing BeadChips into the Hyb Chamber with 
rocker speed at 5. 
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Seal lid onto the Hyb Chamber by applying the back of the lid first and then 
bringing it down to the front to avoid dislodging the Hyb Chamber Insert(s). 
Incubate for 18.5 hours at 58°C. 
 
Prepare for High-Temp Wash & Overnight Incubation: 
Prepare 1X High-Temp Wash buffer by adding 50ml of 10X stock to 450ml of 
RNAse free water. 
Place waterbath insert into heat block, and add 500ml of 1X High-Temp Wash 
buffer. 




The next day, prepare Wash E1BC solution by adding 3ml of E1BC buffer to 1L 
of RNase free water. 
Pre-warm Block E1 buffer (4ml/chip) to room temperature.  
 
Room-Temperature Incubation: 
Remove Hyb Chamber from oven and disassemble. (Observe for bubbles, if any, 
and locate them on the tracking sheet). 
Remove coverseal in a zig-zag manner in a container with 1L of Wash E1BC 
solution. Using tweezers or powder-free gloved hands, place the BeadChip into 
the slide rack submerged in the staining dish containing 250ml of Wash E1BC 
solution. 
Using the slide rack handle, transfer the rack into the Hybex Waterbath insert 
containing High-Temp Wash buffer. 
 
High-Temp Wash: 
Incubate static for 10 minutes with the Hybex lid closed. 
 
1st Room-Temp Wash: 
During the 10 minutes High-Temp Wash buffer incubation, add fresh 250ml of 
Wash E1BC solution to a clean staining dish. 
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After the 10 minutes High-Temp Wash buffer incubation is complete, 
immediately transfer the slide rack into the above prepared staining dish. 
Briefly agitate using rack, then shake on orbital shaker for 5 minutes at 110rpm. 
 
Ethanol Wash: 
Transfer rack to a clean staining dish containing 250ml of absolute ethanol. 
Briefly agitate using rack handle, then shake on orbital shaker for 10 minutes at 
110rpm. 
 
2nd Room-Temp Wash: 
Transfer rack to a clean staining dish containing fresh 250ml of Wash E1BC 
solution. Briefly agitate using rack handle, then shake on orbital shaker for 2 
minutes at 110rpm. 
 
Block: 
Pipette 4ml of Block E1 buffer into the Wash Tray(s). 
Transfer the BeadChip, face up into BeadChip Wash Tray(s) on rocker. 
Rock at medium speed for 10 minutes.  
Prepare Block E1 buffer (cloudy looking, normal) (2 ml/chip) with streptavidin-
Cy3 (2µl of 1mg/ml stock per chip). Use a single conical tube for all BeadChips. 
Store in dark until detection step. 
 
Detect: 
Pipette 2ml of Block E1 buffer + streptavidin-Cy3 into fresh Wash Tray(s). 
Transfer the BeadChip, face up into Wash Tray(s) on rocker. 
Place cover on tray and rock at medium speed for 10 minutes. 
 
3rd Room-Temp Wash: 
Add 250ml of Wash E1BC solution to a clean staining dish. 
Transfer the BeadChip to the slide rack submerged in the staining dish. 
Briefly agitate using rack, and then shake at room temperature on orbital shaker 





Prepare centrifuge with plateholders, paper towels and balance rack. Set speed to 
270rcf. 
Transfer rack of BeadChips from staining dish to centrifuge and spin at room 
temperature for 4 minutes. 
Store dry chips in slide box until scanned. 
 
Scanning: 
Scan the arrays using Illumina® BeadArray Reader. Ensure the signal is strong 
enough, i.e. green colour on the slot instead of red. Check that all the 






Appendix 5: Protocol for single-stranded human cDNA synthesis using 
Superscript III First-Strand Synthesis System for RT-PCR 
 
Single-stranded cDNA was synthesized from 150ng of total RNA from human 
monocyte using the Superscript III First-Strand Synthesis System for RT-PCR 
(Invitrogen Life Technologies, CA, USA), according to the manufacturer’s 
instructions. The initial reaction mixture for cDNA conversion was prepared as 
shown below. 
Reagent Volume for 1 reaction 
50pmol Oligo(dT) 1µl 
10mM dNTP 1µl 
150ng total RNA  Variable 
DEPC-treated water Top up to 13µl 
Final Volume 13 µl 
 
The mixture was incubated at 65 ºC for 5 minutes followed by incubation at 4ºC 
for at least 1 minute. A second reaction mixture was prepared as shown in the 
table below and added to each tube and mixed by gentle pipetting. All tubes were 
incubated at 50ºC for 1 hour, followed by inactivation at 70 ºC for 15 minutes and 
cooling at 4ºC. 
Reagent Volume for 1 
reaction 
5X First Strand Buffer 4µl 
0.1M DTT 1µl 
RNaseOUT recombinant RNase Inhibitor (40U/µl) 1µl 
Superscript III Reverse Transcriptase (200U/µl) 1µl 





Appendix 6: Protocol for rat urine albumin ELISA 
 
Coat 96-well microtiter plate (Corning, MA, USA) with 100µl of rabbit antiserum 
to rat albumin antibody (MP Biomedicals, CA, USA) diluted 1/2000 in 0.1M 
carbonate buffer, 4°C, overnight. 
Thoroughly aspirate and discard the coating antibody and wash with 3 changes of 
400µl of 1X PBS.  
Blocking with 100µl of 1% BSA in 1X PBS with 0.05% Tween 20 for 45 
minutes, room temperature. 
Thoroughly aspirate and discard the blocking solution. Do not wash. 
Add 50µl of standards, diluted urine samples and diluent, as blank, to each well in 
triplicate. Incubate for 2 hours, 37°C. 
Thoroughly aspirate and discard the liquid and wash with 3 changes of 400µl of 
1X PBS. 
Incubate with 50µl of HRP-conjugated sheep polyclonal antibody to rat albumin 
(MP Biomedicals, CA, USA), diluted 1/20000 in 1% BSA in 1X PBS with 0.05% 
Tween 20, for 1 hour at 37°C.  
Thoroughly aspirate and discard the detecting antibody and wash with 4 changes 
of 400µl of 1X PBS. 
Add 50µl of 0.05% OPD substrate (MP Biomedicals, CA, USA) in each well and 
incubate for 10 minutes at room temperature in dark. 
Stop reaction with 60µl of 4.5 N sulphuric acid. Gently mix and incubate for 5 
minutes. 
Read the absorbance at 490 nm using a microplate reader. 
 
Preparation of standards: 
Rat albumin (MP Biomedicals, CA, USA) stock solution = 20mg/ml  
Diluent = 0.05% Tween 20 in 1X PBS 
Dilute the 20 mg/ml stock solution 1/100 to final concentration of 200µg/ml: 10µl 
of stock solution + 990µl of diluent 
Dilute the 200µg/ml rat albumin solution 1/100 to 2µg/ml: 50µl of 200µg/ml rat 
albumin solution + 4950µl of diluent 
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Make a 2X standard serial dilutions from the 2µg/ml rat albumin solution  
Concentration of standards: 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625 ng/ml 
 
Dilution of urine samples: 
Dilute the urine samples 1/10: 50µl of urine sample + 450µl of diluent. 
Further serial dilute the urine samples ranging from 1/10 to 1/100 as shown in the 
table below. 
Dilution factor 
(Final dilution) Volume from first dilution/ µl Volume of diluent/ µl 
1/10 (1/100) 20 180 
1/20 (1/200) 15 285 
1/30 (1/300) 15 435 
1/40 (1/400) 15 585 
1/50 (1/500) 15 735 
1/60 (1/600) 15 885 
1/70 (1/700) 15 1035 
1/80 (1/800) 15 1185 
1/90 (1/900) 15 1335 
1/100 (1/1000) 15 1485 
 
Reagents  
0.1M Sodium carbonate buffer, pH 9.6: 
0.2M Sodium carbonate (Na2CO3)   8ml 
0.2M Sodium bicarbonate (NaHCO3)  17ml 
ddH2O       25ml 
 
0.2M Sodium carbonate (Na2CO3): 
Sodium carbonate (Na2CO3)    21.2g 
ddH2O       1000ml 
 
0.2M Sodium bicarbonate (NaHCO3): 
Sodium bicarbonate (NaHCO3)   16.8g 





1X PBS      50ml 
BSA       0.5g 
Tween 20      25µl 
 
Diluent for standards and urine samples: 
1X PBS      500ml 
Tween 20      250µl 
  
OPD substrate: 
Phosphate-citrate buffer, pH 5.0   6ml 
OPD (o-Diphenylenediamine)   300µl 
30% H2O2*      3µl 
*Add the H2O2 just before use. 
 
Phosphate-Citrate buffer pH 5.0 for OPD substrate: 
0.1M Citrate buffer     24.3ml 
0.2M Phosphate buffer    25.7ml 
ddH2O       50ml 
 
0.1M Citrate buffer: 
Citric acid      3.84g 
ddH2O       200ml 
 
0.2M Phosphate buffer: 
Na2HPO4 (anhydrous)    5.68g 




Appendix 7: Protocol for isolation of monocytes/macrophages from IL-13 
overexpressed rat model of MCNS 
 
Place the spleen in chilled serum-free RPMI 1640 medium and scrap to obtain 
single cell. 
Pass the suspension through 40µm cell strainer and collect the flow through with 
50mL falcon tube. 
Centrifuge at 1800rpm for 5 minutes. 
Decant and resuspend cell pellet in 10ml of 1X lysing buffer and incubate at 37oC 
for 3mins. 
Centrifuge at 1800rpm for 5 minutes. 
Decant and resuspend cell pellet in 10ml of HBSS. 
Repeat steps 5. 
Decant and resuspend cell pellet in 25ml of incomplete medium and transfer to 
175cm2 culture flask for adherence for 2 hrs at 37oC. 
After 2 hours, remove non-adherent cells by thorough washing with warm 1X 
PBS twice. 
Dislodge the cells by incubating with 1X PBS+2mM EDTA at 37oC for 5 minutes 
and GENTLY scrapped the flask with rubber scrapper. 
Transfer the cells to 15mL falcon tube, Centrifuge at 1800rpm for 5 minutes. 
Decant and resuspend in 3mL MACS buffer. 
Remove any cell clumps by passing through cell strainer (5mL polystyrene round-
bottom tube with cell strainer cap) 
Load 10µl of cells into neubauer chamber, count cells at a magnification of 40X. 
Count the cells in the center of the chamber. Count only cells inside the squares. 
Calculate concentration of cell suspension. 
( ) 106 cells/ml = N x 100 
N = Number of cells counted in the center of chamber 
Centrifuge at 1800rpm for 5 minutes. 
Decant and resuspend cell pellet in 80ul of MACS buffer per 107 total cells. 




Mix well and incubate for 15 minutes at 4-8oC.  
Wash cells by adding 1-2mL of MACS buffer per 107 total cells and centrifuge at 
1500rpm for 5 minutes. 
Decant and resuspend cell pellet in 1mL of sterile MACS buffer.  
Place LS column in the magnetic field of MACS® separator. Rinse the column 
with 3mL of MACS buffer. 
Apply cell suspension onto the column. 
Collect unlabelled cells which pass through with 15mL falcon tubes and wash 
column with 3mL of MACS buffer thrice. 
Collect total effluent, which is the unlabelled cell fraction. 
Remove column from the separator and place it on a 15mL falcon tube. Add 5mL 
of MACS buffer onto the column and flush out fraction with the magnectically 
labeled cells by firmly applying the plunger supplied. 
Aliquot 50ul from the desired fraction for purity check using fluorochrome 
conjugated antibody staining. 
Centrifuge both fractions at 1500rpm for 5 minutes and proceed with appropriate 
downstream applications. 
Purity of the cells is analysed by drawing a gate around the total population on the 
FSC vs SSC plot. Record the percentage of positive cells. 
 
Reagents 
Ready to use: 
Hank’s Balance Salt Solution (Gibco 24020-117) 
RPMI 1640 (Gibco 11835030)  




Add 0.5mL of Penicillin/Streptomycin (Gibco 15140) and 100ul of Gentamycin 
(Gibco 15710-064) into 45mL of RPMI. 
 
1X lysing buffer: 
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Dilute the BD Pharm Lyse™ 10X lysing buffer (BD 555899) with distilled water 
to a 1X lysing buffer. 
 
1X PBS + 2mM EDTA: 
Add 3.21ml of 0.5M EDTA to 800ml 1X PBS. 
 
MACS buffer:  
Dissolve 2.01g bovine serum albumin (BSA) in 400ml 1X PBS and add 1.61ml of 





Appendix 8: Protocol for single-stranded rat cDNA synthesis using 
Superscript III First-Strand Synthesis System for RT-PCR 
 
Single-stranded cDNA was synthesized from 25ng of total RNA from rat 
macrophages using the Superscript III First-Strand Synthesis System for RT-PCR 
(Invitrogen Life Technologies, CA, USA), according to the manufacturer’s 
instructions. The initial reaction mixture for cDNA conversion was prepared as 
shown below. 
Reagent Volume for 1 reaction 
50pmol Oligo(dT) 1µl 
10mM dNTP 1µl 
25ng total RNA  Variable 
DEPC-treated water Top up to 13µl 
Final Volume 13 µl 
 
The mixture was incubated at 65 ºC for 5 minutes followed by incubation at 4ºC 
for at least 1 minute. A second reaction mixture was prepared as shown in the 
table below and added to each tube and mixed by gentle pipetting. All tubes were 
incubated at 50ºC for 1 hour, followed by inactivation at 70 ºC for 15 minutes and 
cooling at 4ºC. 
Reagent Volume for 1 
reaction 
5X First Strand Buffer 4µl 
0.1M DTT 1µl 
RNaseOUT recombinant RNase Inhibitor (40U/µl) 1µl 
Superscript III Reverse Transcriptase (200U/µl) 1µl 
Final Volume 7 µl 
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Appendix 9: Protocol for plasmid standard curve generation 
 
Polymerase chain reaction (PCR) was carried out using monocytes cDNA and 
specific primer sequences as shown in the table below to obtain the genes of 
interest. The reactions were run at 95°C for 5 minutes, followed by 40 
amplification cycles of 95°C for 30 seconds, annealing temperature of 60°C for 
30 seconds and 72°C for 30 seconds. A final 9 minutes of extension at 72°C was 
performed after the last amplification cycle, followed by cooling at 4°C. 
 
Nucleotide sequence of primers for the respective genes of interest in rat monocytes 
Gene/Accession # Primers  Nucleotide sequence 5’ - 3’ bp 
Rat IL-12b Forward 5’-CATCTGCTGCTCCACAAGAA-3’ 187 
NM_022611.1 Reverse 5’-GAGACTCAGGGGAACTGCTG-3’  
Rat IL-10 Forward 5’- CATCCGGGGTGACAATAACT-3’ 273 
NM_012854 Reverse 5’- TCTCCCAGGGAATTCAAATG-3’  
Rat CD43 Forward 5’-ACCCTGAGCAGAGGTGGAAA-3’ 163 
XM_344964 Reverse 5’- TGAAGAAAGTGGTGAGCGTG-3’  
Rat CCR2 Forward 5’- CTGCCCCTACTTGTCATGGT-3’ 222 
NM_021866 Reverse 5’- GGCCTGGTCTAAGTGCATGT-3’  
Rat CX3CR1 Forward 5’- TTCCTCTTCTGGACGCCTTA-3’ 273 
NM_133534 Reverse 5’- GCTCCTCTGGGACTCTGTTG-3’  
Rat IL-1b Forward 5’- CTGTGACTCGTGGGATGATG-3’ 210 
NM_031512 Reverse 5’- GGGATTTTGTCGTTGCTTGT-3’  
Rat CD163 Forward 5’- CCCCACTGGACAGAACTTGT-3’ 239 
NM_001107887 Reverse 5’- TTTCCCAAAATGTGCTCCTC-3’  
Rat Arginase Forward 5’-AGCGCCTTTCTCTAAGGGAC-3’ 183 
NM_017134 Reverse 5’- ACAGACCGTGGGTTCTTCAC-3’  
Rat TNFα Forward 5’-ATGTGGAACTGGCAGAGGAG-3’ 195 
NM_012675 Reverse 5’- TGGAACTGATGAGAGGGAGC-3’  
Rat GAPDH Forward 5’- GGTGATGCTGGTGCTGAGTA-3’ 273 
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NM_017008 Reverse 5’- GACTGTGGTCATGAGCCCTT-3’  
Rat CCL3 Forward 5’- TGCCCTTGCTGTTCTTCTCT-3’ 230 
NM_013025 Reverse 5’- CTTGGACCCAGGTCTCTTTG-3’  
Rat CD62L Forward 5’- CCATGAACTGGGAAAATGCT-3’ 197 
NM_019177 Reverse 5’- CTCTGCTTCTTTGGTGAGGG-3’  
Rat CD80 Forward 5’ – CCACTCCTCGGGTTTC – 3’ 184 
N_012926 Reverse 5’ – TTTGCCAGTAGATTCGGT – 3’  
 
The PCR products were cloned into pCR 2.1-TOPO vector using the TOPO® TA 
cloning kit (Invitrogen Life Technologies, CA, USA). The TA cloning reaction 
was set up as shown in the table below. 
Reagent Volume for 1 reaction 
Fresh PCR product 3µl 
Water 1µl 
Salt Solution 1µl 
TOPO vector 1µl 
Final Volume 6µl 
 
The reaction mixture for each gene was mixed gently and incubated at room 
temperature for 15 minutes. Two µl of the reaction mixture was then added to a 
vial of OneShot® TOP10 Chemically Competent E. coli cells and incubated for 15 
minutes on ice before being subjected to heat shock for 30 seconds at 42ºC 
without shaking. The vial was placed on ice for 2 minutes before adding 250µl of 
S.O.C. medium to each vial and incubated for 1 hour at 37ºC with shaking at 
250rpm. 
 
One hundred µl of the incubation mixture was spread onto a pre-warmed Luria-
Bertani (LB) agar plate containing 100µg/ml ampicillin and 40µg/ml 5-bromo-4-
chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) (Promega, WI, USA) for 
blue-white selection. Plates were incubated overnight at 37ºC. Isolated white 
colonies were picked for sub-culturing. Each colony was grown in 3ml of LB 
broth containing 100µg/ml ampicillin at 37ºC with shaking at 250rpm. After 8 
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hours, the bacterial culture was diluted by topping up the LB broth to 10ml and 
was incubated overnight under the same conditions but not more than 16 hours. 
Cells were then centrifuged at 6000g and 4ºC for 15 minutes. The supernatant was 
discarded and plasmids were extracted using the QIAprep Spin Miniprep Kit 
(QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s protocol. 
Concentration of the plasmid DNA stock was measured using NanoDrop 1000 
Spectrophotometer (NanoDrop products, Thermo Scientific, DE, USA). Presence 
of gene inserts was confirmed by EcoRI restriction and agarose gel 
electrophoresis. Serial dilutions were done to get a series of plasmid standards, 
ranging from 109 copy number to 101 copy number. Plasmid standards were run in 
triplicates in real-time PCR using LightCycler® 480 SYBR Green I Master 
reagent (Roche, Germany). Good standard curves should have efficiency of 2 and 




Appendix 10: Study Subject Characteristics 























C1 M 4 NA 1.51 73.15 28.81 7.63 2.75 3.33 9.00 343.52 4.15 
C2 M 4 NA 1.92 352.85 23.13 9.91 5.75 2.51 16.73 150.28 4.36 
C3 M 4 NA 2.78 123.32 27.48 8.46 3.83 3.24 7.57 129.65 2.23 
C4 M 5 NA 1.77 310.24 23.13 8.73 6.19 1.64 8.33 148.98 4.06 
C5 M 5 NA 1.17 47.98 12.17 4.32 0.52 - 4.16 70.73 0.93 
C6 M 5 NA 1.62 330.85 20.66 8.67 6.09 1.81 12.50 137.80 3.82 
C7 M 6 NA 5.93 39.21 33.66 9.82 4.10 8.99 16.93 177.65 1.67 
C8 M 6 NA 1.09 163.52 9.36 5.17 1.15 - 5.94 89.54 2.63 
C9 M 6 NA 2.04 78.96 19.70 5.34 1.71 2.61 5.21 98.64 1.69 
C10 M 7 NA 1.32 63.91 19.89 5.58 3.89 3.44 6.06 249.54 2.24 
C11 M 7 NA 1.36 42.08 10.77 5.59 1.50 0.77 2.39 66.44 0.83 
C12 F 8 NA 1.36 157.27 42.60 8.66 4.31 0.59 11.29 107.66 1.82 
C13 M 9 NA 2.94 145.60 41.98 9.04 4.72 3.42 7.16 157.24 2.67 
C14 F 10 NA 2.13 51.21 13.41 5.50 10.97 7.02 10.37 211.18 2.00 
C15 M 11 NA - - - - - - - - - 
C16 M 11 NA 3.13 173.32 30.15 11.27 8.82 7.21 9.29 294.35 2.01 
C17 F 11 NA 1.54 37.47 16.26 3.20 6.39 3.88 8.49 194.34 1.82 
C18 M 11 NA 1.54 182.20 9.85 6.66 3.68 2.53 8.85 169.47 2.06 
C19 F 12 NA 1.92 45.23 19.07 4.44 2.38 4.82 10.08 249.54 2.37 
C20 M 12 NA 0.83 128.19 4.76 4.11 - - 3.27 65.63 2.81 
C21 F 12 NA 1.90 66.86 22.32 4.69 2.07 1.26 4.40 332.44 2.73 
C22 F 12 NA 3.59 86.51 22.74 10.15 11.13 7.21 11.39 744.58 6.93 
C23 M 13 NA 0.61 104.85 3.52 5.17 1.07 - 5.84 71.20 1.67 
C24 M 13 NA 3.04 191.19 44.02 16.51 6.43 - 38.82 198.88 5.33 
C25 F 13 NA 1.83 182.32 28.03 8.90 5.99 - 11.65 149.28 2.80 
C26 M 13 NA 1.08 205.99 11.48 5.87 1.47 - 5.61 89.54 2.56 
C27 M 17 NA 1.00 50.36 9.91 3.66 2.53 3.49 7.05 232.41 2.03 
C28 F 18 NA 1.31 56.31 14.54 3.29 2.45 3.65 7.05 245.25 2.49 
C29 M 18 NA 2.42 331.86 30.59 9.46 10.46 6.01 11.82 214.73 2.53 
C30 F 19 NA 1.06 34.70 7.00 2.44 - - 2.07 38.41 0.54 
C31 M 19 NA 1.46 71.68 17.02 5.41 - - 18.08 80.86 2.81 
C32 M 19 NA 2.21 167.59 37.06 9.01 0.23 - 25.05 132.53 2.53 
C33 M 19 NA 1.39 66.44 33.96 7.16 4.80 5.69 7.20 385.94 3.69 
C34 M 19 NA 2.41 141.51 32.29 9.49 1.97  24.73 136.06 3.56 
C35 F 19 NA - - - - - - - - - 
C36 F 20 NA 1.03 45.44 14.11 3.43 - - 11.19 50.32 1.64 
C37 M 20 NA 0.42 60.41 4.23 4.82 - 2.95 2.22 40.96 1.11 
C38 F 20 NA 2.59 55.36 24.12 6.77 3.38 2.85 8.72 114.94 1.45 
C39 M 20 NA 2.31 101.11 24.87 6.94 2.65 2.85 4.32 125.66 1.91 
C40 F 21 NA  - -  -  -  - - - -  - 
MC1 M 6 RL 1.82 74.53 15.01 5.08 0.86 1.32 3.28 91.75 1.19 
MC1 M 6 RM 2.12 76.00 25.61 7.53 2.5 2.09 4.16 101.37 1.52 
MC2 F 4 RL 3.25 172.44 36.20 7.61 4.42 4.37 9.70 158.54 2.59 
MC2 F 4 RM 2.26 111.47 27.10 8.12 4.65 1.74 5.94 137.60 2.04 
MC3 M 3 RL 1.58 273.27 21.19 10.3 3.71 1.46 11.19 147.67 3.95 
MC3 M 3 RM 1.75 265.84 19.25 7.25 3.53 1.19 7.75 121.60 3.76 
MC4 M 15 RL 1.22 182.2 9.42 8.33 1.54 3.98 7.41 139.86 1.56 
MC4 M 15 RM 1.03 128.95 11.12 5.11 1.62 3.02 6.04 142.30 1.21 
MC5 F 4 RL 3.52 193.4 47.04 12.56 7.82 5.15 8.96 195.74 3.01 
MC5 F 4 RM 2.53 112.95 30.49 9.55 4.57 3.19 7.82 153.33 1.69 
MC6 F 21 RL 3.03 142.62 36.96 9.96 4.27 3.47 7.49 171.47 2.15 
MC6 F 21 RM 2.75 142.62 34.29 9.04 4.87 3.07 8.22 170.18 2.13 
MC7 F 8 RL 3.70 775.37 56.76 18.22 17.14 11.65 14.75 286.40 5.94 
MC7 F 8 RM 4.36 927.12 79.52 19.95 24.43 13.42 20.77 308.19 6.41 
MC8 F 6 RL 2.61 127.77 28.61 8.62 3.83 2.50 6.10 146.80 1.85 
MC8 F 6 RM 2.56 107.03 24.87 8.37 2.72 1.26 6.10 153.33 1.36 
MC9 M 12 RL 1.95 185.12 30.79 9.74 7.01 0.75 13.24 149.28 2.81 
MC9 M 12 RM 1.32 114.23 24.40 6.83 2.68 OOR < 5.92 106.53 1.94 
MC10 M 7 RL 2.34 98.15 27.10 6.52 2.72 2.03 5.62 114.94 1.69 
MC10 M 7 RM 1.36 62.73 12.87 4.24 0.65 1.20 3.76 87.60 1.26 
MC11 M 10 RL 2.67 309.61 32.34 10.27 5.48 5.02 11.68 245.94 2.80 
MC11 M 10 RM 0.88 177.76 13.26 5.02 1.58 2.69 6.61 139.86 1.50 
MC12 M 23 RL 5.97 753.3 73.65 23.22 17.49 18.87 24.03 462.03 4.41 



























MC13  M 3 RL  - -  -  -  -  -  -  -  -  
MC14 F 4 RM  - -  -  -  -  -  -  -  -  
MC15 M 5 RL 4.54 506.88 70.90 24.31 19.33 6.00 45.66 427.39 5.64 
MC16 M 5 RM  - -  -  -  -  -  -  -  -  
MC17 M 6 RL  - -  -  -  -  -  -  -  -  
MC18 F 7 RM  - -  -  -  -  -  -  -  -  
MC19 M 8 RM 4.62 314.29 81.03 27.26 12.82 1.44 63.93 286.78 6.14 
MC20 F 8 RM  - -  -  -  -  -  -  -  -  
MC21 M 9 RL  - -  -  -  -  -  -  -  -  
MC22 M 10 RM  - -  -  -  -  -  -  -  -  
MC23 M 11 RM  - -  -  -  -  -  -  -  -  
MC24 M 13 RL 1.79 179.52 34.43 10.68 7.01 1.05 11.65 171.19 2.63 
MC25 M 13 RM 1.11 90.78 17.75 5.26 2.77 OOR < 6.47 84.01 1.52 
MC26 M 13 RL 2.13 441.63 34.62 10.80 9.06 4.64 9.50 171.98 5.00 
MC27 M 13 RL  - -  -  -  -  -  -  -  -  
MC28 F 14 RL  - -  -  -  -  -  -  -  -  
MC29 F 14 RL  - -  -  -  -  -  -  -  -  
MC30 F 14 RL  - -  -  -  -  -  -  -  -  
MC31 M 15 RM  - -  -  -  -  -  -  -  -  
MC32 M 15 RL 2.31 1322.72 52.4 39.02 28.39 5.17 45.62 171.87 2.50 
MC33 M 15 RL  - -  -  -  -  -  -  -  -  
MC34 M 16 RM 0.97 38.94 12.31 3.24 OOR < OOR < 10.24 52.33 1.75 
MC35 M 17 RL  - -  -  -  -  -  -  -  -  
MC36 M 17 RM  - -  -  -  -  -  -  -  -  
MC37 F 17 RL 1.95 96.25 22.07 8.54 OOR < OOR < 21.15 104.40 2.67 
MC38 M 19 RL  - -  -  -  -  -  -  -  -  
MC39 F 21 RL  - -  -  -  -  -  -  -  -  
MC40 F 25 RL  - -  -  -  -  -  -  -  -  
F1 M 4 RL 1.36 265.84 19.95 7.08 2.54 OOR < 10.89 113.98 3.26 
F2 F 10 RL 2.86 299.22 25.57 10.64 6.35 7.09 11.82 237.75 2.49 
F3 F 13 RL 2.26 99.63 23.75 7.11 5.92 2.56 5.86 116.28 1.67 
F4 M 13 RL 0.70 82.82 3.35 4.39 2.77 OOR < 4.94 71.61 1.67 
F5 M 15 RL 3.41 369.71 53.46 17.24 13.36 4.21 23.99 294.64 4.68 
F6 M 17 RL  - -  -  -  -  -  -  -  -  




























C1 M 4 NA 6.61 17.60 5.39 101.46 26.60 2.31 63.3 14.22 20.87 
C2 M 4 NA 4.47 23.53 7.19 45.82 21.03 3.35 5.16 OOR < 25.77 
C3 M 4 NA 5.77 6.57 6.80 53.14 8.06 2.00 7.80 24.63 9.63 
C4 M 5 NA 4.91 19.73 4.46 52.83 17.55 2.59 5.04 OOR < 25.19 
C5 M 5 NA 2.83 4.33 3.31 25.40 4.48 0.94 3.59 15.30 4.17 
C6 M 5 NA 4.69 20.37 5.83 25.39 16.22 2.72 4.40 OOR < 21.98 
C7 M 6 NA 3.23 11.45 8.49 25.54 14.71 2.88 30.63 32.22 16.48 
C8 M 6 NA 2.48 10.47 3.28 16.29 11.36 1.74 3.11 OOR < 17.79 
C9 M 6 NA 4.36 9.40 5.74 36.10 8.30 1.22 5.13 27.36 5.41 
C10 M 7 NA 4.24 12.85 3.86 143.36 18.15 1.60 47.43 7.84 3.68 
C11 M 7 NA 2.18 4.75 2.90 26.28 2.55 1.03 3.51 12.83 4.70 
C12 F 8 NA 3.44 7.07 3.39 37.22 15.04 4.02 4.62 OOR < 20.47 
C13 M 9 NA 6.71 16.72 5.83 35.50 11.16 2.61 8.53 38.11 5.94 
C14 F 10 NA 4.32 20.97 6.70 9.33 29.76 3.17 50.89 20.35 20.13 
C15 M 11 NA  - -  -  -  -  -  -  -  -  
C16 M 11 NA 3.16 14.26 4.90 42.64 31.34 1.35 8.40 26.88 23.08 
C17 F 11 NA 3.31 14.26 4.26 28.53 19.20 1.60 36.23 11.36 2.19 
C18 M 11 NA 2.96 15.03 4.04 37.36 24.09 1.74 7.84 15.91 14.02 
C19 F 12 NA 5.20 14.00 4.47 28.64 18.15 1.65 59.61 11.64 17.11 
C20 M 12 NA 1.74 5.64 2.58 11.29 7.94 0.85 1.78 OOR < 17.18 
C21 F 12 NA 4.82 8.40 3.51 9.33 4.94 1.72 49.64 20.52 4.17 
C22 F 12 NA 8.64 23.84 5.46 42.28 33.45 2.77 71.27 28.36 3.98 
C23 M 13 NA 1.78 12.15 2.45 12.58 9.24 1.02 2.18 32.80 18.7 
C24 M 13 NA 5.84 5.69 4.73 34.70 18.15 10.36 12.26 1.98 62.29 
C25 F 13 NA 4.41 17.93 3.65 13.86 24.34 6.61 6.29 OOR < 29.42 
C26 M 13 NA 2.92 10.68 3.07 15.84 9.56 1.60 3.31 OOR < 16.88 
C27 M 17 NA 4.49 9.80 2.81 96.54 15.24 0.98 46.49 10.20 15.06 
C28 F 18 NA 4.15 11.45 3.23 48.30 20.13 1.56 47.12 9.61 3.26 
C29 M 18 NA 4.62 29.60 8.13 33.94 49.50 3.18 9.55 32.22 34.63 
C30 F 19 NA 1.40 2.54 1.90 27.80 2.00 0.56 2.15 8.17 2.58 
C31 M 19 NA 2.89 2.36 3.14 43.72 OOR < 3.40 6.21 OOR < 34.67 
C32 M 19 NA 2.93 2.80 3.25 39.48 OOR < 5.33 6.46 OOR < 35.61 
C33 M 19 NA 6.24 5.46 3.53 39.07 29.76 2.16 75.53 16.47 3.77 
C34 M 19 NA 3.71 4.50 4.15 34.01 18.41 7.00 8.02 OOR < 45.49 
C35 F 19 NA  - -  -  -  -  -  -  -  -  
C36 F 20 NA 1.90 0.86 2.09 17.73 OOR < 1.96 4.00 OOR < 26.66 
C37 M 20 NA 1.09 2.71 1.30 82.83 0.90 0.85 0.59 OOR < 9.91 
C38 F 20 NA 3.83 5.59 6.56 29.09 4.36 1.44 4.52 25.31 4.62 
C39 M 20 NA 4.83 8.12 4.17 45.46 5.41 1.56 7.14 25.66 6.12 
C40 F 21 NA  - -  -  -  -  -  -  -  -  
MC1 M 6 RL 3.23 13.83 3.51 33.68 4.94 2.31 3.51 19.13 4.70 
MC1 M 6 RM 3.83 764.5 5.15 33.47 6.97 1.58 5.20 29.72 5.68 
MC2 F 4 RL 8.34 21.53 7.04 34.08 11.79 2.56 9.03 31.41 8.49 
MC2 F 4 RM 4.69 11.82 3.89 29.51 8.43 1.88 6.55 28.03 5.15 
MC3 M 3 RL 3.45 21.00 6.78 28.45 17.36 6.73 4.72 OOR < 24.76 
MC3 M 3 RM 3.41 16.78 4.82 21.97 18.82 2.10 4.24 OOR < 20.5 
MC4 M 15 RL 2.52 12.21 4.76 13.34 14.71 2.50 7.35 10.34 15.58 
MC4 M 15 RM 2.32 16.96 3.64 15.18 7.81 1.23 8.19 6.94 14.67 
MC5 F 4 RL 8.40 19.48 9.08 40.65 13.70 3.60 10.18 44.41 8.32 
MC5 F 4 RM 5.09 10.11 7.89 40.26 11.16 2.14 7.29 29.72 5.85 
MC6 F 21 RL 6.24 17.01 6.32 25.40 8.92 2.68 6.70 37.11 5.76 
MC6 F 21 RM 5.90 14.26 6.48 33.27 8.67 2.39 6.48 35.44 6.47 
MC7 F 8 RL 10.17 50.03 8.38 71.87 39.37 6.84 11.14 12.19 41.09 
MC7 F 8 RM 12.59 60.47 8.98 73.28 42.42 7.22 12.82 15.85 47.78 
MC8 F 6 RL 6.03 11.53 6.40 45.46 8.55 2.71 5.88 24.63 6.12 
MC8 F 6 RM 4.63 7.98 5.32 30.78 5.41 1.70 4.67 23.61 6.20 
MC9 M 12 RL 5.23 22.65 4.63 22.25 25.3 6.67 7.22 OOR < 35.52 
MC9 M 12 RM 3.27 18.68 3.08 9.75 12.57 3.98 4.88 OOR < 23.55 
MC10 M 7 RL 4.49 12.39 4.35 34.29 8.80 1.98 4.75 23.95 4.79 
MC10 M 7 RM 3.30 4.61 3.11 32.24 4.01 1.00 3.90 14.24 3.73 
MC11 M 10 RL 4.87 26.19 9.69 27.77 33.98 5.83 12.05 30.09 21.98 
MC11 M 10 RM 2.59 11.96 5.88 38.55 13.65 1.46 7.06 8.43 20.13 
MC12 M 23 RL 10.02 55.32 11.67 104.36 92.55 7.58 18.39 65.38 43.88 



























MC13  M 3 RL  - -  -  -  -  -  -  -  -  
MC14 F 4 RM  - -  -  -  -  -  -  -  -  
MC15 M 5 RL 9.94 60.7 9.90 35.81 60.55 21.39 17.88 27.24 67.40 
MC16 M 5 RM  - -  -  -  -  -  -  -  -  
MC17 M 6 RL  - -  -  -  -  -  -  -  -  
MC18 F 7 RM  - -  -  -  -  -  -  -  -  
MC19 M 8 RM 8.75 13.21 5.57 47.31 48.17 22.15 16.13 13.80 85.60 
MC20 F 8 RM  - -  -  -  -  -  -  -  -  
MC21 M 9 RL  - -  -  -  -  -  -  -  -  
MC22 M 10 RM  - -  -  -  -  -  -  -  -  
MC23 M 11 RM  - -  -  -  -  -  -  -  -  
MC24 M 13 RL 5.52 23.23 6.58 31.77 20.71 5.85 7.69 OOR < 35.26 
MC25 M 13 RM 2.67 5.51 4.30 15.36 10.96 2.84 3.62 OOR < 20.05 
MC26 M 13 RL 5.13 25.43 5.91 39.02 32.70 2.65 6.42 3.75 29.48 
MC27 M 13 RL  - -  -  -  -  -  -  -  -  
MC28 F 14 RL  - -  -  -  -  -  -  -  -  
MC29 F 14 RL  - -  -  -  -  -  -  -  -  
MC30 F 14 RL  - -  -  -  -  -  -  -  -  
MC31 M 15 RM  - -  -  -  -  -  -  -  -  
MC32 M 15 RL 2.74 4.39 8.20 40.08 12.93 30.39 6.04 OOR < 33.74 
MC33 M 15 RL  - -  -  -  -  -  -  -  -  
MC34 M 16 RM 1.62 1.45 2.24 25.6 OOR < 2.18 4.13 OOR < 27.37 
MC35 M 17 RL  - -  -  -  -  -  -  -  -  
MC36 M 17 RM  - -  -  -  -  -  -  -  -  
MC37 F 17 RL 3.32 3.23 3.12 36.68 8.28 5.33 6.63 OOR < 39.31 
MC38 M 19 RL  - -  -  -  -  -  -  -  -  
MC39 F 21 RL  - -  -  -  -  -  -  -  -  
MC40 F 25 RL  - -  -  -  -  -  -  -  -  
F1 M 4 RL 3.32 70.09 4.48 31.25 13.67 2.60 4.27 OOR < 24.47 
F2 F 10 RL 4.50 27.76 5.60 85.89 35.82 3.28 10.53 26.07 23.56 
F3 F 13 RL 4.63 9.82 5.83 36.31 6.25 1.88 5.13 24.63 7.70 
F4 M 13 RL 1.38 1.71 0.16 10.13 OOR < 8.55 2.30 OOR < 11.84 
F5 M 15 RL 7.57 42.88 10.25 33.61 48.25 14.42 12.62 16.55 55.38 
F6 M 17 RL  - -  -  -  -  -  -  -  -  





























C1 M 4 NA 23.34 449.00 23.26 9.88 4078.78 9.82 3.54 24.99 636.35 
C2 M 4 NA 18.07 4397.09 26.75 8.06 558.15 14.01 5.07 14.18 158.52 
C3 M 4 NA 15.14 177.30 10.90 9.03 246.46 14.89 1.20 18.99 305.57 
C4 M 5 NA 17.44 4145.75 10.75 8.13 429.35 16.67 4.97 15.19 187.84 
C5 M 5 NA 6.62 699.48 4.36 3.96 290.00 4.39 OOR < 20.30 182.78 
C6 M 5 NA 14.18 3221.46 18.85 7.21 435.08 8.94 4.83 14.79 138.68 
C7 M 6 NA 20.07 285.08 15.38 4.71 1858.8 23.69 4.40 22.62 961.28 
C8 M 6 NA 8.59 1992.27 6.81 5.02 1888.57 4.05 3.25 12.43 148.56 
C9 M 6 NA 19.16 580.49 5.47 6.31 407.55 9.14 3.78 21.24 253.93 
C10 M 7 NA 20.07 1263.57 14.26 7.87 4285.73 3.56 3.12 21.97 767.04 
C11 M 7 NA OOR < 307.44 1.66 3.87 602.21 3.99 OOR < 18.70 444.25 
C12 F 8 NA 12.96 469.20 11.03 7.18 430.44 14.6 2.51 14.48 245.90 
C13 M 9 NA 20.93 2614.17 6.62 11.26 367.18 22.08 2.76 24.63 186.44 
C14 F 10 NA 28.90 1579.84 20.81 7.20 4285.73 19.86 5.17 22.58 1385.74 
C15 M 11 NA  - -  -  -  -  -  -  -  -  
C16 M 11 NA 33.28 1666.30 26.09 4.38 606.12 21.34 4.96 15.94 143.42 
C17 F 11 NA 20.17 1468.50 15.00 5.22 1963.59 14.96 3.28 10.08 452.55 
C18 M 11 NA 20.07 5907.41 33.8 3.15 406.78 13.75 3.02 19.35 157.52 
C19 F 12 NA 19.67 424.98 13.51 8.06 2702.09 12.49 4.09 11.05 717.33 
C20 M 12 NA 6.79 1173.33 3.41 4.08 425.82 3.74 2.43 10.38 135.27 
C21 F 12 NA 11.48 1687.53 3.04 8.25 483.99 6.77 OOR < 20.39 419.70 
C22 F 12 NA 25.00 5320.83 36.76 11.82 2272.96 23.36 4.25 10.94 299.31 
C23 M 13 NA 14.65 441.41 7.83 4.29 1086.92 5.80 4.59 11.04 257.68 
C24 M 13 NA 47.43 894.47 14.45 20.06 701.14 12.47 4.02 13.56 925.48 
C25 F 13 NA 17.27 2265.69 10.59 9.19 390.29 7.11 3.21 6.77 111.85 
C26 M 13 NA 9.56 1692.83 7.57 4.91 588.06 9.97 3.28 12.45 152.25 
C27 M 17 NA 19.47 1773.16 17.62 6.82 1716.6 11.78 3.42 18.23 613.98 
C28 F 18 NA 18.96 1694.81 16.87 7.01 2911.24 10.22 3.28 20.62 594.28 
C29 M 18 NA 39.06 2789.86 28.27 4.41 644.59 15.8 6.55 38.43 275.13 
C30 F 19 NA OOR < 596.81 0.04 2.97 386.36 1.18 OOR < 7.12 189.67 
C31 M 19 NA 20.94 178.23 3.48 9.69 456.94 8.09 2.15 12.06 1078.27 
C32 M 19 NA 28.60 218.10 7.22 10.38 520.17 6.76 3.00 9.18 854.37 
C33 M 19 NA 22.59 2331.63 21.09 9.69 4816.18 5.26 3.85 18.80 621.30 
C34 M 19 NA 39.19 582.25 12.72 14.31 757.59 7.67 3.74 15.53 1310.80 
C35 F 19 NA  - -  -  -  -  -  -  -  -  
C36 F 20 NA 15.37 145.10 1.84 5.86 806.17 1.72 1.78 7.81 1070.94 
C37 M 20 NA OOR < 427.33 5.17 21.21 545.03 12.96 22.34 148.05 556.69 
C38 F 20 NA 11.82 3946.59 11.00 4.61 1472.91 6.58 OOR < 18.48 132.86 
C39 M 20 NA 11.13 392.13 3.73 8.39 406.45 11.03 OOR < 22.84 243.23 
C40 F 21 NA  - -  -  -  -  -  -  -  -  
MC1 M 6 RL 8.96 1631.27 0.92 4.93 865.45 4.99 0.60 7.21 145.48 
MC1 M 6 RM 16.72 769.40 2.21 7.27 3489.40 15.45 2.66 31.51 374.49 
MC2 F 4 RL 20.64 4679.28 18.94 11.02 1679.79 12.58 3.14 15.49 103.80 
MC2 F 4 RM 14.17 1029.43 9.12 8.79 1541.67 12.35 0.97 17.67 270.67 
MC3 M 3 RL 15.04 3282.09 14.96 9.08 5161.15 9.48 4.55 17.29 161.69 
MC3 M 3 RM 15.57 5116.05 8.84 5.77 576.29 7.28 4.50 15.46 132.46 
MC4 M 15 RL 13.89 780.99 18.09 2.81 4181.54 20.07 2.95 32.88 207.60 
MC4 M 15 RM 10.56 586.22 14.91 2.36 848.07 16.06 2.19 34.48 294.47 
MC5 F 4 RL 30.55 4273.83 12.62 12.45 661.32 12.64 3.74 23.33 108.76 
MC5 F 4 RM 21.51 3845.84 6.42 8.47 360.35 11.32 1.74 19.03 153.97 
MC6 F 21 RL 19.16 3431.07 8.81 9.43 2169.57 8.60 2.90 18.99 178.64 
MC6 F 21 RM 20.05 1904.23 7.30 9.35 1280.13 10.27 3.09 14.80 160.44 
MC7 F 8 RL 30.14 4891.94 19.25 13.7 189.50 12.83 7.93 20.64 148.35 
MC7 F 8 RM 37.74 4436.98 23.34 17.07 377.51 14.01 10.13 18.48 135.77 
MC8 F 6 RL 20.93 1448.20 7.20 8.39 3509.30 10.33 2.81 22.87 140.50 
MC8 F 6 RM 22.66 4085.22 6.42 5.34 3774.89 7.63 3.40 21.84 171.37 
MC9 M 12 RL 18.13 991.34 12.46 10.24 298.27 7.60 3.44 9.90 124.13 
MC9 M 12 RM 11.36 473.03 7.19 6.84 375.08 6.37 2.64 9.56 105.19 
MC10 M 7 RL 11.82 5467.19 5.66 6.79 2175.54 7.02 0.20 24.63 131.74 
MC10 M 7 RM 5.35 1441.46 3.56 4.44 2239.20 7.08 OOR < 19.54 211.09 
MC11 M 10 RL 28.03 2955.20 20.44 4.19 1169.50 12.20 4.29 19.80 115.41 
MC11 M 10 RM 14.80 262.87 12.76 2.36 1491.72 14.69 2.58 15.25 242.31 
MC12 M 23 RL 70.90 5512.09 63.45 9.43 535.46 25.48 9.41 34.58 231.76 





























MC13  M 3 RL  - -  -  -  -  -  -  -  -  
MC14 F 4 RM  - -  -  -  -  -  -  -  -  
MC15 M 5 RL 36.45 2308.21 31.86 24.13 457.42 16.22 6.24 14.26 102.30 
MC16 M 5 RM  - -  -  -  -  -  -  -  -  
MC17 M 6 RL  - -  -  -  -  -  -  -  -  
MC18 F 7 RM  - -  -  -  -  -  -  -  -  
MC19 M 8 RM 73.96 1884.72 30.16 28.95 778.27 17.35 6.72 26.94 1301.63 
MC20 F 8 RM  - -  -  -  -  -  -  -  -  
MC21 M 9 RL  - -  -  -  -  -  -  -  -  
MC22 M 10 RM  - -  -  -  -  -  -  -  -  
MC23 M 11 RM  - -  -  -  -  -  -  -  -  
MC24 M 13 RL 13.33 1205.36 13.77 11.58 386.21 6.86 3.33 10.85 198.18 
MC25 M 13 RM 8.99 1137.93 6.75 5.82 244.78 3.05 2.15 5.60 133.47 
MC26 M 13 RL 24.18 5174.04 11.35 8.47 282.80 6.74 6.40 12.59 171.36 
MC27 M 13 RL  - -  -  -  -  -  -  -  -  
MC28 F 14 RL  - -  -  -  -  -  -  -  -  
MC29 F 14 RL  - -  -  -  -  -  -  -  -  
MC30 F 14 RL  - -  -  -  -  -  -  -  -  
MC31 M 15 RM  - -  -  -  -  -  -  -  -  
MC32 M 15 RL 33.37 163.06 10.61 8.79 402.87 10.32 3.09 16.01 1505.34 
MC33 M 15 RL  - -  -  -  -  -  -  -  -  
MC34 M 16 RM 11.76 38.39 3.42 5.72 3376.08 4.08 1.33 14.83 1183.51 
MC35 M 17 RL  - -  -  -  -  -  -  -  -  
MC36 M 17 RM  - -  -  -  -  -  -  -  -  
MC37 F 17 RL 32.44 186.49 9.21 10.66 245.18 8.71 2.93 10.60 1581.40 
MC38 M 19 RL  - -  -  -  -  -  -  -  -  
MC39 F 21 RL  - -  -  -  -  -  -  -  -  
MC40 F 25 RL  - -  -  -  -  -  -  -  -  
F1 M 4 RL 11.15 2401.70 14.76 6.90 784.30 6.01 4.35 11.56 131.31 
F2 F 10 RL 28.73 2226.18 22.13 4.60 1371.87 21.34 4.77 13.23 123.15 
F3 F 13 RL 15.14 1591.13 8.61 6.31 5022.46 10.33 2.25 14.06 290.74 
F4 M 13 RL OOR < 3483.38 20.71 5.74 332.53 40.37 0.81 6.74 258.84 
F5 M 15 RL 31.36 2270.58 23.15 18.38 372.14 12.43 5.03 13.79 157.60 
F6 M 17 RL  - -  -  -  -  -  -  -  -  




















C1 M 4 NA 15.34 78.90 1.83 73.74 78.55 
C2 M 4 NA 9.03 83.85 4.42 74.78 86.33 
C3 M 4 NA 5.08 89.83 4.13 70.26 91.11 
C4 M 5 NA 5.74 79.09 0.63 77.35 53.56 
C5 M 5 NA 3.50 91.92 2.33 80.61 85.95 
C6 M 5 NA 3.21 91.54 1.90 77.23 73.19 
C7 M 6 NA 7.03 90.79 0.81 90.09 86.26 
C8 M 6 NA 8.84 85.65 4.31 30.17 52.43 
C9 M 6 NA 2.47 85.30 0.43 55.54 50.90 
C10 M 7 NA 10.76 78.50 9.22 81.66 87.71 
C11 M 7 NA 9.00 83.15 4.38 62.91 65.04 
C12 F 8 NA 5.61 90.05 2.75 84.69 66.45 
C13 M 9 NA 4.63 92.93 1.65 69.39 82.58 
C14 F 10 NA 3.40 91.32 2.55 81.61 86.44 
C15 M 11 NA 0.70 87.25 1.40 81.34 61.36 
C16 M 11 NA 8.79 74.56 10.05 42.15 76.96 
C17 F 11 NA 5.40 84.95 7.26 77.55 78.17 
C18 M 11 NA 1.88 95.66 0.74 86.68 83.76 
C19 F 12 NA 1.99 92.98 3.17 76.95 67.44 
C20 M 12 NA 3.73 83.45 8.71 79.06 82.25 
C21 F 12 NA 8.44 85.75 4.20 84.79 61.86 
C22 F 12 NA 4.53 83.33 10.4 85.26 76.50 
C23 M 13 NA 3.95 91.37 0.00 88.33 60.00 
C24 M 13 NA 3.61 76.81 2.62 72.89 42.01 
C25 F 13 NA 2.86 91.00 4.18 83.51 83.92 
C26 M 13 NA 5.19 87.27 5.06 49.19 71.21 
C27 M 17 NA 15.34 81.02 2.96 95.20 83.50 
C28 F 18 NA 1.67 85.84 5.98 94.09 76.94 
C29 M 18 NA 5.86 90.73 1.25 66.52 55.51 
C30 F 19 NA 2.88 92.71 1.64 91.31 92.94 
C31 M 19 NA 3.56 93.57 0.82 86.56 64.03 
C32 M 19 NA 1.68 88.90 0.79 86.46 40.46 
C33 M 19 NA 9.49 86.28 3.25 87.39 93.79 
C34 M 19 NA 1.95 92.08 2.68 86.79 74.02 
C35 F 19 NA 2.29 93.16 2.23 94.17 94.39 
C36 F 20 NA 1.71 91.97 1.96 78.03 75.37 
C37 M 20 NA 8.17 85.03 3.81 88.40 89.96 
C38 F 20 NA 1.40 94.21 1.66 90.45 84.68 
C39 M 20 NA 1.38 93.59 1.51 92.25 87.00 
C40 F 21 NA 1.13 93.89 0.71 84.54 76.98 
MC1 M 6 RL 5.41 91.98 0.96 86.29 77.57 
MC1 M 6 RM 3.03 92.90 1.06 88.86 87.81 
MC2 F 4 RL 4.20 88.32 1.78 79.24 86.68 
MC2 F 4 RM 3.96 91.90 1.58 85.11 79.72 
MC3 M 3 RL 22.72 68.54 0.00 52.11 66.88 
MC3 M 3 RM 13.40 81.58 3.68 70.42 48.08 
MC4 M 15 RL 3.67 93.11 0.29 76.41 47.35 
MC4 M 15 RM 2.20 87.42 0.63 74.59 72.79 
MC5 F 4 RL 9.23 86.48 3.01 79.85 88.09 
MC5 F 4 RM 4.56 85.18 3.82 81.91 83.84 
MC6 F 21 RL 8.77 88.75 0.76 84.45 51.56 
MC6 F 21 RM 2.42 93.68 0.98 91.87 94.61 
MC7 F 8 RL 0.37 93.61 0.12 90.15 28.39 
MC7 F 8 RM 1.07 87.06 0.37 87.33 44.79 
MC8 F 6 RL 22.53 74.27 2.13 81.05 83.36 
MC8 F 6 RM 5.09 89.09 0.00 81.85 64.84 
MC9 M 12 RL 2.39 91.56 1.28 71.01 62.10 
MC9 M 12 RM 2.25 89.67 4.93 89.13 86.00 
MC10 M 7 RL 5.01 92.39 0.69 91.05 87.39 
MC10 M 7 RM 6.34 90.36 2.19 95.43 85.73 
MC11 M 10 RL 5.07 84.80 0.00 88.94 81.19 
MC11 M 10 RM 3.83 91.07 3.28 89.92 1.67 
MC12 M 23 RL  - -  -  - - 



















MC13  M 3 RL 4.66 86.99 4.03 86.07 68.53 
MC14 F 4 RM 0.54 93.35 5.65 79.98 76.89 
MC15 M 5 RL 0.10 92.09 0.03 91.29 59.65 
MC16 M 5 RM 1.96 88.79 2.64 53.11 74.61 
MC17 M 6 RL 3.56 89.80 3.25 71.64 53.31 
MC18 F 7 RM 4.99 86.72 4.02 76.45 38.46 
MC19 M 8 RM 1.46 84.75 3.33 55.99 31.98 
MC20 F 8 RM 1.98 75.90 0.77 79.81 71.50 
MC21 M 9 RL 3.40 90.24 3.09 80.06 49.01 
MC22 M 10 RM 2.93 88.81 4.15 91.33 77.28 
MC23 M 11 RM 8.19 79.39 8.76 63.83 19.51 
MC24 M 13 RL 3.26 89.82 0.66 88.19 56.52 
MC25 M 13 RM 9.90 74.22 6.06 82.56 50.27 
MC26 M 13 RL 2.93 93.05 2.16 84.50 69.66 
MC27 M 13 RL 4.47 87.07 5.11 77.49 69.97 
MC28 F 14 RL 2.64 85.84 4.55 87.81 82.09 
MC29 F 14 RL 2.64 84.79 2.35 81.63 70.20 
MC30 F 14 RL 5.19 89.79 1.48 62.30 31.14 
MC31 M 15 RM 5.40 87.87 0.38 86.43 32.17 
MC32 M 15 RL 1.18 95.22 0.95 91.86 84.84 
MC33 M 15 RL 9.99 83.01 3.70 66.73 74.38 
MC34 M 16 RM 0.51 85.78 0.74 88.59 56.18 
MC35 M 17 RL 6.08 89.35 1.53 84.11 78.24 
MC36 M 17 RM 15.37 65.30 5.24 62.07 56.33 
MC37 F 17 RL 3.21 92.82 1.05 79.24 70.02 
MC38 M 19 RL 2.34 78.91 1.41 81.12 67.88 
MC39 F 21 RL 6.88 82.16 6.22 78.58 69.36 
MC40 F 25 RL 0.61 91.00 0.68 90.32 59.50 
F1 M 4 RL 15.16 68.57 10.32 63.05 66.18 
F2 F 10 RL 5.28 91.10 0.19 90.04 92.50 
F3 F 13 RL 3.90 84.55 3.90 82.78 87.25 
F4 M 13 RL 3.02 79.72 1.81 74.17 65.78 
F5 M 15 RL 1.28 91.72 0.31 81.94 74.21 
F6 M 17 RL 3.10 88.75 7.30 92.77 77.57 
F7 F 22 RL 0.96 83.26 0.20 72.82 58.39 





Appendix 11: List of DEGs 
List of genes differentially expressed in resting monocytes isolated from MCNS patients in 
paired relapse and remission 
ENTREZ_




Potassium inwardly-rectifying channel, subfamily J, member 
15 0.24 
91662 NLRP12 NLR family, pyrin domain containing 12 0.25 
79689 STEAP4 STEAP family member 4 0.27 
10215 OLIG2 Oligodendrocyte lineage transcription factor 2 0.27 
7850 IL1R2 Iinterleukin 1 receptor, type II  0.28 
123041 SLC24A4 
Solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 4  0.31 
80820 EEPD1 
Endonuclease/exonuclease/phosphatase family domain 
containing 1 0.34 
5654 HTRA1 HtrA serine peptidase 1  0.34 
10170 DHRS9 Dehydrogenase/reductase (SDR family) member 9  0.34 
10630 PDPN Podoplanin 0.35 
1050 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 0.35 
4668 NAGA N-acetylgalactosaminidase, alpha- 0.36 
27151 CPAMD8 
C3 and PZP-like, alpha-2-macroglobulin domain containing 
8  0.38 
53346 TM6SF1 Transmembrane 6 superfamily member 1 0.38 
135228 CD109 CD109 molecule 0.38 
9770 RASSF2 Ras association (RalGDS/AF-6) domain family member 2  0.39 
51330 TNFRSF12A Tumor necrosis factor receptor superfamily, member 12A  0.39 
120939 TMEM52B Transmembrane protein 52B 0.39 
25900 HOM-TES-103 Intermediate filament family orphan 1  0.39 
4739 NEDD9 
Neural precursor cell expressed, developmentally down-
regulated 9  0.39 
55129 ANO10 Anoctamin 10 0.41 
6274 S100A3 S100 calcium binding protein A3  0.41 
57761 TRIB3 Tribbles pseudokinase 3  0.42 
27239 GPR162 G protein-coupled receptor 162 0.42 
50856 CLEC4A C-type lectin domain family 4, member A  0.42 
5468 PPARG Peroxisome proliferator-activated receptor gamma  0.42 
11270 NRM Nurim (nuclear envelope membrane protein)  0.42 
27287 VENTX VENT homeobox 0.43 
26090 ABHD12 Abhydrolase domain containing 12 0.43 
1040 CDS1 
CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1  0.43 
53834 FGFRL1 Fibroblast growth factor receptor-like 1 0.43 
54014 BRWD1 Bromodomain and WD repeat domain containing 1  0.44 
116362 RBP7 Retinol binding protein 7, cellular  0.44 
8751 ADAM15 ADAM metallopeptidase domain 15  0.44 
27097 TAF5L 
TAF5-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa  0.44 
9638 FEZ1 Fasciculation and elongation protein zeta 1 (zygin I)  0.45 
7106 TSPAN4 Tetraspanin 4  0.45 
1524 CX3CR1 Chemokine (C-X3-C motif) receptor 1  0.45 
5049 PAFAH1B2 
Platelet-activating factor acetylhydrolase 1b, catalytic 
subunit 2 (30kDa)  0.45 
284013 VMO1 
Vitelline membrane outer layer 1 homolog (chicken) [ Homo 




Leukocyte immunoglobulin-like receptor, subfamily A (with 
TM domain), member 2  0.46 
929 CD14 CD14 molecule  0.46 
977 CD151 CD151 molecule (Raph blood group) 0.46 
4000 LMNA Lamin A/C 0.46 
146722 CD300LF CD300 molecule-like family member f  0.46 
3084 NRG1 Neuregulin 1  0.46 
2534 FYN FYN oncogene related to SRC, FGR, YES  0.46 
1960 EGR3 Early growth response 3  0.46 
136 ADORA2B Adenosine A2b receptor  0.47 
11260 XPOT Exportin, tRNA  0.47 
8864 PER2 Period circadian clock 2 0.47 
202309 GAPT GRB2-binding adaptor protein, transmembrane 0.48 
134553 C5orf24 Chromosome 5 open reading frame 24  0.48 
91663 MYADM Myeloid-associated differentiation marker  0.48 
1903 S1PR3 Sphingosine-1-phosphate receptor 3  0.48 
11009 IL24 Interleukin 24  0.49 
3556 IL1RAP Interleukin 1 receptor accessory protein  0.49 
2153 F5 Coagulation factor V (proaccelerin, labile factor)  0.49 
26499 PLEK2 Pleckstrin 2  0.49 
4987 OPRL1 Opiate receptor-like 1  0.49 
2359 FPR3 Formyl peptide receptor 3  0.49 
64748 LPPR2 Lipid phosphate phosphatase-related protein type 2  0.49 
116254 GINM1 Glycoprotein integral membrane 1  0.49 
4923 NTSR1 Neurotensin receptor 1 (high affinity)  0.50 
8111 GPR68 G protein-coupled receptor 68  0.50 
57673 KIAA1553 BEN domain containing 3  0.50 
65059 RAPH1 
Ras association (RalGDS/AF-6) and pleckstrin homology 
domains 1  0.50 
257106 ARHGAP30 Rho GTPase activating protein 30 0.50 
55356 SLC22A15 Solute carrier family 22, member 15  0.50 
9778 KIAA0232 KIAA0232 0.50 
6002 RGS12 Regulator of G-protein signaling 12  0.50 
64761 PARP12 Poly (ADP-ribose) polymerase family, member 12 2.00 
8535 CBX4 Chromobox homolog 4  2.00 
94274 PPP1R14A Protein phosphatase 1, regulatory (inhibitor) subunit 14A 2.00 
94039 ZNF101 Zinc finger protein 101  2.00 
79980 DSN1 DSN1, MIS12 kinetochore complex component  2.00 
3696 ITGB8 Integrin, beta 8  2.01 
4621 MYH3 Myosin, heavy chain 3, skeletal muscle, embryonic  2.01 
10912 GADD45G Growth arrest and DNA-damage-inducible, gamma  2.01 
54979 HRASLS2 HRAS-like suppressor 2 2.01 
8654 PDE5A Phosphodiesterase 5A, cGMP-specific  2.01 
6547 SLC8A3 
Solute carrier family 8 (sodium/calcium exchanger), member 
3  2.01 
5664 PSEN2 Presenilin 2 2.01 
55647 RAB20 RAB20, member RAS oncogene family  2.01 
2786 GNG4 Guanine nucleotide binding protein (G protein), gamma 4 2.01 
3665 IRF7 Interferon regulatory factor 7  2.01 
5610 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2  2.01 
4683 NBN Nibrin  2.02 
56265 CPXM1 Carboxypeptidase X (M14 family), member 1  2.02 
1847 DUSP5 Dual specificity phosphatase 5  2.02 
22875 ENPP4 
Ectonucleotide pyrophosphatase/phosphodiesterase 4 
(putative)  2.02 
221188 GPR114 G protein-coupled receptor 114  2.02 
156 
 
11124 FAF1 Fas (TNFRSF6) associated factor 1  2.02 
713 C1QB Complement component 1, q subcomponent, B chain 2.02 
2298 FOXD4 Forkhead box D4  2.02 
7292 TNFSF4 Tumor necrosis factor (ligand) superfamily, member 4 2.02 
11322 TMC6 Transmembrane channel-like 6 2.02 
51715 RAB23 RAB23, member RAS oncogene family  2.02 
4277 MICB MHC class I polypeptide-related sequence B  2.02 
25819 CCRN4L CCR4 carbon catabolite repression 4-like (S. cerevisiae)  2.03 
55843 ARHGAP15 Rho GTPase activating protein 15  2.03 
4938 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa  2.03 
26272 FBXO4 F-box protein 4 2.03 
57511 COG6 Component of oligomeric golgi complex 6 2.03 
9781 RNF144 Ring finger protein 144A  2.03 
25893 TRIM58 Tripartite motif containing 58  2.04 
29087 THYN1 Thymocyte nuclear protein 1  2.04 
3569 IL6 Interleukin 6  2.04 
4582 MUC1 Mucin 1, cell surface associated  2.04 
53335 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein)  2.04 
253782 LASS6 Ceramide synthase 6 2.04 
1728 NQO1 NAD(P)H dehydrogenase, quinone 1  2.04 
84693 MCEE Methylmalonyl CoA epimerase  2.04 
5524 PPP2R4 Protein phosphatase 2A activator, regulatory subunit 4  2.04 
710 SERPING1 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  2.04 
27040 LAT Linker for activation of T cells  2.04 
2882 GPX7 Glutathione peroxidase 7  2.04 
152189 CMTM8 CKLF-like MARVEL transmembrane domain containing 8  2.05 
148753 FAM163A Family with sequence similarity 163, member A  2.05 
653573 GCUD2 Gastric cancer up-regulated-2  2.05 
387921 NHLRC3 NHL repeat containing 3  2.05 
8115 TCL1A T-cell leukemia/lymphoma 1A  2.05 
54464 XRN1 5'-3' exoribonuclease 1  2.05 
285093 FLJ33590 Receptor (chemosensory) transporter protein 5 (putative)  2.05 
113452 TMEM54 Transmembrane protein 54  2.06 
3728 JUP Junction plakoglobin  2.06 
9830 TRIM14 Tripartite motif containing 14  2.06 
2146 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit  2.06 
4939 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa  2.06 
684 BST2 Bone marrow stromal cell antigen 2  2.06 
25996 REXO2 RNA exonuclease 2  2.07 
221178 SPATA13 Spermatogenesis associated 13  2.07 
4352 MPL Myeloproliferative leukemia virus oncogene  2.07 
671 BPI Bactericidal/permeability-increasing protein  2.08 
917 CD3G CD3g molecule, gamma (CD3-TCR complex)  2.08 
147841 SPC24 SPC24, NDC80 kinetochore complex component  2.08 
57730 ANKRD36B Ankyrin repeat domain 36B  2.08 
79792 GSDMD Gasdermin D  2.08 
3592 IL12A Interleukin 12A  2.08 
481 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide  2.08 
23015 GOLGA8A Golgin A8 family, member A  2.08 
55689 YEATS2 YEATS domain containing 2  2.08 
472 ATM Ataxia telangiectasia mutated  2.08 
11332 ACOT7 Acyl-CoA thioesterase 7  2.08 
116071 BATF2 Basic leucine zipper transcription factor, ATF-like 2  2.08 
92745 SLC38A5 Solute carrier family 38, member 5  2.09 
55835 CENPJ Centromere protein J  2.09 
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56344 CABP5 Calcium binding protein 5  2.09 
239 ALOX12 Arachidonate 12-lipoxygenase  2.09 
197259 MLKL Mixed lineage kinase domain-like  2.09 
3915 LAMC1 Laminin, gamma 1 (formerly LAMB2)  2.09 
23362 PSD3 Pleckstrin and Sec7 domain containing 3  2.09 
1117 CHI3L2 Chitinase 3-like 2  2.10 
10563 CXCL13 Chemokine (C-X-C motif) ligand 13  2.10 
10225 CD96 CD96 molecule  2.10 
10460 TACC3 Transforming, acidic coiled-coil containing protein 3  2.10 
3635 INPP5D Inositol polyphosphate-5-phosphatase, 145kDa  2.10 
56829 ZC3HAV1 Zinc finger CCCH-type, antiviral 1  2.10 
575 BAI1 Brain-specific angiogenesis inhibitor 1  2.10 
7318 UBA7 Ubiquitin-like modifier activating enzyme 7  2.10 
4130 MAP1A Microtubule-associated protein 1A  2.11 
9619 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1  2.11 
7035 TFPI 
Tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor)  2.11 
285761 DCBLD1 Discoidin, CUB and LCCL domain containing 1  2.12 
2615 LRRC32 Leucine rich repeat containing 32  2.12 
79156 PLEKHF1 
Pleckstrin homology domain containing, family F (with 
FYVE domain) member 1  2.12 
932 MS4A3 
Membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific)  2.12 
164284 APCDD1L Adenomatosis polyposis coli down-regulated 1-like  2.12 
85363 TRIM5 Tripartite motif containing 5  2.12 
558 AXL AXL receptor tyrosine kinase  2.12 
26147 PHF19 PHD finger protein 19  2.13 
27334 P2RY10 Purinergic receptor P2Y, G-protein coupled, 10  2.13 
51016 FAM158A ER membrane protein complex subunit 9  2.13 
146 ADRA1D Adrenoceptor alpha 1D  2.13 
94240 EPSTI1 Epithelial stromal interaction 1 (breast)  2.13 
4172 MCM3 Minichromosome maintenance complex component 3  2.13 
6752 SSTR2 Somatostatin receptor 2  2.14 
27018 NGFRAP1 
Nerve growth factor receptor (TNFRSF16) associated 
protein 1  2.14 
389119 FAM212A Family with sequence similarity 212, member A  2.14 
7465 WEE1 WEE1 G2 checkpoint kinase  2.14 
3725 JUN jun proto-oncogene  2.14 
50619 DEF6 Differentially expressed in FDCP 6 homolog (mouse)  2.14 
6947 TCN1 
Transcobalamin I (vitamin B12 binding protein, R binder 
family)  2.14 
51463 GPR89A G protein-coupled receptor 89B  2.15 
6304 SATB1 SATB homeobox 1  2.15 
142 PARP1 Poly (ADP-ribose) polymerase 1  2.15 
26275 HIBCH 3-hydroxyisobutyryl-CoA hydrolase  2.15 
10392 NOD1 Nucleotide-binding oligomerization domain containing 1 2.15 
154075 SAMD3 Sterile alpha motif domain containing 3  2.15 
84068 SLC10A7 Solute carrier family 10, member 7  2.15 
55876 GSDMB Gasdermin B  2.16 
2021 ENDOG Endonuclease G 2.16 
57153 SLC44A2 Solute carrier family 44 (choline transporter), member 2  2.16 
63939 FAM217B Family with sequence similarity 217, member B  2.16 
24147 FJX1 Four jointed box 1 (Drosophila)  2.16 
54497 HEATR5B HEAT repeat containing 5B  2.16 
6238 RRBP1 Ribosome binding protein 1  2.17 
2017 CTTN Cortactin  2.17 
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3437 IFIT3 Interferon-induced protein with tetratricopeptide repeats 3  2.17 
4174 MCM5 Minichromosome maintenance complex component 5  2.18 
6773 STAT2 Signal transducer and activator of transcription 2, 113kDa  2.18 
10673 TNFSF13B Tumor necrosis factor (ligand) superfamily, member 13b  2.18 
28960 DCPS Decapping enzyme, scavenger  2.18 
820 CAMP Cathelicidin antimicrobial peptide  2.18 
115362 GBP5 Guanylate binding protein 5  2.18 
54832 VPS13C 
Vacuolar protein sorting 13 homolog C (S. 
cerevisiae) [ Homo sapiens (human) ] 2.18 
65008 MRPL1 Mitochondrial ribosomal protein L1  2.18 
26230 TIAM2 T-cell lymphoma invasion and metastasis 2  2.19 
79960 PHF17 Jade family PHD finger 17  2.19 
55422 ZNF331 Zinc finger protein 331  2.19 
5414 SEPT4 Septin 4  2.19 
23043 TNIK TRAF2 and NCK interacting kinase  2.19 
150864 ALS2CR13 Family with sequence similarity 117, member B  2.19 
64407 RGS18 Regulator of G-protein signaling 18  2.19 
580 BARD1 BRCA1 associated RING domain 1  2.19 
55544 RBM38 RNA binding motif protein 38  2.19 
81788 NUAK2 NUAK family, SNF1-like kinase, 2  2.19 
2273 FHL1 Four and a half LIM domains 1  2.20 
6372 CXCL6 Chemokine (C-X-C motif) ligand 6  2.20 
5786 PTPRA Protein tyrosine phosphatase, receptor type, A  2.20 
80162 ATHL1 ATH1, acid trehalase-like 1 (yeast)  2.20 
8555 CDC14B Cell division cycle 14B  2.20 
6689 SPIB Spi-B transcription factor (Spi-1/PU.1 related)  2.21 
8835 SOCS2 Suppressor of cytokine signaling 2  2.21 
445347 TARP TCR gamma alternate reading frame protein  2.21 
132320 SCLT1 Sodium channel and clathrin linker 1  2.21 
6772 STAT1 signal transducer and activator of transcription 1, 91kDa  2.21 
5698 PSMB9 Proteasome (prosome, macropain) subunit, beta type, 9  2.21 
64919 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein)  2.21 
26255 PTTG3 Pituitary tumor-transforming 3, pseudogene  2.21 
970 CD70 CD70 molecule  2.22 
10346 TRIM22 Tripartite motif containing 22  2.22 
1429 CRYZ Crystallin, zeta (quinone reductase)  2.22 
55062 WIPI1 WD repeat domain, phosphoinositide interacting 1  2.22 
50615 IL21R Interleukin 21 receptor  2.23 
2354 FOSB FBJ murine osteosarcoma viral oncogene homolog B  2.23 
84561 SLC12A8 Solute carrier family 12, member 8  2.23 
10681 GNB5 Guanine nucleotide binding protein (G protein), beta 5  2.23 
8542 APOL1 Apolipoprotein L, 1  2.23 
24141 LAMP5 Lysosomal-associated membrane protein family, member 5  2.23 
5451 POU2F1 POU class 2 homeobox 1  2.24 
10398 MYL9 Myosin, light chain 9, regulatory  2.24 
8345 HIST1H2BH histone cluster 1, H2bh  2.25 
10079 ATP9A histone cluster 1, H2bh 2.25 
2644 GCHFR GTP cyclohydrolase I feedback regulator  2.25 
3431 SP110 SP110 nuclear body protein  2.25 
11118 BTN3A2 Butyrophilin, subfamily 3, member A2  2.26 
84446 BRSK1 BR serine/threonine kinase 1  2.26 
10018 BCL2L11 BCL2-like 11 (apoptosis facilitator)  2.26 
80344 WDR23 DDB1 and CUL4 associated factor 11  2.26 
10561 IFI44 Interferon-induced protein 44  2.26 




Pro-platelet basic protein (chemokine (C-X-C motif) ligand 
7)  2.26 
57214 CEMIP Cell migration inducing protein, hyaluronan binding  2.26 
65987 KCTD14 Potassium channel tetramerization domain containing 14  2.26 
8479 HIRIP3 HIRA interacting protein 3  2.27 
3554 IL1R1 Interleukin 1 receptor, type I  2.27 
3006 HIST1H1C Histone cluster 1, H1c  2.27 
8807 IL18RAP Interleukin 18 receptor accessory protein  2.27 
118932 ANKRD22 Ankyrin repeat domain 22  2.28 
83707 TRPT1 tRNA phosphotransferase 1  2.28 
54923 LIME1 Lck interacting transmembrane adaptor 1  2.28 
23586 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58  2.28 
56672 C11orf17 A kinase (PRKA) interacting protein 1  2.28 
7124 TNF Tumor necrosis factor  2.28 
10235 RASGRP2 
RAS guanyl releasing protein 2 (calcium and DAG-
regulated)  2.28 
8320 EOMES Eomesodermin  2.29 
4599 MX1 
Myxovirus (influenza virus) resistance 1, interferon-
inducible protein p78 (mouse) [ Homo sapiens (human) ] 2.29 
1152 CKB Creatine kinase, brain  2.29 
128553 TSHZ2 Teashirt zinc finger homeobox 2 2.30 
958 CD40 CD40 molecule, TNF receptor superfamily member 5  2.30 
5627 PROS1 Protein S (alpha)  2.30 
4050 LTB Lymphotoxin beta (TNF superfamily, member 3)  2.30 
644314 MTE Metallothionein 1I, pseudogene  2.30 
160365 CLECL1 C-type lectin-like 1  2.30 
9368 SLC9A3R1 
Solute carrier family 9, subfamily A (NHE3, cation proton 
antiporter 3), member 3 regulator 1  2.30 
595 CCND1 Cyclin D1  2.30 
55337 C19orf66 Chromosome 19 open reading frame 66  2.30 
51337 C8orf55 Thioesterase superfamily member 6  2.31 
2069 EREG Epiregulin  2.31 
3925 STMN1 Stathmin 1  2.31 
284040 CDRT4 CMT1A duplicated region transcript 4  2.31 
6039 RNASE6 Ribonuclease, RNase A family, k6  2.31 
60468 BACH2 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 2  2.32 
987 LRBA 
LPS-responsive vesicle trafficking, beach and anchor 
containing  2.32 
84532 ACSS1 Acyl-CoA synthetase short-chain family member 1  2.33 
55601 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60  2.33 
2669 GEM GTP binding protein overexpressed in skeletal muscle  2.33 
894 CCND2 Cyclin D2  2.33 
3627 CXCL10 Chemokine (C-X-C motif) ligand 10  2.34 
899 CCNF Cyclin F  2.34 
8334 HIST1H2AC Histone cluster 1, H2ac  2.34 
8349 HIST2H2BE Histone cluster 2, H2be  2.34 
90634 N4BP2L1 NEDD4 binding protein 2-like 1  2.34 
10045 SH2D3A SH2 domain containing 3A  2.35 
80231 CXorf21 Chromosome X open reading frame 21  2.35 
24138 IFIT5 Interferon-induced protein with tetratricopeptide repeats 5  2.35 
89853 MVB12B Multivesicular body subunit 12B  2.35 
84900 RNFT2 Ring finger protein, transmembrane 2  2.35 
151888 BTLA B and T lymphocyte associated  2.35 
11184 MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1  2.35 
7982 ST7 Suppression of tumorigenicity 7  2.35 
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10365 KLF2 Kruppel-like factor 2  2.36 
9744 ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1  2.36 
54809 SAMD9 Sterile alpha motif domain containing 9  2.36 
5883 RAD9A RAD9 homolog A (S. pombe) [ Homo sapiens (human) ]  2.37 
90843 TCEAL8 Transcription elongation factor A (SII)-like 8  2.37 
4929 NR4A2 Nuclear receptor subfamily 4, group A, member 2  2.37 
26999 CYFIP2 Cytoplasmic FMR1 interacting protein 2  2.37 
90952 ESAM Endothelial cell adhesion molecule  2.38 
79586 CHPF Chondroitin polymerizing factor  2.38 
493861 EID3 EP300 interacting inhibitor of differentiation 3  2.38 
152485 ZNF827 Zinc finger protein 827  2.38 
1111 CHEK1 Checkpoint kinase 1  2.38 
3620 INDO Indoleamine 2,3-dioxygenase 1  2.38 
374659 HDDC3 HD domain containing 3  2.39 
90488 C12orf23 Transmembrane protein 263  2.39 
56300 IL1F9 Interleukin 36, gamma  2.39 
1879 EBF1 Early B-cell factor 1  2.39 
200316 APOBEC3F 
Apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3F  2.40 
6526 SLC5A3 
Solute carrier family 5 (sodium/myo-inositol cotransporter), 
member 3  2.40 
3674 ITGA2B 
Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa 
complex, antigen CD41)  2.40 
4063 LY9 Lymphocyte antigen 9  2.40 
664 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3  2.40 
5294 PIK3CG 
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit gamma  2.40 
2113 ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1  2.40 
825 CAPN3 Calpain 3, (p94)  2.41 
8013 NR4A3 Nuclear receptor subfamily 4, group A, member 3  2.41 
9258 MFHAS1 Malignant fibrous histiocytoma amplified sequence 1  2.41 
4121 MAN1A1 Mannosidase, alpha, class 1A, member 1  2.42 
3690 ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)  2.42 
6925 TCF4 Transcription factor 4  2.42 
130589 GALM Galactose mutarotase (aldose 1-epimerase)  2.42 
5569 PKIA Protein kinase (cAMP-dependent, catalytic) inhibitor alpha  2.43 
6037 RNASE3 Ribonuclease, RNase A family, 3  2.43 
5270 SERPINE2 
Serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2  2.43 
1672 DEFB1 Defensin, beta 1  2.44 
23225 NUP210 Nucleoporin 210kDa  2.44 
113246 C12orf57 Chromosome 12 open reading frame 57  2.44 
8418 CMAH 
Cytidine monophospho-N-acetylneuraminic acid 
hydroxylase, pseudogene  2.45 
6638 SNRPN Small nuclear ribonucleoprotein polypeptide N  2.45 
9246 UBE2L6 Ubiquitin-conjugating enzyme E2L 6  2.45 
1511 CTSG Cathepsin G  2.46 
93082 LINCR Neuralized E3 ubiquitin protein ligase 3  2.46 
5920 RARRES3 Retinoic acid receptor responder (tazarotene induced) 3  2.46 
171558 PTCRA Pre T-cell antigen receptor alpha  2.46 
5984 RFC4 Replication factor C (activator 1) 4, 37kDa  2.46 
154043 CNKSR3 CNKSR family member 3  2.47 
9524 GPSN2 Trans-2,3-enoyl-CoA reductase  2.47 
7001 PRDX2 Peroxiredoxin 2  2.47 
10403 NDC80 NDC80 kinetochore complex component  2.47 
10966 RAB40B RAB40B, member RAS oncogene family  2.47 
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94120 SYTL3 Synaptotagmin-like 3  2.48 
22837 COBLL1 Cordon-bleu WH2 repeat protein-like 1  2.48 
5144 PDE4D Phosphodiesterase 4D, cAMP-specific  2.49 
10150 MBNL2 Muscleblind-like splicing regulator 2  2.49 
4033 LRMP Lymphoid-restricted membrane protein  2.49 
345778 MTX3 Metaxin 3  2.49 
56204 FAM214A Family with sequence similarity 214, member A  2.50 
84681 HINT2 Histidine triad nucleotide binding protein 2  2.50 
1647 GADD45A Growth arrest and DNA-damage-inducible, alpha  2.50 
10188 TNK2 Tyrosine kinase, non-receptor, 2  2.50 
7277 TUBA4A Tubulin, alpha 4a  2.51 
8365 HIST1H4H Histone cluster 1, H4h  2.51 
2621 GAS6 Growth arrest-specific 6  2.51 
6891 TAP2 
Transporter 2, ATP-binding cassette, sub-family B 
(MDR/TAP)  2.51 
641 BLM Bloom syndrome, RecQ helicase-like  2.51 
286530 P2RY8 Purinergic receptor P2Y, G-protein coupled, 8  2.52 
160518 DENND5B DENN/MADD domain containing 5B  2.52 
9601 PDIA4 Protein disulfide isomerase family A, member 4  2.52 
11040 PIM2 Pim-2 oncogene  2.53 
3669 ISG20 Interferon stimulated exonuclease gene 20kDa  2.53 
51449 PCYOX1 Prenylcysteine oxidase 1  2.53 
25780 RASGRP3 
RAS guanyl releasing protein 3 (calcium and DAG-
regulated)  2.54 
200350 FOXD4L1 Forkhead box D4-like 1  2.54 
6363 CCL19 Chemokine (C-C motif) ligand 19  2.54 
51266 CLEC1B C-type lectin domain family 1, member B  2.54 
23224 SYNE2 Spectrin repeat containing, nuclear envelope 2  2.54 
84519 ACRBP Acrosin binding protein  2.55 
123606 NIPA1 Non imprinted in Prader-Willi/Angelman syndrome 1  2.56 
4925 NUCB2 Nucleobindin 2  2.56 
57801 HES4 Hes family bHLH transcription factor 4  2.56 
64785 GINS3 GINS complex subunit 3 (Psf3 homolog)  2.56 
3662 IRF4 Interferon regulatory factor 4  2.56 
9212 AURKB Aurora kinase B  2.56 
2788 GNG7 Guanine nucleotide binding protein (G protein), gamma 7  2.56 
55755 CDK5RAP2 CDK5 regulatory subunit associated protein 2  2.56 
3601 IL15RA Interleukin 15 receptor, alpha  2.57 
6775 STAT4 Signal transducer and activator of transcription 4  2.57 
23705 CADM1 Cell adhesion molecule 1  2.57 
5557 PRIM1 Primase, DNA, polypeptide 1 (49kDa)  2.58 
2869 GRK5 G protein-coupled receptor kinase 5  2.59 
27242 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21  2.59 
309 ANXA6 Annexin A6 2.59 
3202 HOXA5 Homeobox A5  2.59 
2762 GMDS GDP-mannose 4,6-dehydratase  2.59 
1039 CDR2 Cerebellar degeneration-related protein 2, 62kDa  2.60 
125050 RN7SK RNA, 7SK small nuclear  2.60 
59345 GNB4 
Guanine nucleotide binding protein (G protein), beta 
polypeptide 4  2.60 
10384 BTN3A3 Butyrophilin, subfamily 3, member A3  2.61 
59 ACTA2 Actin, alpha 2, smooth muscle, aorta  2.61 
656 BMP8B Bone morphogenetic protein 8b  2.62 
6614 SIGLEC1 Sialic acid binding Ig-like lectin 1, sialoadhesin  2.62 
51561 IL23A Interleukin 23, alpha subunit p19  2.62 
1437 CSF2 Colony stimulating factor 2 (granulocyte-macrophage)  2.62 
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5037 PEBP1 Phosphatidylethanolamine binding protein 1  2.63 
80342 TRAF3IP3 TRAF3 interacting protein 3  2.63 
26586 CKAP2 Cytoskeleton associated protein 2  2.63 
151313 FAHD2B Fumarylacetoacetate hydrolase domain containing 2B  2.63 
3978 LIG1 Ligase I, DNA, ATP-dependent  2.63 
84875 PARP10 Poly (ADP-ribose) polymerase family, member 10  2.63 
23780 APOL2 Apolipoprotein L, 2  2.63 
83666 PARP9 Poly (ADP-ribose) polymerase family, member 9  2.64 
51203 NUSAP1 Nucleolar and spindle associated protein 1  2.64 
54739 XAF1 XIAP associated factor 1  2.64 
994 CDC25B Cell division cycle 25B  2.65 
2744 GLS Glutaminase  2.66 
54602 NDFIP2 Nedd4 family interacting protein 2  2.66 
4693 NDP Norrie disease (pseudoglioma)  2.67 
25865 PRKD2 Protein kinase D2  2.67 
26157 GIMAP2 GTPase, IMAP family member 2  2.67 
55303 GIMAP4 GTPase, IMAP family member 4  2.67 
9402 GRAP2 GRB2-related adaptor protein 2  2.68 
10667 FARS2 Phenylalanyl-tRNA synthetase 2, mitochondrial  2.69 
8743 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10  2.69 
5150 PDE7A Phosphodiesterase 7A  2.69 
4489 MT1A Metallothionein 1A  2.70 
90701 SEC11C SEC11 homolog C (S. cerevisiae) [ Homo sapiens (human) ]  2.70 
29993 PACSIN1 Protein kinase C and casein kinase substrate in neurons 1  2.71 
51303 FKBP11 FK506 binding protein 11, 19 kDa  2.71 
6480 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1  2.72 
983 CDC2 Cyclin-dependent kinase 1  2.72 
100133941 CD24 CD24 molecule  2.73 
115361 GBP4 Guanylate binding protein 4  2.73 
55024 BANK1 B-cell scaffold protein with ankyrin repeats 1  2.73 
92797 HELB Helicase (DNA) B  2.74 
51471 NAT8B 
N-acetyltransferase 8B (GCN5-related, putative, 
gene/pseudogene)  2.74 
23457 ABCB9 ATP-binding cassette, sub-family B (MDR/TAP), member 9  2.75 
8613 PPAP2B Phosphatidic acid phosphatase type 2B  2.75 
4094 MAF 
v-maf avian musculoaponeurotic fibrosarcoma oncogene 
homolog  2.76 
473 RERE Arginine-glutamic acid dipeptide (RE) repeats  2.76 
55204 GOLPH3L Golgi phosphoprotein 3-like  2.76 
4343 MOV10 
Mov10, Moloney leukemia virus 10, homolog (mouse) 
[ Homo sapiens (human) ]  2.77 
10800 CYSLTR1 Cysteinyl leukotriene receptor 1  2.78 
113263 GLCCI1 Glucocorticoid induced transcript 1  2.79 
634 CEACAM1 
Carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein)  2.80 
2530 FUT8 Fucosyltransferase 8 (alpha (1,6) fucosyltransferase)  2.80 
2999 GZMH Granzyme H (cathepsin G-like 2, protein h-CCPX)  2.80 
3017 HIST1H2BD Histone cluster 1, H2bd  2.80 
4940 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa  2.80 
51176 LEF1 Lymphoid enhancer-binding factor 1  2.81 
10039 PARP3 Poly (ADP-ribose) polymerase family, member 3  2.81 
149628 PYHIN1 Pyrin and HIN domain family, member 1  2.81 
4502 MT2A Metallothionein 2A  2.82 
7466 WFS1 Wolfram syndrome 1 (wolframin)  2.82 
10826 FAXDC2 Fatty acid hydroxylase domain containing 2  2.82 
10314 LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial)  2.83 
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2274 FHL2 Four and a half LIM domains 2  2.83 
4818 NKG7 Natural killer cell granule protein 7  2.83 
7188 TRAF5 TNF receptor-associated factor 5  2.84 
8801 SUCLG2 Succinate-CoA ligase, GDP-forming, beta subunit  2.85 
3695 ITGB7 Integrin, beta 7  2.85 
284439 SLC25A42 Solute carrier family 25, member 42  2.85 
400754 FLJ45337 FLJ45337 protein  2.86 
2731 GLDC Glycine dehydrogenase (decarboxylating)  2.87 
80063 ATF7IP2 Activating transcription factor 7 interacting protein 2  2.88 
55840 EAF2 ELL associated factor 2  2.88 
3983 ABLIM1 Actin binding LIM protein 1  2.89 
259266 ASPM 
Asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila)  2.92 
55281 TMEM140 Transmembrane protein 140  2.92 
55615 PRR5 Proline rich 5 (renal)  2.93 
10581 IFITM2 Interferon induced transmembrane protein 2  2.93 
140465 MYL6B 
Myosin, light chain 6B, alkali, smooth muscle and non-
muscle  2.94 
11262 SP140 SP140 nuclear body protein  2.94 
3434 IFIT1 Interferon-induced protein with tetratricopeptide repeats 1  2.94 
5168 ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2  2.94 
80017 C14orf159 Chromosome 14 open reading frame 159  2.95 
55165 CEP55 Centrosomal protein 55kDa  2.96 
1991 ELA2 Elastase, neutrophil expressed  2.96 
80021 TMEM62 Transmembrane protein 62  2.96 
114881 OSBPL7 Oxysterol binding protein-like 7  2.98 
54981 NMRK1 Nicotinamide riboside kinase 1  2.98 
10578 GNLY Granulysin  2.99 
116843 C6orf192 Solute carrier family 18, subfamily B, member 1  2.99 
120 ADD3 Adducin 3 (gamma)  2.99 
440270 GOLGA8B Golgin A8 family, member B  2.99 
126306 JSRP1 Junctional sarcoplasmic reticulum protein 1  3.00 
57520 HECW2 
HECT, C2 and WW domain containing E3 ubiquitin protein 
ligase 2  3.00 
9500 MAGED1 Melanoma antigen family D, 1  3.00 
83888 FGFBP2 Fibroblast growth factor binding protein 2  3.00 
9124 PDLIM1 PDZ and LIM domain 1  3.02 
150094 SNF1LK Salt-inducible kinase 1  3.02 
84705 GTPBP3 GTP binding protein 3 (mitochondrial)  3.04 
10276 NET1 Neuroepithelial cell transforming 1 3.05 
26010 LOC26010 Spermatogenesis associated, serine-rich 2-like  3.05 
9133 CCNB2 Cyclin B2  3.05 
79132 DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58  3.05 
6504 SLAMF1 
Signaling lymphocytic activation molecule family member 
1  3.06 
1669 DEFA4 Defensin, alpha 4, corticostatin  3.06 
974 CD79B CD79b molecule, immunoglobulin-associated beta  3.06 
57714 KIAA1618 KIAA1618 3.06 
1875 E2F5 E2F transcription factor 5, p130-binding  3.07 
1668 DEFA3 Defensin, alpha 3, neutrophil-specific  3.07 
3112 HLA-DOB Major histocompatibility complex, class II, DO beta  3.08 
57733 GBA3 Glucosidase, beta, acid 3  3.08 
3543 IGLL1 Immunoglobulin lambda-like polypeptide 1  3.10 
51251 NT5C3 5'-nucleotidase, cytosolic IIIA  3.11 
6004 RGS16 Regulator of G-protein signaling 16  3.12 
8744 TNFSF9 Tumor necrosis factor (ligand) superfamily, member 9  3.12 
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1594 CYP27B1 Cytochrome P450, family 27, subfamily B, polypeptide 1  3.13 
57185 NPAL3 NIPA-like domain containing 3  3.13 
84281 MGC13057 Chromosome 2 open reading frame 88  3.14 
7980 TFPI2 Tissue factor pathway inhibitor 2  3.18 
2537 IFI6 Interferon, alpha-inducible protein 6  3.18 
9735 KNTC1 Kinetochore associated 1  3.18 
81567 TXNDC5 Thioredoxin domain containing 5 (endoplasmic reticulum)  3.19 
201475 RAB12 RAB12, member RAS oncogene family  3.20 
10562 OLFM4 Olfactomedin 4  3.21 
728358 DEFA1B Defensin, alpha 1B  3.21 
8993 PGLYRP1 Peptidoglycan recognition protein 1  3.21 
64151 NCAPG Non-SMC condensin I complex, subunit G  3.22 
389692 MAFA 
v-maf avian musculoaponeurotic fibrosarcoma oncogene 
homolog A  3.22 
79037 PVRIG 
Poliovirus receptor related immunoglobulin domain 
containing  3.24 
400986 ANKRD36C Ankyrin repeat domain 36C  3.25 
9214 FAIM3 Fas apoptotic inhibitory molecule 3  3.25 
1440 CSF3 Colony stimulating factor 3 (granulocyte)  3.25 
3430 IFI35 Interferon-induced protein 35  3.25 
1870 E2F2 E2F transcription factor 2  3.26 
65244 SPATS2 Spermatogenesis associated, serine-rich 2  3.26 
50650 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3  3.26 
10750 GRAP GRB2-related adaptor protein  3.27 
84433 CARD11 Caspase recruitment domain family, member 11  3.27 
11119 BTN3A1 Butyrophilin, subfamily 3, member A1  3.28 
2766 GMPR Guanosine monophosphate reductase  3.29 
3934 LCN2 Lipocalin 2  3.29 
60489 APOBEC3G 
Apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G  3.29 
7298 TYMS Thymidylate synthetase  3.30 
5551 PRF1 Perforin 1 (pore forming protein)  3.30 
113130 CDCA5 Cell division cycle associated 5  3.31 
973 CD79A CD79a molecule, immunoglobulin-associated alpha  3.31 
145864 HAPLN3 Hyaluronan and proteoglycan link protein 3  3.31 
22806 IKZF3 IKAROS family zinc finger 3 (Aiolos)  3.32 
7083 TK1 Thymidine kinase 1, soluble  3.33 
7153 TOP2A Topoisomerase (DNA) II alpha 170kDa  3.33 
57674 RNF213 Ring finger protein 213 3.33 
4049 LTA Lymphotoxin alpha  3.33 
388125 NLF2 C2 calcium-dependent domain containing 4B  3.33 
129607 CMPK2 
Cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial  3.34 
26053 AUTS2 Autism susceptibility candidate 2  3.37 
10046 MAMLD1 Mastermind-like domain containing 1  3.37 
9636 ISG15 ISG15 ubiquitin-like modifier  3.37 
55008 HERC6 
HECT and RLD domain containing E3 ubiquitin protein 
ligase family member 6  3.37 
51466 EVL Enah/Vasp-like  3.37 
29851 ICOS Inducible T-cell co-stimulator  3.38 
5730 PTGDS Prostaglandin D2 synthase 21kDa (brain)  3.38 
5157 PDGFRL Platelet-derived growth factor receptor-like  3.38 
9585 KIF20B Kinesin family member 20B  3.40 
8718 TNFRSF25 Tumor necrosis factor receptor superfamily, member 25  3.42 
3676 ITGA4 
Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor)  3.42 
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79022 TMEM106C Transmembrane protein 106C  3.43 
3512 IGJ 
Immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides  3.45 
8820 HESX1 HESX homeobox 1  3.46 
140691 TRIM69 Tripartite motif containing 69  3.46 
923 CD6 CD6 molecule  3.47 
3161 HMMR Hyaluronan-mediated motility receptor (RHAMM)  3.48 
3001 GZMA 
Granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3)  3.49 
10410 IFITM3 Interferon induced transmembrane protein 3  3.49 
890 CCNA2 Cyclin A2  3.51 
80008 TMEM156 Transmembrane protein 156  3.51 
25849 PARM1 Prostate androgen-regulated mucin-like protein 1  3.53 
91624 NEXN Nexilin (F actin binding protein)  3.54 
84941 HSH2D Hematopoietic SH2 domain containing  3.55 
26040 SETBP1 SET binding protein 1  3.56 
28951 TRIB2 Tribbles pseudokinase 2  3.58 
65258 MPPE1 Metallophosphoesterase 1  3.61 
143888 KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 2  3.61 
1667 DEFA1 Defensin, alpha 1  3.65 
7049 TGFBR3 Transforming growth factor, beta receptor III  3.68 
27314 RAB30 RAB30, member RAS oncogene family  3.69 
246778 IL27 Interleukin 27  3.72 
219285 SAMD9L Sterile alpha motif domain containing 9-like  3.72 
203328 SUSD3 Sushi domain containing 3  3.74 
9941 ENDOGL1 Endo/exonuclease (5'-3'), endonuclease G-like  3.75 
51191 HERC5 
HECT and RLD domain containing E3 ubiquitin protein 
ligase 5  3.75 
3710 ITPR3 Inositol 1,4,5-trisphosphate receptor, type 3  3.75 
160897 GPR180 G protein-coupled receptor 180  3.76 
81618 ITM2C Integral membrane protein 2C  3.78 
291 SLC25A4 
Solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 4  3.79 
6491 STIL SCL/TAL1 interrupting locus  3.80 
3820 KLRB1 Killer cell lectin-like receptor subfamily B, member 1  3.84 
3833 KIFC1 Kinesin family member C1  3.85 
10964 IFI44L Interferon-induced protein 44-like  3.85 
9768 KIAA0101 KIAA0101  3.85 
11065 UBE2C Ubiquitin-conjugating enzyme E2C  3.86 
80176 SPSB1 
SplA/ryanodine receptor domain and SOCS box containing 
1  3.88 
3487 IGFBP4 Insulin-like growth factor binding protein 4  3.89 
1901 S1PR1 Sphingosine-1-phosphate receptor 1  3.89 
57713 SFMBT2 Scm-like with four mbt domains 2  3.90 
4316 MMP7 Matrix metallopeptidase 7 (matrilysin, uterine)  3.93 
857 CAV1 Caveolin 1, caveolae protein, 22kDa  3.94 
999 CDH1 Cadherin 1, type 1, E-cadherin (epithelial)  3.95 
3911 LAMA5 Laminin, alpha 5  3.95 
3902 LAG3 Lymphocyte-activation gene 3  3.95 
3959 LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein  3.96 
23495 TNFRSF13B Tumor necrosis factor receptor superfamily, member 13B  3.99 
81030 ZBP1 Z-DNA binding protein 1  4.03 
26228 BRDG1 Signal transducing adaptor family member 1  4.04 
84166 NLRC5 NLR family, CARD domain containing 5  4.07 
6518 SLC2A5 
Solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5  4.07 
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26137 ZBTB20 Zinc finger and BTB domain containing 20  4.08 
23231 SEL1L3 
sel-1 suppressor of lin-12-like 3 (C. elegans) [ Homo sapiens 
(human) ]  4.10 
84969 TOX2 TOX high mobility group box family member 2  4.11 
91543 RSAD2 Radical S-adenosyl methionine domain containing 2  4.14 
608 TNFRSF17 Tumor necrosis factor receptor superfamily, member 17  4.19 
643 CXCR5 Chemokine (C-X-C motif) receptor 5  4.20 
27033 ZBTB32 Zinc finger and BTB domain containing 32  4.21 
163702 IL28RA Interferon, lambda receptor 1  4.21 
3003 GZMK Granzyme K (granzyme 3; tryptase II)  4.24 
57559 STAMBPL1 STAM binding protein-like 1  4.25 
27075 TSPAN13 Tetraspanin 13  4.27 
29121 CLEC2D C-type lectin domain family 2, member D  4.28 
915 CD3D CD3d molecule, delta (CD3-TCR complex)  4.32 
1088 CEACAM8 Carcinoembryonic antigen-related cell adhesion molecule 8  4.34 
9022 CLIC3 Chloride intracellular channel 3  4.34 
699 BUB1 BUB1 mitotic checkpoint serine/threonine kinase  4.36 
9697 TRAM2 Translocation associated membrane protein 2  4.37 
91523 PCED1B PC-esterase domain containing 1B  4.38 
113791 PIK3IP1 Phosphoinositide-3-kinase interacting protein 1  4.40 
4061 LY6E Lymphocyte antigen 6 complex, locus E  4.42 
55501 CHST12 Carbohydrate (chondroitin 4) sulfotransferase 12  4.43 
6711 SPTBN1 Spectrin, beta, non-erythrocytic 1  4.45 
3560 IL2RB Interleukin 2 receptor, beta  4.46 
399665 FAM102A Family with sequence similarity 102, member A  4.55 
952 CD38 CD38 molecule  4.57 
132299 OCIAD2 OCIA domain containing 2  4.60 
8357 HIST1H3H Histone cluster 1, H3h  4.68 
914 CD2 CD2 molecule  4.69 
54855 FAM46C Family with sequence similarity 46, member C  4.72 
64108 RTP4 Receptor (chemosensory) transporter protein 4  4.76 
474344 GIMAP6 GTPase, IMAP family member 6  4.76 
3002 GZMB 
Granzyme B (granzyme 2, cytotoxic T-lymphocyte-
associated serine esterase 1)  4.76 
5790 PTPRCAP 
Protein tyrosine phosphatase, receptor type, C-associated 
protein  4.79 
54847 SIDT1 SID1 transmembrane family, member 1  4.91 
84174 SLA2 Src-like-adaptor 2  4.92 
54900 LAX1 Lymphocyte transmembrane adaptor 1  4.96 
991 CDC20 Cell division cycle 20  4.98 
2833 CXCR3 Chemokine (C-X-C motif) receptor 3  5.02 
939 CD27 CD27 molecule  5.09 
5450 POU2AF1 POU class 2 associating factor 1  5.13 
389289 ANXA2R Annexin A2 receptor  5.18 
57172 CAMK1G Calcium/calmodulin-dependent protein kinase IG  5.25 
51237 MZB1 Marginal zone B and B1 cell-specific protein  5.30 
3593 IL12B Interleukin 12B 6.02 
3702 ITK IL2-inducible T-cell kinase  6.18 
925 CD8A CD8a molecule  6.24 
81606 LBH Limb bud and heart development  6.39 
930 CD19 CD19 molecule  6.45 
26051 PPP1R16B Protein phosphatase 1, regulatory subunit 16B  6.57 
9381 OTOF Otoferlin  6.73 
114836 SLAMF6 SLAM family member 6  7.07 
91353 IGLL3 Immunoglobulin lambda-like polypeptide 3, pseudogene  7.15 
4283 CXCL9 Chemokine (C-X-C motif) ligand 9  7.30 
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924 CD7 CD7 molecule 8.23 
919 CD247 CD247 molecule 8.94 
8519 IFITM1 Interferon induced transmembrane protein 1  9.39 
9806 SPOCK2 
Sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 2  9.53 
3429 IFI27 Interferon, alpha-inducible protein 27  26.23 
Each gene is given a representative ENTREZ_GENE_ID, gene symbol, gene description and fold 
change (relative to paired remission; values lesser than or equal to 0.5 represent downregulation of 
genes by 2- or more fold; values greater than or equal to 2 represent upregulation of genes by 2- or 




Appendix 12: Biochemistry profile of rats 
 











RC1 19.00 133.00 32.00 1.87 
RC2 10.00 148.00 36.20 2.03 
RC3 26.00 353.00 44.50 1.88 
RC4 32.00 246.00 42.10 1.65 
RC5 15.00 234.00 35.30 2.00 
RT1 518.00 313.00 45.50 2.53 
RT2 448.00 645.00 48.40 3.02 
RT3 1414.00 986.00 40.70 2.67 
RT4 266.00 600.00 19.70 2.31 
RT5 203.00 1095.00 54.80 3.51 
RT6 250.00 1067.00 45.70 6.37 
RT7 156.00 213.00 33.20 1.28 
RT8 464.00 21015.00 51.30 2.97 
RT9 210.00 805.00 23.80 1.98 
RT10 530.00 2250.00 30.00 2.52 
RC denotes control rats; RT denotes IL-13 overexpressed rats 
